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SUMMARY
A brief general introduction to cephalosporin antibiotics is presented in Chapter One, 
with particular reference to the structural elucidation o f cephalosporin C which is considered 
as the parent substance from which the first cephalosporins o f clinical importance were 
derived. Attention is also drawn to the importance o f stability and degradation studies o f the 
pure antibiotic compound to pharmaceutical industry.
In Chapter Two, the synthesis and characterisation of some reference standards and 
related compounds is reported, together with lists o f suppliers and chemical structures o f the 
cephalosporin antibiotic samples employed in the present work.
Extensive use o f high-resolution *H (270 and 400 MHz) and 13 C (67.8 MHz) NMR has 
been made to study the general and specific spectral features o f some cephalosporins and 
their derivatives. The application o f NMR spectra to the identification o f these antibiotics is 
given in Chapter Three. The data secured are also employed for confirmation o f structure of 
esters obtained from industry and those compounds prepared in our own laboratories. Some 
quaternary carbon atoms have been differentiated by the use o f spin-lattice relaxation time 
(T i) measurements.
One of the aims o f this thesis is to assess the potential o f *H NMR spectroscopy in 
providing information about the degradation o f cephalosporins under various experimental 
conditions. Chapter Four describes the results o f this study; efforts were made to determine 
the structure of the degradation products. A 1H NMR study o f the effect o f p-lactamase 
enzyme on a group o f penicillins was also carried out, and the results are presented and 
discussed as a supplement to Chapter Four.
In Chapter Five, results obtained for the binding of cephalosporin antibiotics and 
derivatives to serum albumin using spectrofluorimetric and spin-lattice relaxation 
measurement techniques are reported and discussed.
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The cephalosporin antibiotics first appeared in clinical practice in the late 1940s. They 
represent a large group of closely related semi-synthetic compounds derived from 
cephalosporin C, a natural antibiotic produced by the mould Cephalosporium acremonium. 
They are bactericidal, with a wide spectrum of activity and, similarly to the penicillins, they 
act by inhibiting synthesis of the bacterial cell wall. Because of their relatively low toxicity 
to man, exhibiting no reaction in some patients allergic to penicillins and relative lack of 
dangerous side effects, they quickly assumed a major role in chemotherapy. At present, 
several derivatives of cephalosporins have been reported in the literature. The latest edition 
of the Martindale Extra Pharmacopeia1 ( 1989) lists 41 cephalosporins in clinical use.
1.1 H istory of the cephalosporins
In 1945, after the discovery of the chemotherapeutic properties of penicillin, an antibiotic- 
producing species of cephalosporium was isolated from a sewage outfall in Sardinia . Then, 
in 1948, further studies on this organism in Oxford showed it to produce several antibiotics, 
one of which was penicillin N.
Five years later, this penicillin was shown to be contaminated with a second substance, 
cephalosporin C (Fig. 1.1), containing a p-lactam ring, but more resistant to hydrolysis by the 
enzyme P-lactamase3.This substance was the original member of the large group of 
substances now classified as cephalosporins.
HOOC
>:c h (c h 2) 3c o n  w h
"c o 2h
n h 2
—  v.p^CHjOAc 
b  CO;H
Oa
Fig. 1.1 .'Structureof a) PenicillinN and b) CephalosporinC.
- 1 -
By the end of 1957, larger quantities of cephalosporin C had been produced by the 
Medical Research Council and Glaxo laboratories in the U.K. After a detailed chemical 
study, Abraham and Newton published the structure of cephalosporin C in 19614, which was 
confirmed with an X-ray crystallographic study5.
The isolation of the nucleus of cephalosporin C, 7-aminodesacetoxycephalosporanic 
acid (7-ADCA), in 1960s6*7, enabled pharmaceutical manufacturers (Lilly, Glaxo, Squibb, 
Fujisawa etc..) to produce many thousands of cephalosporins by various derivatization 
procedures.
Later, in the 1970s, widely-distributed cephalosporin-producing micro-organisms were 
found8. More recently, cephalosporins have been obtained from bacteria of the 
Flavobacterium species9.
These developments opened the way to the preparation of large numbers of 
semisynthetic cephalosporins for evaluation as therapeutic agents. The first clinically 
important analogue to be described was cephalothin10, which has been widely used, 
especially in the USA. The first cephalosporin to be used in the United Kingdom was 
cephaloridine, which has the same group at position 7 as cephalothin but with 
methylpyridinium replacing acetoxymethyl(CH2  OCOMe) at position 3.
1.2 Definition, stereochemistry and nomenclature of the cephalosporin antibiotics
Cephalosporins are a series of compounds containing the 7-amino-cephalosporanic acid [ 
7-amino-3- (hydrox>methyl)-8-oxo-l-thia-5-azabicyclo[4.2.0]- oct-3-ene-4-carboxylic acid 




Nn < ^ C H 2OCOCH
Fig. 1.2 illustrates the essential structural features of the naturally occuring forms of the 
cephalosporin antibiotics.
The molecular framework is a 4-membered p-lactam ring, which is fused through the 
nitrogen and the adjacent tetrahedral carbon atom (C-6 ) to a second heterocyclic ring, a six- 
membered dihydrothiazine ring. The compounds have a carboxyl group on the carbon atom 
attached to the p-lactam nitrogen (C-4), and an acylated amino group on the carbon atom 
adjacent to the carbonyl carbon of the P-lactam ring (C-7).
The cephalosporins and the cephamycins have the same basic structure except that the 
later has a methoxy group instead of hydrogen on the amide-bearing carbon-7.
The stereochemistry of the p-lactam ring of the cephalosporins involves asymmetric 
centres at C- 6  and C-75’11,12, and the absolute configurations of these centres are known to 
be 6 -R and 7-R. The fused rings are not coplanar but are folded along the C- 6  to N-5 bond to 
give a butterfly-like molecular shape. The configuration of the fused ring is such that the 
hydrogen on the carbon atom at the ring junction(C-6 ) is cis to the hydrogen on the amide- 
bearing carbon atom (C-7)l j . For the description of the cephalosporin stereochemistry, the R 
configuration will refer to H- 6  and H-7 being behind the plane of the paper, S configuration, 
in front. Similarly, when substitution occurs at C-3, C-4 and C-7, a  substitution denotes the 
group behind the plane of the paper, and p, above the plane. The stereochemical placement 
of the ring substituents is designated by the a  and p notations. Accordingly, the hydrogens
RCONI
Fig. 1.2 : Cephalosporin antibiotics : a) Cephalosporins, X=H.
b) Cephamycins, X=OCH3 .
on the |3-lactam ring and the 7-methoxy group of the cephamycins are a-, and the 
7-acylamino group is p.
The nomenclature of the cephalosporins and cephamycins presents some difficult 
problems. The Chemical Abstract formal indexing names for these antibiotics are too 
cumbersome for general use. For example, the official name for cephalosporin C (Fig. 1.1b, 
p.l) is : 3{acetoxymethyl)-7-(D-5-amino-5- carboxy-valeramido)-8-oxo-5-thia-l-azabicyclo 
(4.2.0]octa- 2-carboxylic acid. One simplification designates the unsubstituted bicyclic ring 
system of the cephalosporins, the fused dihydrothiazine-azetidinone (p-lactam) T2  (see 
Fig. 1.3 below), as cepham6. Thus,the cephalosporins are generally 3-acetoxymethyl 
-7-acylamino-3-cephem-4-carboxylic acids 1.3. This nomenclature is widely used, especially 
in chemical literature dealing with the cephalosporins. A further simplification with 
narrower structural latitude is the use of the term "cephalosporanic acid" to designate the 




Although convenient, this naming becomes restrictive for the cephalosporins (and 
cephamycins) in which the 3-acetoxymethyl groupings has been replaced by other 
substituents.
An alternative nomenclature is the use of the Internationally approved names of 
cephalosporins and cephamycins rather than the more informative but cumbersome 
systematic chemical names, or the proprietary names, of which there are, in most instances, 
several for each compound.
Degradation products derived from cephalosporins are termed by Internationally 
approved names, e.g., desacetylcephalothin, desacetoxycephalothin, desacetylcephalothin 
lactone. To avoid any confusion, in this thesis, the atoms are numbered as shown below :
When the double bond is in the C3—C4 or C2--C3 position, it will be denoted as a
1.3 C hem istry of cephalosporins
1.3.1 S tru c tu ra l elucidation o f cephalosporin C
(note: prior to modem physical methods)
As cephalosporin C is considered as the parent substance from which the first 
cephalosporins to find clinical use were derived, and as it contains the (3-lactam- 
dihydrothiazine structure, which is the main nucleus for all cephalosporins, this section is 
concerned with the work which led to the determination of its chemical structure.
It was the extensive degradative, physical and physico-chemical studies of Abraham and 
Newton4  that provided the chemical evidence for a definitive structure for cephalosporin C. 
Some of the degradative results demonstrated its resemblence to penicillin N 1.514,15.
1
3-cephem (A ) or 2-cephem (A ) cephalosporin, respectively.
;CHCHjCH£H2CONH-CH—£ H / £ ( c H 3) ,
J> 6 I /  IM—  kJ—c h - c o o h
- 5 -
Both behaved as monoaminodicarboxylic acids. They contained D-a-aminoadipic acid 
linked by the 8 -carbonyl to the rest of the molecule, and showed an infrared absorption band 
at 5.62|l, characteristic of the C=0 stretching vibration of the p-lactam ring. Both yielded a 
mole of a CO2  in hot dilute inorganic acid hydrolysis. After Raney nickel desulphurization, 
hydrolysis yielded L-alanine, valine, and glycine.
On the other hand, other degradative results showed marked differences between the 
two. Cephalosporin C hydrolysis did not produce penicillamine but yielded sulphur- 
containing fragments which contained no nitrogen. Two moles of ammonia were obtained 
from a hydrolysis of cephalosporin C that liberated only one mole of ammonia from 
penicillin N. The valine obtained from desulphurization and hydrolysis of cephalosporin C 
was racemic; penicillin N yielded D-valine. Cephalosporin C had an UV absorption band at 
260 nm (£=9600) absent in the penicillin. These observations, showed that the hypothesis 
that a modified p-lactam-thiazolidine ring system was present in cephalosporin C, would 
have to be abandoned.
Consideration of a number of degradation products of cephalosporin C indicated that it 
contained the partial structure L6 , (Scheme 1.1, p.7) Jeffery et al.16 (1960) reported that 
2-(D-4-amino-4- carboxybutyl)thiazole-4-carboxylic acid J_/7 was formed when 
cephalosporin C was kept in neutral aqueous solution at 37*C. This could be accounted for 
by opening of the p-lactam ring, fission of the bond between the sulphur atom and the 
remainder of the molecule, and a nucleophilic attack of the sulphur on the amide carbon of 
the side chain. Acid hydrolysis of cephalosporin C produced a neutral 
p-acylamidoacetaldehyde fraction, which, upon oxidation with silver oxide, yielded the 
acylamido acetic acid 1.8. Raney-nickel desulphurization, followed by hydrolysis, degraded 
cephalosporin C to an acylated diaminopropionic acid 1.9 (see Scheme 1.1, p.7).
1
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The rest of the stmcture-determination of cephalosporin C proved more difficult 
because the dihydrothiazine ring was novel to antibiotics and was little known chemically. 
Nevertheless, several experiments supplied the necessary facts to prove that structure 1.10 ( 
Scheme 2.2, p.8 ) satisfied all the known properties of cephalosporin C. First, hydrogenolytic 
hydrogenation of 1 .1 0 , followed by hydrolysis with hot acid, yielded a-oxovaleric acid 1 .1 1 . 
As the 1H NMR spectrum of cephalosporin C failed to reveal gem-dimethyl groups (as in 
penicillin), and the UV absorption at 260 nm required that some sort of chromophore be 
associated with the nucleus outside the p-lactam ring, the investigators therefore postulated 




HOOC— C = rC  —  CH2—
5N —
This finding provided five of the seven unplaced carbon atoms of the partial structure 
1.6. The liberation of one mole of acetic acid from cephalosporin C by mild acid or alkaline 
hydrolysis established the nature of the remaining C2  fragment The presence of a band at 
5.77 }i in the infrared spectrum of the antibiotic suggested that the acetic acid was derived 
from an acetoxyl group. Before final chemical proof for 1.10 was obtained, Hodgkin 
Maslen5 established by X-ray analysis that the sulphur-containing ring of cephalosporin C 
was six-membered and substituted by an acetoxymethyl group.
The chemical degradations which confirmed structure 1.10 were, in 
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The expected configuration, with cis hydrogen atoms attached to C$ and C7 , was 
confirmed by the X-ray crystallographic analysis5.
The isolation of the 2,4-dinitrophenylosazone of hydroxyacetone after ozonolysis of 
cephalosporin C and treatment of the product with Raney nickel and a solution of 
2,4-dinitrophenylhydrazine in 2N HQ, was consistent with the position assigned to the 
double bond in structure 1 .1 0 .
1.3.2 Total chemical synthesis of cephalosporins
17—22Most of the attempts for total synthesis of cephalosporins proved to be difficult . This 
is mainly due to the unusually high degree substitution of carbon atom 3, in addition to the
reactivity of the P-lactam structure, which renders these antibiotics specially vulnerable to
12chemical attack. Morin and co-woricers described a chemical procedure for the conversion 
of a penicillin to a desacetoxycephalosporin. They subjected phenoxymethylpenicillin 
sulphoxide 1.12 to Pummerer reaction conditions, p-toluene sulphonic acid in boiling xylene. 
The reaction mechanism involved esterification, rearrangement, and-cleavage to an 
intermediate unsaturated sulphenic acid, in which the sulphur then attacked the terminus of 









A detailed total chemical synthesis of cephalosporins has been given by Woodward et 
al.23. Instead of the dihydrothiazine ring, these workers chose the P-lactam ring as the initial 
monocycle from which to construct the cephalosporin nucleus.
1.3.3 Semisynthesis of clinically useful cephalosporins
The isolation of the cephalosporin C nucleus, 7-aminocephalosporanic acid (7-ACA, Fig.
cephalosporins for evaluation as therapeutic agents. It was used as the starting material of 
many new compounds [see Table 1.1, p. 12] by acylation of the amine at the C7 position 
using : a) acid chloride, b) mixed anhydride, or c) dicyclohexylcarbodiimide methods in 
aqueous or nonaqueous solvents and sodium bicarbonate or an organic base as an acid 
acceptor. Further chemical modifications of position 3 and 7 in cephalosporin C 1.10 (Fig.
1.4), has resulted in a series of antibiotics with different characteristics. Substitution at the 
7-amino group tends to affect antibacterial action whereas at position 3 it may have more of 
an effect on pharmacokinetic properties.
Fig. 1.4 : The cephalosporin C molecule 1.10 showing the two groups (RCO and R ’) in 
which modifications might profitably be made, and its nucleus, 7-ACA 1.14, into which new 
groups can readily be incorporated.
The main objectives in the synthesis of the first-generation cephalosporins at that time 
were:
1. Preparation of cephalosporins with high intrinsic activity not only against penicillinase-




R= HOOCfH (CH2)3-  f R'= OCOCH3 j X = H
nh2
- 1 0 -
producing bacteria, but also against a range of Gram-negative ones that were penicillin- 
resistant and P-lactamase-resistant.
2. Preparation of cephalosporins clinically useful when given by mouth.
The resistance of 7-a-methoxycephalosporins (cephamycins) to p-lactamases suggested 
that a hydrogen atom at C-7 of the p-lactam ring (X in Fig. 1.4) might be replaced with 
advantage by a methoxyl group (OCH3 )24’25.
The above expectations have been largely fulfilled by the development of two important 
series of broad spectrum cephalosporins. The first series represented by cephalexin 1.15 as 
the first orally-active cephalosporin to find wide clinical use. The second series is represented 
by cephalothin 1.16 and cephaloridine 1.17 as the first injectable cephalosporins effective 
against Gram-negative organisms [see Table 1.1, p. 12].
1.4 Biological properties of cephalosporins
1.4.1 Pharmacological action and pharmacokinetic characteristics of 
cephalosporins
The cephalosporins are bactericidal and, similarly to the penicillins, they act by inhibiting 
synthesis of bacterial cell wall.
The first-generation cephalosporins (represented by cephalothin, Table 1.1, p. 12) has 
good activity against a wide spectrum of Gram positive bacteria, and a modest one against 
Gram negative. As mentioned in section 1.3.3 chemical modifications of position 3 and 7 has 
resulted in a series of more potent cephalosporins. The second-generation compounds 
(represented by cefuroxime and cephamandole) have been characterised by their greater 
stability to hydrolysis by P-lactamases produced by Gram negative bacteria, while the third- 
generation (referred to as extended spectrum) cephalosporins, such as cefotaxime and 
cefsulodin, are even more stable to hydrolysis by p-lactamases than cefuroxime and 
cephamandole, with a wider spectrum and greater potency of activity against Gram negative
Table 1.1 : Some representatives of the a) orally and b) parenterally active semi-synthetic 
cephalosporins and their properties.
RCONHv= c
Trivial name 1st launch X
Company year country
R Activity and properties
(a) Orally active cephalosporins: 
Cephalexin W5 EliLilly 1969 USA




EliLilly 1979 UK H PhCH(NH2) Cl
Bristol 1977 France
(b) Parenterally active cephalosporins: 
Cephalothin 1J6 EliLilly 1964 USA
Cephaloridine 1J7 Glaxo 1964 UK
-CH,OAc
Fair activity against 
G+ve, less activity against 
G-ve, very well absorbed 
and stable to P-lactamases. 
More active than cephalexin 
against H.inluenza. Some­
what unstable chemically 
and in serum.
Very similar toH5, but 
more sustained blood conc.
Active against G+ve and 
non-P-lactamase- 
producing G-ve organisms. 
Metabolically unstable. 
Similar spectrum to ceph­




Hoechst, 1981 France 
Roussel
Glaxo 1987 UK
C -  CH20C0CHj y ery actjve against G-ve 
NO Me
NH
MSD 1978 USA OMe
H j r \
. uivie bacteria. Metabolically
unstable.
H. C- CHjOCO Active against broad range
11 -  - - o f G+ve & G-ve organisms
Metabolically stable.
: Broad spectrum, active 





Most cephalosporins can only be administered parenterally, as they are either 
inactivated by the stomach acid or not significantly absorbed from the intestine. Those agents 
that are absorbed from the gastrointestinal tract, such as cefadroxil and cephalexin, Table 1.1, 
are characterised by having electronegative substituents which improve their stability to 
gastric acid.
In general, cephalosporins administered orally in doses of 250 mg, 500 mg and 1 g 
produce peak plasma concentrations ranging from 6  to 30 jig/ml within two hours. Those 
given parenterally achieve average peak plasma concentrations of 40 jig/ml after 30 min of 
an intramuscular dose of 1 g1.
Most cephalosporin antibiotics are 20 to 85 % bound to serum albumin as is fully 
discussed in Chapter 5. Serum protein binding inhibits drug passage across the capillary 
lining to tissues, the effect being greatest for cephalosporins having more than 85 %
Ofkbinding . A high degree of binding may also prolong the presence of the drug in the blood, 
which partly explain the long serum half-life (X\a) ° f  compounds such as ceftriaxone with a 
ti /2  of 8.5 hrs. Generally, most cephalosporins are eliminated rapidly, with serum half-lives 
of 1 to 2 hrs, by the kidneys via glomerular filtration and active renal tubular secretion. In 
only a few cephalosporins is metabolism an important method of elimination. Hydrolysis of 
the P-lactam ring occurs within the body and produces inactive drug. Specific esterases 
metabolically remove 3-acetyl groups on the dihydrothiazine ring of compounds such as 
cefotaxime and cephalothin, which are then converted to the antibacterially inactive lactone 
of these substances26,33.
1.4.2 Mechanism of action of cephalosporins
Bacteria are completely enclosed in a cell wall, which give them shape and form and 
protects them from harmful influences such as osmotic shock. Synthesis of bacterial cell
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walls takes place in three distinct stages which occur at 3 different sites in the cell: the first 
stage involves synthesis of uridine nucleotide precursers, UDP-acetyl-muramyl-pentapeptide 
and UDP-acetyl-glucosamine, in the cytoplasmic region of the cell. The second stage is the 
utilization of the UDP, together with other substrates in the cell membrane, to introduce new 
disaccharide-pentapeptide units into the growing peptidoglycan of the cell wall, via a 
membrane-bound phospholipid. The third stage is the cross-linking of the linear 
peptidoglycan strands which takes place outside the cell membrane to foim a peptide bridge,
27 28i.e. synthesis of the rigid component of the cell wall .
The action mechanism of the (3-lactam antibiotics has been studied since the late 1940s. 
Strominger and Tipper29  have shown that inhibition of bacteria by these compounds is likely 
to occur by reaction of penicillins and cephalosporins with transpeptidase enzymes important 
for the peptidoglycan cross-linking in the third stage of the cell wall synthesis (see Fig. 1.5). 
The bacterium is then unable to contain the high osmotic pressure of the cell contents, and 
the cell ultimately bursts.
UDP-N-acetyl-glucosarcine + UDP-N-acctylmununic acid pentapepdde 
(NAcGc-NAcMur)„
UDP-linked precursor disaccharide














(NAcGlc-NAcMurX, +1 , 
extended peptidoglycan
Fig.1.5
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It has been suggested that the inhibition of the cross-linking enzymes by penicillin
01 09
and cephalosporins ’ involves a substrate analogue mechanism : the highly stressed 
amide group of the P-lactam ring is conformationally similar to the D-alanyl-D-alanine bond 
of the peptidoglycan pentapeptide. Consequently, the enzymes mistake P-lactam antibiotics 
for their normal substrates and react with them (irreversibly) to yield stable covalent esters 
which lack catalytic activity (see Fig. 1.6 below).
RCONH
RCONK ^ S . / C H
n  r CH
S  *0 ~ COOH
protein protein (enzyme)
Fig.1.6
This irreversible acylation interferes with the synthesis of the cell wall in dividing cells, 
producing an osmotically unstable protoplast and eventually leading to the destruction of the 
cell. The exact molecular mechanism by which penicillins and cephalosporins inhibit cell 
wall synthesis in bacteria is not known33. In general, however, the dependence of the 
biological activity of an intact P-lactam function is rationalised by the above arguments. Van 
Heyningen and Ahem (1968)34 and Morin and co-workers (1969)7 have attempted to 
correlate activity with stability of the p-lactam of various cephalosporins. If the p-lactam is 
too stable, as in A -cephalosporins, the cephalosporin will presumably not acylate the 
transpeptidase and therefore will be biologically inactive. Such inactivity is indeed seen in 
the A2 -cephalosporins34.
Note on side effects of cephalosporins
Cephalosporins generally cause few side effects. Hypersensitivity reactions are less 
common than with the penicillins and almost no cross-reactivity to cephalosporins have been 
reported in patients who have previously reacted to penicillins. Other hypersensitivity
C HN
CO,H
reactions to cephalosporins include fever, arthralgia and exanthema. Some of the new
cephalosporins have a 3-methylthiotetrazole side-chain, a moiety which confers a risk of
reduced synthesis of prothrombin with subsequent risk of bleeding, and of disulfiram-like
1 35reaction in patients consuming alcohol following a cephalosporin dose * .
1.5 Stability and degradation of p-lactam antibiotics
P-lactam antibiotics are the most widely used class of antimicrobial agents. Numerous 
penicillins and cephalosporins and their derivatives are now in regular clinical use, and many 
other new molecules belonging to this group of antibiotics are developed every year. Hence, 
stability and degradation studies related to the pure antibiotic compound should contribute to 
problems of their formulations and shelf-life, and data obtained are of great significance to 
pharmaceutical industry, also necessary for better understanding of these new agents.
In order to understand the factors affecting the antibacterial activity of p-lactam 
antibiotics, many studies have been done on the cleavage reaction of their p-lactam ring in 
alkaline aqueous solution and on those catalysed by p-lactamases with use of a variety of 
analytical methods such as iodometry36, chromatography36,37-39, UV spectroscopy4 0 -4 2  
and microbiological assays43.
Despite the resemblence in structure between the penicillins and cephalosporins (Fig. 1.7) 





Fig. 1.7 : Structures of a) a penicillin and b) a cephalosporin.
Opening of the p-lactam ring of the penicillins by dilute alkali, penicillinase or reaction 
with amino groups yield mainly a-penicilloates (R,R). The penicilloate structure is relatively
-16 -
stable, although epimerization may occur to give (3 (R,S), y  (S,R) and 5 (S,S) 
diastereoisomers, which differ from the a  compound in configuration at C-5 and/or C-6 41’45.
The presence of a A3 double bond in the cephalosporin ring system as well as a 
substituent in position 3 leads to more extensive cleavage on hydrolytic degradation of the 
molecule, compounded by the fact that most of the degradation products are unstable.
A detailed account of the various mechanisms and sites involved in the degradation 
processes of p-lactam antibiotics is given in chapter four of this thesis, with more emphasis 
on those of cephalosporins which have been little studied in these respects.
Systematic studies on the degradation of cephalosporin derivatives are of interest for 
several reasons: a) a correlation between degradation and antibiotic activity has been shown 
in the first and second-generation cephalosporins36, b) some degradation products may be 
involved in allergic reactions46, and c) the stability of the compounds has to be known for 
the synthesis of derivatives47 and the formulation of drugs.
The following is a brief review of the degradation of P-lactam antibiotics in various 
experimental conditions, as reported in the literature:
1.5.1 Effect of acid
The acidic degradation rates of penicillins are known to depend on the side-chain 
structure48,49. Benzylpenicillin is extremely acid unstable50, while ampicillin is the most 
acid stable51. The side-chain reactivity of the penicillin molecule is attributed to the 
rearrangement initiated by the attack of the side chain amido carbonyl upon the P-lactam to 
produce the corresponding penicillenic and penillic acids52.
Compared to the penicillins, cephalosporins are relatively insensitive to acid regardless 
of the N-acyl side chain because of the decreased nucleophilicity of the nitrogen in the 
dihydrothiazine ring53, p-lactams of these cephalosporins exhibit half-lives of about 25 hr at
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pH 1.0 and 35° and are several times more stable than ampicillin under the same
or
conditions . However, in case of 3-acetoxymethylcephalosporins, such as cephalothin, the 
acetyl function is hydrolysed faster than the p-lactam moiety to yield the corresponding 
desacetyl compounds, which are easily converted to the lactones (see Scheme 4.9, chapter 4, 
P-120. The desacetoxycephalosporin derivatives, such as cephalexin and cephradine, were
'If.
fairly acid stable even in strong acid solutions .
1.5.2 Effect of alkali
Some investigators stated that the enhanced sensitivity of alkaline degradation of 
cephalosporins and penicillins may be attributed mainly to a suppression of the usual amide 
resonance resulting from the nonplanarity in the p-lactam nitrogen atom54,55. Alkaline 
hydrolysis of cephalosporins results in cleavage of the P-lactam ring; however, the 
hydrolysis products formed seemingly do not correspond to those of penicillins, namely, 
penillic, penicilloic, and penicillenic acids. Some analogous compounds may have a transient 
existence during the hydrolysis27 . The sensitivity of cephalosporins to degrade varied greatly 
with different 3-methylene substituents. In a series of 7-acylated cephalosporins, those with 
good leaving groups at position 3 were the most reactive; cephalexin and cephradine (with 
non-leaving groups at position 3) were the most resistant to the hydroxide-ion-catalysed 
degradation . The significant influence of the substituents at the 3-methylene position upon 
the chemical reactivity of the p-lactam may be attributed to the long-range inductive effect 
on the electrophilicity of the p-lactam carbonyl carbon atom toward hydroxide-ion attack56  
and/or the leavability of the 3-methylene moiety, which may lower the energy of the 
transition state57.
1.5.3 Enzymatic and aminolytic hydrolysis
Enzymology occupies a prominent place in the understanding of the mode of action of 
cephalosporins and penicillins and in appreciating some of the basis for bacterial resistance. 
p-Lactamases hydrolyse the P-lactam ring; the penicillins are converted to inactive
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penicilloic acids; opening of the p-lactam ring of the cephalosporins is followed by more 
complex rearrangements. Of the three possible sites of enzymatic cleavage of cephalosporins, 
discussed by Pollock (1965)58, the P-lactamase activity at site b (Fig. 1.8) has received far 




Fig. 1.8 : Sites of enzymatic cleavage in cephalosporins.
Most observations during the p-lactamase decomposition and aminolysis of 
cephalosporins suggested that the initial product of the former involved hydrolysis of the 
P-lactam ring accompanied by elimination of the leaving group59, while the product of the 
aminolysis involved only the hydrolysis of the P-lactam ring60.
Table 1.2 (p.20) lists some of the analytical methods for the investigation of 
cephalosporin degradations, as reported in the literature.
Table 1.2a : Some o f  the analytical methods for the investigation o f  cephalosporin 
degradations as reported in literature:
Cephalosporin Analytical
method
Kinetics o f  
degradation
evidence o f  
degrad, products
Reference
Benzyl- UV 1st order pcnicilloic, Garke 194961
penicillin HPLC epimerization pcnicillcnic & Blaha 197637
1H NMR & degradation pcnillic acids Dcgalacn 197962
Cephazolin residual antib. pseudo 1st order none Rattie ct al.
analogue det.iodometrically pH 2-10 197963




Tsuji et al. 
198164




Indelicato et el. 
1972,7465-66
Cefaclor Isolation of pyrazine dione Dinner
etc degrad, products + thiophene 197767
Various
cephalosporins
UV, 1H NMR reactivity 1h & 13c n m r






















HPLC entire pH range evidence of 
lactones etc.
Yam ana et al. 
(1976)36








None Sabath et al. 
196541




None Faraci et al. 
(1984)59
Cephacetrile HPLC Assay desacetyl (use 
enzyme), lactone
Mangia et al. 
(1979)71
Cephalothin desacetyl and 
lactone





















Cephalosporin Analytical' Kinetics o f evidence o f Referenc
method degradation degrad, produce
Cephalexin UV, HPLC rate constant None, no hard Das Gupta
pH4-7 evidence (1981)40
Cephradine *H NM R Alkaline piperazincdione Cohen 1973?4
degradation isolated Indelicato 197265
Cefotaxime HPLC. electro­ use of standard Fabre 198575
chemical detection lactone Fabre et al. 198676
Cefamandole constant pH pseudo 1st conversion o f 77Indelicato





HPLC (nafate) Fabre 198278













a antib.=anlibiotic, dct.=dctcrmincd, dcgrad.=dcgradalion, . alk.=alkalinc, 
Microbiol.=Microbiological, Polarog.=Polarography, epimer.=epimerization.
Aims and objects of the present work
This introduction has brought to light several aspects of the cephalosporin antibiotics 
which require further investigation.
The sources of materials used in this work are described in Chapter Two. This section 
includes a variety of synthetic procedures to produce reference standards and related 
compounds.
The abundance of cephalosporin antibiotics ( and of (5-lactam antibiotics in general) in 
present day clinical use presents a major challenge to pharmaceutical analysts both from the 
view points of specific identification and quantification, and detection of impurities and 
products of degradation and isomerization. The value of NMR spectroscopy in differentiating 
groups of closely related compounds is well known and of direct application to 
cephalosporin derivatives which form a group of this kind. Some work of this nature has
oo 04
already been carried out at Bath * but as a result of the recent introduction of several 
novel cephalosporin antibiotics, an extension of such NMR investigations has been 
undertaken as part of this Thesis (Chapter 3).
The value of NMR spectroscopy in studies of the stability and degradation of p-lactam 
antibiotics of the penicillin class has already been demonstrated44 ,6 2 ,8 5  and it appeared 
logical to extend its application to the same problem in regard to the cephalosporins. This 
aspect forms a second theme of this Thesis (Chapter 4).
Finally the question of the binding of cephalosporin antibiotics to serum albumin has 
been taken up on account of the key role it plays in determining the pharmacokinetics of 
p-lactam antibiotics. Binding studies reported in the literature mostly employ classical 
techniques, and that of spectrofluorimetry has been employed in the present work by use of 
state-of-the-art instrumentation. However, evidence of binding parameters may also be 
gained from NMR relaxation times, and this alternative technique has also been investigated
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in  regard to cephalosporins (Chapter 5 o f  this T h esis).
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CHAPTER TWO
Source of materials
2.1 Drug samples obtained from the manufacturers
Table 2.1 below lists the drug samples employed in the present investigation and their 
manufacturers. Details of their chemical structures are given in Table 2.2 (p.33). The 
compounds are listed alphabetically by generic name in Table 2.2 to enable easy reference to 
structure throughout the Thesis and to avoid undue duplication of formulae.
Table 2.1:
Drug name Batch No. Manufacturer
Benzylpenicillin Na 3DP8578A Glaxo, England
7-ADCA UCC 2749 Glaxo, England
Cephalexin KT/17 Glaxo, England
Cephradine 5M80710 Squibb, USA
Cefadroxil CCD8U0914 Bristol Sermoneta, 
Latina,Italy
Cefaclor 82K774 Eli Lilly, England
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Cefoxitin Na 18423 MSD, Hertfordshire
(Mefoxin)
Cefuroxime Na 8CP114B Glaxo, England
(Zinacef)
Cefotaxime Na 0045 Roussel, England
(Claforan)
Ceftizoxime Na E9149A Wellcome Foundation,
(Cefizox) Dartford
Ceftriaxone Na 707 Roche, Hertfordshire
(Rocephin)
Cefixime Na RM 27 Cyanamid, USA
Ceftazidime pentahydrate B6166LE Glaxo, England
(Fortum)
Cefsulodin Na 85-192591 Ciba-Geigy,
(Monospor) Horsham
Cephamandole Li G95-39M Eli Lilly, England
Cephamandole nafate FF2J05C Eli Lilly, England
Cephazolin Na 5SJ36 Eli Lilly, England
Cefatrizine 20410 Bristol laboratories, 
Syracuse, USA
Moxalactam 2 NH4 C34-2W6-84 EliLilly,
(1-O-analogue) USA
Cefotaxime lactone 8A0291B Roussel UCLAF
Cefotaxime free 8A4124B Roussel UCLAF
acid
Desacetylcefotaxime 8A0203B Roussel UCLAF
2.2 Synthesis of some cephalosporin degradation products and related 
compounds
2.2.1 Introduction
The following compounds were synthesised by standard methods or modifications 
thereof. The original reference is given in the relevent section. The other compounds used in 
the present work were either obtained from the original researchers or from commercial 
companies.
2.2.2 Experimental
Melting points were determined on a Gallenkamp electrically heated melting point 
apparatus. Kieselgel 60 F254 (silica gel) plates were used for thin-layer chromatography 
(TLC) and were visualised using an iodine vapour chamber. Solvent evaporation under 
reduced pressure was carried out using a Buchi Rotavapour R110 rotary evaporator. 
Lyophilization was carried out using an Edwards Modulyo freeze-drier operating at ~ -4073 
mbar.
1H and 13 C NMR were recorded on a Jeol JNM-GX-270 spectrometer (full operating
details are given in Chapter three, p.38). Unless otherwise stated assignments were
established by comparison with published data and/or on the basis of expected chemical
13shift, signal multiplicity and the use of DEPT C NMR pulse sequences.
2.2.3 Compounds prepared
2.2.3.1 Desacetylcephalothin lactone 2.2
The compound was synthesised according to the method of Neidleman et al.86, as 
follows:
To a solution of 550 mg of cephalothin Na 2A in 6  ml of distilled water were added 5 ml 
of acetone and 2 ml of concentrated hydrochloric acid (HC1, pH 1.4). The reaction mixture 
was stirred at room temperature ( 24°C) overnight. The formation of the lactone, followed by
TLC ( EtOH : CHG3 : CH3 COOH, 50 : 100 : 7.5 ), took place 1/2 hour after acidification in
<Lthe form of^white precipitate. The total yield of desacetylcephalothin lactone 2.2 was 338 mg 
(62%), collected by filtration, washed with water, and dried in vacuum desiccator. The 
material 2 .2  was further purified to remove residual traces of 2 T, as follows : to the crude 
product 2.2 in 75 ml of acetone/ ethyl acetate ( 1 : 2 )  was added 10 ml of 5% aqueous 
NaHCC>3 , followed by 10 ml of water. The mixture was shaken vigorously, then the phases 
were allowed to separate (for at least 2 hours). The upper layer, containing the lactone 2.2 
completely free of residual unreacted material, was concentrated in vacuo on a rotary
evaporator at room temperature. Crystalline 2.2 separated, m.pt. 225 - 228*C (with
86decomposition); literature (Neidleman et al., 1970 ) :  228 - 230*C (with decomposition).
2 -CH2 ), 3.87, 3.93 ppm (dd, ArCH2 ), 5.17 ppm (brs, lactone CH2 ), 5.20 ppm (d, J=5 Hz,
thienyl), 9.33 ppm (d, J=8.4 Hz, NH exchangeable), (see also Table 3.3, p.64).
22 3 3 . Preparation of cephalothin free acid 2 J 87
A solution of the sodium salt of cephalothin 2.1 (1.0 g) in 30 ml of distilled water was 
chilled in an ice bath with constant stirring. The pH was adjusted to 1.8 - 2.0 by dropwise 
addition of 6 N HQ. The precipitated cephalothin free acid 2.3 was then filtered and washed 





The H NMR spectral data are consistent with structure 2.2 (in DMSO-d6 ) : 3.49 ppm (s,
6 -H), 5.97 ppm (dd, J=5 & 8.4 Hz, 7-H), 7.07 ppm (m, 2H, thienyl), 7.49 ppm (m, 1H,
yield was -85%.





The *H NMR data are consistent with structure 2.3 (ppm, D M SO -^) : 2.03 ppm (s, 
OCOMe), 3.49, 3.63 ppm (dd, J=18 Hz, 2-CH2), 3.80 ppm (dd, J=14.5 Hz, ArCH2), 4.90 
ppm (dd, J=13 Hz, 3’-CH2), 5.10 ppm (d, J=4.8 Hz, 6 -H), 5.71 ppm (dd, J=4.8 Hz, 7-H), 6.94 
ppm (m, 2H, thienyl), 7.21 ppm (m, 1H, thienyl), 9.1 ppm (d, J=8.1 Hz, NH, exchangeable).
2J2.3J3 Preparation of desacetylcephalothin 25
2.5 was obtained from the 4-p-nitrobenzyl ester of desacetylcephalothin 2.4 (kindly 
supplied by Dr. M. Johnson, University of Chicago) by catalytic hydrogenolysis for the 
removal of the p-nitrobenzyl group, according to the method of Kukolja et al.88, as follows:
A solution of 500 mg of the p-nitrobenzyl ester 2.4 in 30 ml tetrahydrofuran (THF) and 
15 ml methanol containing 1 ml of IN HC1 and 500 mg of 10% palladium on carbon was 
stirred at 25*C for 2 hours under 60 psi H2. The reaction mixture was filtered, and washed 
successively with 10 ml THF, 5 ml MeOH, and 5 ml ethyl acetate. The filtrates were 
combined and evaporated to dryness in vacuo. The residue was redissolved in 10 ml ethyl 
acetate-water (1 :1), and the pH was adjusted to 7.0 with IN NaOH. The aqueous phase was 
separated, washed with ethyl acetate, and lyophilized to yield the sodium salt of 2.5. 
Otherwise, to obtain the free acid 2.5, the organic layer was removed and discarded 
(containing the p-nitrobenzyl polymer). The aqueous layer was extracted once more with 
ethyl acetate, acidified to pH 4.25 by addition of IN HC1, and lyophilized. The powder was
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*H NMR (ppm, DMSO-d6) : 3.31, 3.48 ppm (dd, J=18 Hz, 2 -CH2), 3.86,4.18 ppm (dd, 
J=12.4 Hz, 3’-CH2), 4.9 ppm (d, J=4.9 Hz, 6 -H), 5.48 ppm (dd, J=4.9 and 8.4 Hz, 7-H), 6.9 
ppm (m, 2H, thienyl), 7.4 ppm (m, 1H, thienyl), 9.0 ppm (d, J=8.4 Hz, NH, exchangeable). 
(See also Table 4.7, p.173).
2J2.3.4 Preparation of p-nitrobenzyl ester of cephalothin 2.6
The ester 2.6 was obtained from cephalothin (free acid) 23  according to the method of 
Mobashery et al.(1986)87, as follows :
A suspension of cephalothin (450 mg, 1.14 mmol), p-nitrobenzyl bromide (300 mg, 
1.39 mmol), NaHC0 3  (110 mg, 1.25 mmol), in a 5 :4  mixture of dimethylformamide (DMF) 
and p-dioxan (3 ml) was stirred at room temperature (- 24*C) overnight. The solution was 
then poured into a mixture of saturated CaCl2 and ethyl acetate (10 ml). The organic layer 
was subsequently washed with 2 ml saturated CaQ2, 3 ml water, 2 ml saturated NaHC(>3 , 
and 2 ml water. After drying the ethyl acetate layer over anhydrous magnesium sulphate, it 
was evaporated to dryness in a Buchi rotavaporizer. The resulting residue was crystallized 
from ethyl acetate at -208C to afford a yield of 45 % of a pale yellow solid. TLC, 5 :4  : 0.5 :
0.5 toluene-p-dioxan-EtOH absolute- dilute ammonia solution, one spot Ry=0.49, m.pt. 
138-140°C, (literature87, 147-148#C).
- 30-
Elemental micro-analysis : Found C, 51.80%; H, 3.94%; N, 7.87%.
C23H 2i N 30 z S 2 requires: C, 51.97%; H, 3.98%; N, 7.90%.




NaHC03 *  
(in DMF/p-dioxan)
h 2o r '





22.3 JS 7-(2-phenyIacetamido)desacetoxy-A3-cephalosporanic acid 2.8
A sample of the p-nitrobenzyl ester of 7-(2-phenylacetamido)desacetoxy
A -cephalosporanic acid 2.7 was kindly supplied by Glaxo Laboratories, Greenford. The
88protective ester function was removed according to the method of Kukolja et al. (1985) , as 
follows:
A solution of 5.2 g of the p-nitrobenzyl ester of 7-(2-phenylacetamido 
desacetoxycephalosporanic acid 2.7 in 150 ml of methanol containing 10 ml of IN HC1 and
5.2 g of 10% palladium on carbon was stirred at 25*C for 2 hours under 60 psi H2 . The 
reaction mixture was filtered and the filtrate was concentrated to give a gum. The gum was 
dissolved in 40 ml of water and 40 ml ethyl acetate. The mixture was neutralised to pH 7.0 
by addition of IN NaOH, and the organic layer was removed and discarded. The aqueous 
layer was either washed once more with ethyl acetate (to remove the p-nitrobenzyl polymer) 
and then lyophilized to yield the sodium salt of 2.8, or acidified to pH 4.25 by addition of IN 
HQ. The aqueous acid solution was lyophilized to afford ~ 1.62 g (30%) of 2.8 as the free 
acid. M.pt. 186-188*C (with decomposition), (noliteraturem.pt.)
T h e (T able 3 .3 , p .6 4 ) and lo C N M R  data (Table 3 .5 ,p .7 6 ) w ere con sisten t with structure 
2 .8 .
CH„—CONV r r ^ S
2.8
2 .2 .3 .6  S y n th e s is  o f  c e p h -2 -e n e  2.9
7-p h en ylacetam id o-3-m eth y l-2 -cep h em -4-carb oxy la te  2 .9  w as syn th esised  in  ou r
89lab oratories accord in g  to the m ethod o f  Lam m ert et al. , as fo llo w s  :
A  m ixtu re o f  0 .4 8 3 g  (0 .001M ) o f  4 -p -n itro b en zy l-7 -p h en y la ceta m id o —3-m eth yl-A 3-  
cep h a losp orin  2 .7 , 10 m l tetrahydrofuran (T H F), 10 m l o f  water, and 0 .2 4  g  (0 .001M ) o f  
so d iu m  su lp h id e nonahydrate (Na2S.9H 2 O, m o l.w t 2 4 0 )  w as stirred in  an ice -ta th  for 3 0  
m in u tes. HC1 (1 m l, IN ) w as added and the T H F  w as evaporated on  a rotavaporizer and the  
so lu tio n  then  extracted  w ith  10 m l eth y l acetate. T he extract w as d iscarded . T h e pH o f  the  
aq u eou s layer w as adjusted to  3.2 w ith  h ydroch loric acid, and the o ily  product com m en ced  to  
crysta llize . T h e  crysta llin e  acid  233 w as then  co llec ted  b y  filtration, w ashed  w ith  eu iyl acetate  
and dried in  a vacu u m  oven  overnight.
Y ie ld , 0 .3 1 4  g  (65% ); m .pt. 170-173°C  . (literature : 1 6 7 -1 6 9 )89 . (S e e  T ables 3.17 (p .9 9 )  





Cephalosporins of general formula
(alphabetically listed by generic name, 
as listed in the 29th Ed. of Martindale1)
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COOH
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Table 2.2 (continued) 
Generic name
c e f o t a x i m e
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Table 2.2 (continued)
Generic name
c e f t r i a x o n e
c e fu r o x im e
c e p h a l e x i n
c e p h a l o r i d i n e
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Generic name R X
cephamandole
nafate
\ \  / / - “ -CO-
O-CHO
as above
cephazolin ^ N'n- c h 2- c o -
, N - N  ,
3 A1C H r S - ^ s ^ c H .
cephradine
3'__ 2' 7 /
N H :
CH,
S' 2 '= \ i " * H ?CH3
moxalactam /)^~CH— CC— N^; -*>0^
(complete formula) , ./ C00H 9 J ^ n
s' 0 y ^ CH2_ s 'io n '-
COOH 1c -:3
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CHAPTER THREE
High-field proton (270 & 400 MHz) and carbon-13 (67.8 MHz) 
NMR analysis of some cephalosporins and their derivatives
3.1 Aim
General spectral features of some cephlosporins and their derivatives, as well as specific 
resonances, are given and discussed and their application to the identification of these 
antibiotics is outlined.
3.2 Introduction
NMR spectroscopy combines the advantages of high specificity with rapid analysis and 
minimal sample preparation. Numerous reports on the *H and 13 C NMR spectra of 
cephalosporins have appeared in the literature 9 0 -9 4  . Many of these deal with spectral 
assignments of derivatives in organic solvents such as deuterochlorofoim, while others use 
NMR spectroscopy to determine the structure of underivatised cephalosporins. The 1H and
13 C NMR data for a variety of penicillin and cephalosporin antibiotics have recently been
,83 84 reviewed ’ .
In this work, high-field *H (270 and 400 MHz) and 13C (67.8 MHz) NMR data, 
obtained in our own laboratories, under standard conditions, of some cephalosporins and 
their derivatives are presented. Some of our data are novel, run at high-field to clarify 
features of lower resolution spectra and to provide information on isomeric nature where 
appropriate. The work includes confirmation of the structure of esters obtained from industry 
and those prepared in our own laboratories, and also of lactones and some reference 
compounds of potential value to degradation studies.
Spin-lattice relaxation time ( T  i ) measurements have been utilised for the identification 
and discrimination of some quaternary carbon atoms.
3.3 Experimental
3.3.1 Instrumentation
The natural-abundance 13 C NMR spectra were recorded at 67.8 MHz on a Jeol JNM- 
GX-270 Fourier Transform (F.T.) spectrometer. Proton noise-decoupled spectra with NOE 
{Nuclear Overhauser Enhancement) were recorded under the following conditions: ambient 
temperature (20°C), spectral width 18050 Hz (=266 ppm), 16K data points (zero filled to 32 
K), a 4.0 |is pulse with a 0.454 sec. acquisition time and a 0.213 sec pulse delay. The normal 
proton noise-decoupled spectra were supplemented by DEPT95  (Distortionless Enhancement 
by Polarization Transfer) experiments set to measure CH, CH3 (positive) and CH2  (inverted) 
(pulse angle= 135°), or CH alone (pulse angle= 90°); Cq resonances are absent in 135° and 
90* DEPT.
The 270 MHz JH FT NMR spectra were recorded on the Jeol JNM-GX-270 
instrument, operating at an ambient temperature, using a 32 K data points and a frequency of
3001.2 Hz giving a digital resolution of 0.18 Hz. A 5.0 jls pulse corresponding to a tilt angle 
of 30°C was employed with a 5.459 sec acquisition time and a 0.541 s pulse delay between 
pulses. The 1H-1H 2D correlated spectroscopy (COSY) experiments on ceph-2-enes were 
performed by Dr. Sarah Branch, Department of Pharmaceutical Chemistry, University of 
Bath.
The 400 MHz *H FT NMR spectra were recorded on a Jeol-GX400 spectrometer, at 
Department of Chemistry, University of Bristol ( range -0.4 to 9.6 ppm ). A sweep width of 
4000 Hz was employed with 32 K data points, thus giving a digital resolution of 0.24Hz. 
The pulse width was 0.6 }is and the repetition rate was 5.277 sec (acquisition time plus 2.0 
sec pulse delay).
The inversion-recovery method96 was used for the spin-lattice relaxation time (T i)  
measurements for carbons 3 and 4. The carbon-13 spectra were recorded on Jeol-GX270 
spectrometer with 10 different 1 values ranging from 0.05-10 sec, under the following
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conditions : ambient temperature (20°C), spectral width 18050 Hz, 16 K data points, a 21 fis 
pulse (PW1) corresponding to an angle of 90° and a 42 }ls pulse (PW2) corresponding to a 
180° angle and a 1 0  sec pulse delay between pulses.
3.3.2 Materials and methods
Cephalosporin antibiotics samples were provided by various pharmaceutical companies 
(details in Chapter 2, Table 2.1). They were generally of a purity suitable for pharmaceutical 
formulations. Some of the cephalosporin esters, lactones and other derivatives were 
synthesised in our laboratories (see Chapter 2, section 2.2).
Samples were prepared in 5 mm o.d. tubes as 5-10 %w/v solutions in D2 O, DMSO-d6 , 
CDCI3 and other deuterated solvents. Tetramethylsilane (TMS) and sodium 
2,2-dimethyl-2-silapentane-5- sulphonate (DSS) were used as chemical shift standards, 
5=0.00 ppm. In most experiments with DjO as solvent the large singlet at 5//=4.80 ppm due 
to HOD was used as a reference (DSS complicates the higher field region of the spectrum ).
Alkali metal salts of cephalosporins were freely soluble in D2 O while the solution of 
free acids was promoted by minimal quantities of alkali (usually NaHCOs), or acid 
(triflouroaceticacid, TFA) in the case of p-lactams with amino substituents such as 
cephalexin. The cephalosporin esters were examined in CDQ3 or DMSO-d^.
Assignments of proton and carbon-13 signals were based on the expected chemical 
shift considerations and signal multiplicities, and on correlations with published data and 
reference spectra.
Carbon-13 assignments were aided by the use of DEPT pulse sequences, allowing the 
distinction between the various orders of carbon protonation. In addition, some 13 C ^H  
coupled spectra were run to aid the assignments of complicated spectra. Also 1H- 1H 2D 
COSY experiments were employed to aid the confirmation of ceph-2-ene configuration at
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95C-4. DEPT and COSY techniques have been recently reviewed .
Chemical shift (5 ppm) data for each cephalosporin or related compounds in the 
appropriate solvent, as well as the multiple! separations (first-order J values), were obtained 
from the instrumental print-outs.
3.4 Results and  discussion
The 1H NMR data of cephalosporins, cephalosporin esters, and other related compounds are 
listed in Tables 3.1 (p.51-54), 3.2 (p.63) and 3.3 (p.64), respectively. The 13 C NMR spectral 
characteristics of the above are listed in Tables 3.4 (p.74-75), 3.5 (p.76), those of the esters 
were discussed in detail in section 3.4.8 (p.8 8 ). These data include cephalosporins recently 
introduced into clinical practice.
The general structure, ring numbering and absolute stereochemistry of the free acid foim 
of the antibiotic is given in formula 3.1; the structures of the esters and lactones are given in 
fo rm u lae^  and 3.3, respectively; details of substituents and generic names are included in 
the Tables for easy reference.
R
3.23.1 3.3
Cephlosporin cephalosporin ester cephalosporin lactone
(cephem nucleus) 6 -R, 7-R 6 -R, 7-R
6 -R, 7-R
Tables 3.1-3.3 summarise recorded *11 NMR data for a variety of cephalosporin 
derivatives, while Fig. 3.1 (p.41) illustrates a typical *H spectrum obtained for cephalothin as
one of the most common cephalosporin antibiotics.
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Fig. 3.1 : H NMR spectrum o f cephalothin Na, recorded at 270 MHz in D 2 O to illustrate
characteristic spectral features of cephalosporin antibiotics. (Experimental conditions as in section 3.3.1)
3.4.1 1H NMR features of cephalosporins
From the above mentioned Tables and Figure the *H NMR spectral characteristics of 
cephalosporin derivatives can be classified into : a) common and b) specific
spectral features.
3.4.1.1 Common lH NMR spectral features
(i.e.,common to all examples)
1. p-lactam ring 6-H and 7-H proton resonances
Most characteristic of the *H NMR spectra of all cephalosporins, having an intact 
(3-lactam ring, in D2 O are the two single-proton doublets centred at 4.85 - 5.35 ppm and 5.50 
- 5.95 ppm for the 6 -H and 7-H, respectively, in the (3-lactam ring, forming an AB doublet 
pair, with 3J coupling values of 4-5 Hz (Table 3.1) characteristic of cis_ protons in 
lactams97, 98. Furthermore, the cephalosporins p-lactam protons are characterised by their 
large chemical shift separations (A6t7=0.5-0.9 ppm) compared to those of the penicillin 
antibiotics (e.g.,benzylpenicillin, A56=0.06 ppm). Green et al.93, reported that this feature is 
distinctive enough to enable differentiation of cephalosporins from penicillins.
The *H NMR spectra of the free acids, lactones and esters of cephalosporins in 
deuterochlorofoim (CDCI3 ) or deuterated dimethylsulphoxide (DMSO-dg) are characterised 
by a single-proton double doublet (dd) centred at 5.60-6.00 ppm and a single-proton doublet 
centred at 4.75-5.15 ppm for the 7-H and 6 -H, respectively, in the p-lactam ring. The 7-H 
double doublet signal is attributed to coupling with 6 -H on the one side (J=4.5-5.2 Hz) and 
with the amido proton on the other (J=8.0-9.3 Hz). This assignment is confirmed by 
deuteration (addition of D2 O), when the dd collapses to a doublet with the same coupling 
constant (4-5 Hz) as that shown by the 6 -H doublet; the amido proton doublet at 6.10 - 6.40 
ppm (in CDCI3 ) and 9.1 - 9.6 ppm (in DMSO-dg) disappears. This is illustrated by the 
spectra of cefotaxime Na in DMSO-dg (Fig. 3.2a, p.43) before and after addition of a drop of 
D2 O and shaking (Fig. 3.2b). In the latter case the amido proton in D2 O undergoes exchange
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w i t h  d e u te r iu m  s o  t h a t  o n l y  t h e  d o u b l e t s  f o r  t h e  6 -  a n d  7 - H  a p p e a r .
/  J
NH,d "- r i l l  J  J .J i  LiU__
rr
; to a
Rg. 32 : 270 MHz *H NMR spectrum of cefotaxime Na in DMSO-dg. Insert : partial 
spectrum after addition of D2 O and shaking to illustrate the collapse of the 7-H double 
doublet to a doublet. (Experimental conditions as in section 3.3.1).
In cephalosporins with a methoxy group replacing the usual proton at position-7 in the 
|3-lactam ring (e.g. 7-OMe of cefoxitin and moxalactam) the 6 -H resonates as a singlet at 
5.10 - 5.12 ppm because there is no 7-H with which it can couple to form the characteristic 
doublet of the AB system.
2. Thiazinyl ring  protons 2 -CH 2  resonances
The 1H NMR spectra of cephalosporin derivatives are further characterised by the two-
proton AB doublet pairs, due to the methylene group at position-2 of the dihydrothiazine
ring, having the two protons in different chemical environments. They are distinguished from
the lactam resonances by their higher chemical shifts (range 3.0-3.9 ppm) and
characteristically large separations ( J ~ 18 Hz), typical of saturated geminal methylene
99protons in which the coupling range is given as -20 to +40 Hz ; similar features are also 
shown by esters and free acids [Tables 3.2 and 3.3]. Although the 2 -CH2  signal appeared as 
two well resolved doublets, with the inner lines more intense than the outer (Fig. 3.1, p.41),
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their chemical shift separations (0.10-0.35 ppm) are much smaller compared to those of 
p-lactam protonsCAg 7 0.5-0.9 ppm). Generally, the chemical shift of the 2 -CH2 protons 
reported above is relatively low for methylene protons. This is due to the deshielding effect 
of the adjacent sulphur atom and olefinic group. The 2 -CH2  resonances are lower field in 
1-oxo-analogues, such as moxalactam (centred at 4.36 and 4.53 ppm, J= 17.2 Hz, Table 3.1), 
due to the greater deshielding influence of oxygen compared with that of sulphur.
3.4.13. Specific !H NMR spectral features
1. Signals to higher field of 6.0 ppm
a) 3-proton (methyl) singlets 
Certain 3-proton singlets due to methyl attached to carbon in the range 2.0 - 3.0 ppm, 
nitrogen or oxygen in the range 3.5 - 4.0 ppm are valuable aids to identification. In 
compounds having more than one methyl group in their structure, care is required to 
differentiate them (this is not always easy). Table 3.7 below summarises the chemical shift 
ranges of the various types of the methyl groups of cephalosporins.
Table 3.7 : Summary of the chemical shift ranges of various types 
of methyl groups of cephalosporins:
Me type Examples 8  range in ppm
3-Me cephalexin, cefadroxil 1.90-2.15 s
-OCOMe cephalothin, cefotaxime 2.05-2.10 s
Ar-Me cephazolin 2.70 - 2.75 s
7-OMe cefoxitin, moxalactam 3.40-3.51s
NMe cephamandole, ceftriaxone 3.55 - 4.00 s
NOMe cefuroxime, ceftizoxime 3.90 - 4.00 s
s = singlet, A t = Aromatic.
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b) CH2 of 3-CH2X type derivatives
Most of the cephalosporin derivatives are of this type which add an additional 4-line AB 
signal, causing further complexities to cephalosporin spectra. This signal falls between the 
6 -H, 7-H (4.9 - 6.0 ppm) and 2-CH2 (3.0 - 3.9 ppm) resonances, having chemical shift range
o
of 3.95 - 5.65 ppm (overlap may occur) and is further identified by separations ( J(////), 12.5 
-14.5 Hz) of magnitudes intermediate between those of the other two systems (Fig. 3.1, p.41, 
shows a typical example). In such cases care is needed to distinguish the three AB doublet 
pairs especially as part of the peaks might overlap each other, or be obscured by the HOD 
peak when D20  is used as solvent, or might partially overlap other signals, as in the case of 
moxalactam (Fig. 3.3 below) where the outer peak of the 3-CH2 S- signal overlaps that of the 
NMe. The position and coupling constant values of these doublets in D2 0 , can have a role in 
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Fig. 3.3 : Partial 270 MHz *H NMR spectrum (expansion) of moxalactam (di-ammonium 
salt in D2 0 ) illustrating the overlap of part of 3-CH2S signal with that of NMe. 
(Experimental conditions as in section 3.3.1)
Table 3 .8 :5  (ppm) and J (Hz) values of the various 3 -CH2 X signals of cephalosporins
X Example 5 range 2  J value (Hz)
-OH desacetylcephalothin 4.0 - 4.50 dd -13 .0
-OCOMe cefotaxime 4.70-5.15 dd 12.5 -13.5
-OCONH2 cefoxitin 4.60-4.90 dd 12-13
-SAr ceftriaxone 3.95-4.50 dd 13.5
-C 5 H 5 N + cefsulodin 5.30-5.65 dd 14.5
dd = double doublet, Ar = Aromatic.
From the Table above, the doublet pair signal due to 3-CH 2 ^ +C is lower field
(5.30 - 5.65 ppm) compared to the resonances of the other 3 -CH2 -X types, due to the greater 
deshielding effect of the positively charged nitrogen of the pyridyl ring; the doublets are 
further characterised by their relatively higher separations (2 J, 14.5 Hz). The AB doublet 
pair signal of the 3 -CH2 X is observed at a much lower field than that of 2 -CH2  because of 
the greater deshielding effect of the adjacent X group, in addition to the effect of the olefinic 
group (the A3 :4  double bond).
c) 3-X type derivatives
In these examples X is a group other than alkyl, e.g., chlorine as in cefaclor, or 
hydrogen as in ceftizoxime. Spectra are characterised by the absence of the 4-line AB signal, 
due to 3 -CH2 X, in the region 4.0 - 5.5 ppm, and in most cases the absence of signals above
3.0 ppm. Furthermore, ceftizoxime shows a double doublet (dd) near 6.27 ppm (Fig. 3.4 
below) with separations 6.3 and 2.0 Hz. These couplings are also apparent on the 2 -CH2 
signals (dd), [Table 3.1].
Fig.3.4 : Partial 1H NMR spectrum of 
ceftizoxime Na in D2  O showing the dd near J  
6.27 ppm due to C3 -H.
d) 3-CH=CH2 type
This is represented by cefixime (Fig. 3.5 below and Table 3.1, p.53). The compound is 
characterised by the signals due to the -CHa-=CHt,Hc group, resonating as double doublet 
centred at 6.73 ppm (11.2, 17.5 Hz) for Ha, doublet at 5.42 ppm (17.5 Hz) for Ht  and 





Fig. 3.5 : Partial XH NMR spectrum (at 270 MHz, in D2 0) of cefixime Na showing signals 
due to the -CHa=CHbHc group. (Experimental conditions as in section 3.3.1).
e) ArCH, ArCH2 type
The methine group attached to aromatic rings (ArCH-), such as in cephalexin, 
cephamandole and cefsulodin, or attached to a cyclohexadiene ring as in cephradine, shows a 
narrow one-proton singlet which is often situated in between the two p-lactam doublets 
(range 4.50 - 5.30 ppm). The position of the peak depends on the nature of the groups 
attached to the methine group, as was the case with cephamandole nafate [Table 3.1, p.54], 
where the methine peak appeared further downfield (6 .2 0  ppm) due to the greater deshielding 
effect of the (OCHO) group substituted on the methine group. Furthermore, the solvent used 
might affect the peak position, especially in compounds having a p-amino group substituted
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on the methine group, such as cephalexin; the observed chemical shift value (5.28 ppm) in 
D2O-TFA (Table 3.1) is much lower than that reported in the literature (4.59 ppm). This is 
because in our study the p-amino group was protonated in the presence of TFA (NH3+ has a 
greater deshielding influence than NH2 ); in the literature study , Na2 CC>3 was used to 
dissolve the sample thus the amino group was not ionised in alkaline solution.
The methylene protons of A1CH2 type, may either give rise to a shaip two-proton singlet 
in the range 3.80 - 5.60 ppm, depending on the nature of the aromatc ring, e.g. cefoxitin 
(3.94 ppm) and cephazolin (5.55 ppm) [Table 3.1], or show an AB doublet pair resonance 
ranging from 3.80 - 3.90 ppm (J ~ 16.0 Hz), such as in cephalothin and cephaloridine. This 
doublet pair signal is differentiated from the other AB systems by the smaller chemical shift 
separations (0.05-0.10 ppm, Fig. 3.1, p.41).
2. Signals to lower field of 6 ppm
a) Aromatic signals
Low field signals due to the aromatic protons occur in all spectra of the cephalosporins 
listed in Table 3.1 (pp.51-54), except that of cephradine which displays a vinylic resonance 
(5.77 ppm, s, 2-proton, and 6.18 ppm, s, 1-proton). Ceftizoxime and cefixime also have 
vinylic resonances (plus the aromatic signals). The multiplicity of these aromatic signals can 
be used for identity purposes. Hence, by examining the nature of the aromatic proton signal 
which usually falls between 7 and 8  ppm the approach for identifying these cephalosporins 
can be summarised below:
(i) Phenyl type, as for cephalexin, cefaclor, cephamandole and cefsuldin. At lower magnetic 
fields (60 and 100 MHz) they give rise to a sharp five-proton singlet in the region 7.35 - 7.45 
ppm, but at higher fields (270 and 400 MHz) they appeared as multiplets ranging from 7.35 
to 7.60 ppm, due to resolution of short and long couplings between the five-protons [Table 
3.1].
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(ii) p-HOC(,H 4 —R type, represented by cefadroxil, moxalactam and cefatrizine. They are 
identified by their characteristic AB doublet pair (2-proton intensity) resonances in the 
aromatic region of their spectra, centred at 6.85 - 6.90 ppm and 7.20 - 7.30 ppm (J=8.5 - 9.0 
Hz) [Table 3.1], with additional lines due to long range coupling. This pattern is typical of 
p-disubstituted benzene ring 10°. The coupling constant is characteristic of coupling 
between aromatic protons situated ortho to each other.
(iii) Thienyl type, e.g cephalothin, cephaloridine and cefoxitin. These show a two-proton 
doublet at 7.0 - 7.05 ppm and a one-proton triplet at 7.28 - 7.37 ppm, for the thiophene ring, 
with additional lines due to long range coupling. This pattern is typical of 2-substituted 
thienyls.
(iv) Furyl aromatic type, as in cefuroxime. The pattern observed [Table 3.1, p.53] is 
characteristic of 2,-monosubstituted furyl derivatives100. The signal at the lowest field is a 
one-proton apparent doublet centred at 7.68 ppm (J=1.8 Hz) which showed evidence of 
further long range splitting (as small inflexions on the doublet) as observed in the 400 MHz 
spectrum (Fig. 3.6, p.50). Upfield of this signal is a one-proton doublet centred at 6 .8 8  ppm 
with a larger separation (J=3.7 Hz) and at the highest field is a doublet of doublets ranging 
from 6.61 - 6.63 ppm (J=3.70 and 1.80 Hz). The signals were attributed to Cs'-H, C^-H and 
C3 '-H, respectively. The larger coupling constant (J=3.7 Hz) is most probably due to the 
ortho coupling between the C4 '- and C3 '- protons, whilst the smaller coupling (J=1.80 Hz) 
may be attributed to meta coupling between the C5 '- and C3 '-  protons91.
(v) Aromatic singlets type, cefotaxime, ceftriaxone and cephazolin are identified by the 
simplicity of the 6-10 ppm region of the 1H NMR spectra displaying a one-proton singlet at
6.97,7.00 and 9.30 ppm, respectively [Table 3.1].
(vi) Signals due to pyridyl protons : These are of great diagnostic value as they appear lower 
than 8.00 ppm, as additional low field resonances. Spectra of cephaloridine and cefsulodin
are distinguished by their thienyl and phenyl proton resonances, respectively; furthermore, 
they are identified by their additional lower field resonances (8 .0  - 1 0 .0  ppm) due to the 




7 .7  7 .6 7. 4  7 .J
' I 1 1 ' I  1 I ' 1 1 1 I 1
7.C  t . i  6 .3  6 . /
'"T
6 .6
Fig. 3.6: Expansion of 400 MHz NMR spectrum of cefuroxime Na in D2 O ( the region 
6.60 - 7.75 ppm) to illustrate the signals due to furyl ring protons. See text (p.49) for details. 
(Experimental conditions as in section 3.3.1).
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Fig. 3.7 : Expansion of 400 MHz H NMR spectra in D2 O of a) cephaloridine Na and b)
cefsulodin Na showing the aromatic region (7.0-9.0 ppm). See text p.49 for details. 
(Experimental conditions as in section 3.3.1).
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Tabic 3.1:1II NMR characteristics of some ccphalosprins (salts and free acids).
Compound and Solvcnla 2 -CII2  G-11,7-11
form O.F.
Ref.
Cephalexin (free acid) D2 O-TFA
/ ? - \  270 3.16,3.42 d 4.97,5.60 d
R= \ _ . / ~ ~ ch(nh3» (18.7) (4.4)
400 3.15,3.42 d 4.96,5.64 d
R ’= Me (18.6) (4.4)
DSS
Ccfadroxil (free acid) D2 O-TFA
' 270 3.04,3.34 d 4.86,5.53 d
R= (18.5) (4.4)
400 3.02,3.31 d 4.84,5.50 d
R'= Me ' (18.6) (4.6)
HOD
Ccphradinc hydrate D2 O
*'r—x2 ' 270 3.36,3.60 d 5.14,5.68 d
R=
R’= ci HOD
(4.4)r =4/( /  > - ch(n^  (18.7)
'5  6'
400 3.35,3.59 d 5.13,5.67 d
R’= Me (18.3) (4.4)
DSS
Cefaclor (free acid) D2 O-TFA
270 3.31,3.72 d 5.04,5.64 d
(17.7) (4.8)
R' c° V r i f ? (continued overleaf)o
:o;
A rofR  M iscellaneous Reference^)
7.51-7.57 m 3-Me 2.07 s 9 0 ,9 1
ArCH 5.28 s
7.51-7.55 m 3-Mc 2.07 s
ArCH 5.28 s
6.87,7.31 d 3-Me 1.94 s 90
(8.7) ArCH 5.10 s
6.84-6.86 in 3-Mc 1.92 s
7.27-7.29 in ArCH 5.08 s
3-Mc 2.15 s.R C ll 4.68 s 90,91
3’,4’-H5.77 s ,6 ’-H 6.18 s
2 ‘,5’-protons 2.69-2.95 m
3-Mc 2.14 s, RCH 4.67 s








Ccphaiolhin (liv e  neiil) D M SO -do  
R% '0 ^'S*'-08? 





R_ 0 - ch>
R ’= C H , - Nx\  / /
Cefoxilin Na
R= < Q U h,-
R ’ =  *CH2OCONH2 
7-O M e
Cefotaxime Na


































6-H 5.03 d (4.8)
















2’,3'-H 6.92-6.95 m ArCH2 3.77,3.84 d(14.5)
4'-H 7.20-7.22 m 3-CH2 4.81,5.07 d (13.2)
Nil 9.06 d (8.1)
2’,3,-H7.04 d 
4 ’-H 7.37 t
2’,3,-H 7.00 m 
4 ’-H 7.33 m
2’,3’-H 7.00 m 
4‘-H 7.32 m
2’,3'-H7.04m 
4 ’-H 7.36 m 
2',3'-H7.03 m 
4'-H 7.36 m




3-CH2 0  4.70,4.87 d(12.5)
OCOMe 2.06 s
ArCH2 3.83,3.89 d(15.7)
3-CH20  4.67,4.83 d (12.5)
ArCH2 3.81,3.86 d (15.9) 
3-CH2N 5.32,5.54 d (14.5) 
C5H3N+8.06,8.54 m 
8.95 d ((>)
ArCH2 3.94 s 
3-CH20  4.63,4.79 d(12.5) 
ArCH2 3.94 s 
3-CH20  4.63,4.79 d(12.7)
OCOMe 2.10 s.NOMe 4.00 s 
3-CH20  4.72,4.89 d (12.4) 
OCOMe 2.10 s, NOMc 4.00 s 






Ceftizoxime Na D 2 O
R= 4 0 0  2-Ha 3 .61 ,3 .66  dd 5 .15 ,5 .81  d
H ,N ^ S s /  NOCH, (2 .0 ,18 .4 ) (4.7)
K’= -H 2-11,, 3.41,3.46(1(1
(6 .3 ,18 .8)
HOD
Ceftriaxone Nu
R= T / ' T ' lH ,N ^Ss /  NOCH,




3 .44 ,3 .70  d 
(18.0)
5 .16 ,5 .75  d 
(4.7)








3.60 ,3 .73  d 
(17.4) 
3 .58 ,3 .70  d 
(17.3)
5 .24 ,5 .81  d 
(4.7)
5 .21 ,5 .79  d 
(4.6)
Ceftazidime Na
R= hh^ J T R ocCh3.
tO,N»
d 2o
400 3 .25 ,3 .69  d 
(18.0)
5.33 ,5 .91  d 
(4.9)
R -  c , - Q HOD
Ccfazolin Na 
R= n ; n,




3.43, 3.79 d 
(17.7)







3 .40 .3 .66  d 
(18.0)
3 .41 .3 .66  d 
(18.0)
5 .21 .5 .81  d 
(4.8)
5 .21 .5 .81  d 
(4.7)
R ’=  'CHjOCONH, DSS
ArH 6.97 s NOCH3 3.94 s 
C3 *116.26,6.28 dd 
(7 .0 ,6 .3 )
ArH 6.97 s




2 ’ 6.62m, 3 ’ 6 .8 8 d 
4 ’ .7.68 d
2 ’ 6.62 dd(l .8,3.7) 
3 ’ 6 .8 8  dd (0.6,3.7) 
4 ’ 7.68 dd (0.6,1.8)
NM e 3.58 s,N O C H 3 3.94 s 
3 -CII2 S 4 .0 2 ,4 .3 2  d (l3 .6 )
NOCH2 - 4.57 s, Hc 5.26 d (l 1.2)
Ub 5.43 d(17.5), Hfl 6.75 dd(l 1.2,17.5) 
NOCH2  4.54 s, Hc 5.23 d(11.4)
H6  5.41 d (17.7), Ha 6.72 dd(l 1.4,17.7)
NOC(M e) 2  1.519s, 1.512s 
3-CH2  5 .38 ,5 .63  dd(14.5) 
C5 II5 N+ 8,12m, 8 .6 I111, 9.0m
ArCH3 2.72 s, NC112  5.55 s 
3 -CH2 S 3 .9 6 ,4 .5 0  d(13.7)
NOM c 3.99 s
3-CH20  4.67,4.86 d(12.5)
N O M e4 .0 s





Ccfamandolc Li D 2 O
270 3 .33 ,3 .07  d 5 0 2 ,5 .3 0  d
R= H(> { C / <:h (17.0) (4.6)
N n 400 3 .34 ,3 .68  d 5 .03 .5 .57  d
R'" - s -<  iVa UV.H)
DSS ,
Ccfamandolc nafalc D^O
^  HC/ ^ u h r v . r i i  40U 3 .30 .3 .62  d 5 .01 ,5 .8  d
R'=as for ccf. Li DSS
Ccfsulodin N a , D ? 0
3> '
h0-O " i h'
(4.0)
R= 4 0 0  3 .02,3.51 d 5 .11 ,5 .67  d
I (18.0) ( 4  7 i5' S 0 2Na v
R ’=  CHr-*N \_ C 0 N H , H O D  
12' ll'
Ccfatrizine (in prop- D i O *
ylene glycol)
R= HO-ZfAcH- 400 3-18’3-61<1 5« .5.a3d




270 4 .37 ,4 .52  d 6 -H 5.1 Is
R =  w  c o o h  (17.3) 7-OM c 3.43
n-m 4 0 0  4 .36 ,4 .53  d 6 -H 5.07s,5.09s
R " cHj- s A 1^  <17-2) 7-OMe 3.40s, 3.49s
CH)
£ 1 - 0 - an a lo g u e) HOD
5 H -7.38-7.48 m 
5117.40-7.48 in
5117.37-7.53 m
3 ’lo 5 ’- 7.36-7.37m  
2 ‘, 6 ’- 7.55m
2 ’,6'-8.041  




a Solvent : D2 0 = Deuterium oxide, TFA= 'Hifluoroaceticacid, DMSO-d^ 55 Deulerated 
dimcthylsulfoxide. O.F,= Operating frequency in MHz; Ref.= Reference signals : HOD at 
4.80 ppm, DSS at 0 .00 ppm, and TMS at 0.00 ppm. b D2 0 -Na2  CO3
NM e 3.98 s. A rC H -5.24s 
3-CH2S 3.97,4.26 d(13.6) 
NM e 3.99s, ArCII 5.26s 
'J-ClIjS 3.98,4.27 d (l3 .7 )
MMc 3.97s, OCHO 8.28 d
3-CH2S 3.98,4.24 d
ArCH 5.26s (base), 6.17s (nafalc)
ArCH 5.15s, 3-CH2 5.30,5.55 d(14.5) 
Ar-9’,11’ 8.31 d(6.4)
Ar-8’,12’ 9.05 d(6.4)
3-CH2S 5 .30 ,5 .55  dd (14.5) 
ArCH 6.9s, ArH 8.53t 
CII3 (solvale) 1.44 d
NM e 3.97s, ArCH 4.50s 
3-CH2S 4 .0 1 ,4 .1 8  d (13.6) 
N M e 3.95s, 3.97s 
ArCH 4,43s, 4.47s 






3.4.2 Identification scheme for cephalosporins based upon JH NM R data
It is clear from the discussion in the previous section and from the spectral data of Table 3.1 
(pp.51-54) that each individual cephalosprin has its own specific *H NMR features. Hence, 
in this section, an analytical scheme, based upon 1H NMR information, is devised for the 
identification of cephalosporin analogues having an intact (3-lactam ring, in the single drug 
form rather than in a formulation.
Assuming we have one of the cephalosporins in Table 3.1 as an unknown then before 
recording the *H NMR spectrum, its solubility properties need to be established.
Step 1 : Solubility :
a) If the material is sufficiently soluble in deuterium oxide (D2 O) it is probably an alkali- 
metal salt.
b) If it is sparingly soluble in D2 O, but freely dissolves on acidification (add few drops of 
trifluoroacetic acid, TFA), a cephalosporin with an amino substituent is indicated.
c) If it is insoluble or sparingly soluble in D2 O and a dilute acid fails to promote 
dissolution, but a dilute alkali dissolves it, then it is probably a free acid.
d) If the substance is insoluble in D2 O, and a dilute acid or alkali fails to bring about 
dissolution, it must be an ester and will require CDG3 or DMSO-d6 f°r solubility.
Having recorded the 1H NMR spectrum of the sample in the appropriate solvent:
Step 2 : Presence of the common 1H NMR spectral features of A3 -cephalosporin.
Key points in the identification of cephalosporins from the *H NMR spectra are the 
presence of the following characteristic features common to all A3-cephalposporins :
(a) 6 -H, 7-H AB doublet pair resonance in D2 O in the range 4.75-5.20 ppm and 5.50-6.00
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ppm, respectively, with 3 J values of 4-6 Hz characteristic of cis protons in an intact lactam 
ring, and relatively large chemical shift separations (0.5-0.9 ppm). One exception, is the case 
of cefoxitin with a methoxy group replacing the proton at position-7; here the 6 -H resonates 
as a singlet at 5.10-5.12 ppm, confirmed by the presence of a sharp three-proton singlet at 
3.50 ppm (also in the case of moxalactam, see group 4 below).
(b) 2 -CH2  4-line AB signal in the region 3.0-3.9 ppm of separation 18 Hz, due to the non­
equivalent methylene protons of the dihydrothiazine ring (which is lower field in 
moxalactam).
Having identified features (a) and (b) for the presence of a cephalosporin, specific 
evidence of identification among this group may now be sought.
Step 3 : For the purpose of simplifying the identification, the cephalosporins are divided into 
4 groups, depending on similarity in chemical structure, and on the spectral features of 
substituents at C-3 and C-7 :
Group 1 : These are the amino derivative cephalosporins (detected by their solubility 
properties), e.g., cephalexin, cefadroxil, cephradine, cefaclor and cefatrizine. The first 3 
compounds are characterised by having a sharp three proton singlet in the range 1.90 - 2.15 
ppm assigned to the vinylic 3-methyl group; cefaclor may be distinguished by the absence of 
any signal upfield to 3 ppm; cefatrizine displays an additional AB doublet pair resonance 
(5.30,5.60 ppm, J= 14.5 Hz) due to the CH2 S at position 3 . Cephalexin and cefaclor spectra 
are quickly identified by their 5-proton aromatic singlet (broad at base) near 7.50 ppm. 
Cefadroxil displays its typical AB aromatic resonance (two doublets centred at 6.85 and 7.30 
ppm, J=9 Hz) as does cefatrizine. Cephradine’s spectrum shows diagnostic broad signals at 
5.80 and 6.20 ppm due to vinylic methylene of the cyclohexadiene grouping. The spectrum of 
cefatrizine may be distinguished by having additional peaks due to the solvate, propylene
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glycol {CH3 CHOHCH2 OH), with an intense broad singlet at 1.40 - 1.45 ppm due to the 
Me group and the further splitting of the peaks due to the aromatic protons in the region 8.0 -
9.0 ppm.
Group 2: These are the 7 -(2 ’-thienyl)acetamido-A3-cephalosporin analogues, e.g., 
cephalothin, cephaloridine and cefoxitin; their spectra are well distinguished by a one-proton 
triplet at 7.34 ppm and a two-proton doublet at 7.00 ppm from the thienyl ring. The Ar- 
methylene group gives rise to a two-proton singlet at 3.95 ppm for cefoxitin, and an AB 
doublet pair resonance centred at 3.88 ppm (J=16 Hz) for both cephalothin and 
cephaloridine. The latter is identified by its additional low field resonance (8 -10  ppm) due 
to the pyridyl protons, while the singlet 6 -H (5.12 ppm) and C7 -OMe (3.51 ppm) resonances 
of the cefoxitin spectrum are likewise diagnostic.
Group 3: Spectra of cefotaxime, ceftriaxone, ceftizoxime, cefixime and cephazolin are 
characterised by the simplicity of the 6 - 1 0  ppm region, displaying only a sharp one-proton 
aromatic singlet at 7.00, 6.97, 6.97, 7.02 and 9.30 ppm, respectively. Both cefotaxime and 
ceftriaxone display a sharp three-proton singlet at 4.00 ppm for the -OCH3 group; the former 
displays another Me signal at 2.10 ppm and a 3 -CH2 O AB doublet-pair resonance centred at
4.72 ppm, 4.90 ppm (J=12.5 Hz); The latter is distinguished by a CH2 S AB signal (4.02, 
4.32 ppm; J=13.6 Hz) and a shaip 3-proton singlet at 3.60 ppm, due to the N-Me group. 
Ceftizoxime is distinguished by the double doublet near 6.2 ppm, with separations 6.3 and
2.0 Hz due to the vinylic C3 -H signals , cefixime by the vinylic resonance at 5.24,5.42 and
6.73 ppm due to the 3 -CH=CH2 group.
Group 4: This group consists of the cephalosporins of Table 3.1 (pp.51-54) not mentioned in 
the previous groups. These are: cefuroxime, cephamandole, cefsulodin and the 1-O-analogue 
moxalactam. Their spectra are differentiated from those of the previous groups by aromatic
signal multiplicities to low field of 6 ppm. Cefuroxime displays a one-proton doublet at 7.68 
ppm (J=1.8 Hz), one-proton doublet at 6.88 ppm (J=3.7 Hz) and a one-proton double doublet 
centred at 6.62 ppm (J=1.8 and 3.7 Hz). The distinguishing feature of cefsulodin spectrum is 
a low field complex : a two-proton doublet at 9.05 ppm (J=6.5 Hz), a two-proton doublet at 
8.31 ppm (J=6.5 Hz) (due to pyridyl protons), a two-proton multiplet centred at 7.55 ppm 
and a three-proton multiplet centred at 7.36 ppm (due to phenyl protons). Cephamandole 
shows a broad five-proton multiplet in the range 7.38-7.48 ppm; moxalactam two 2-proton 
doublets centred at 6.85 and 7.23 ppm (J=8.5 Hz) (ArA2 B2  system). Both these features are 
also displayed by some of group 1 cephalosporins (amino derivatives). The solubility 
properties and other spectral features allow the differentiation of the two groups. Of these, 
cephamandole is identified by its additional AB doublet pair resonance (3.97, 4.27 ppm, 
J=13.6 Hz) due to the 3 -CH2 S group, while the 6-H singlet (5.10 ppm), the C7 -OMe singlet 
(3.43 ppm) and the relatively low field AB doublet pair (4.37 and 4.52 ppm, J=17.3 Hz) of 
the 2 -CH2  characteristic of the 1-oxo-analogues, resonances of the moxalactam spectrum are 
likewise diagnostic.
The above analytical scheme of identification may only yield initial evidence of structure 
and must be confirmed by a complete spectral analysis ensuring that all the other resonance 
features accord, both in position and intensity, with the proposed structure.
3.4.3 *11 NM R diagnostic features o f cephalosporonate esters
1 ^The H NMR spectra of A -cephalosporonate esters in deuterochloroform (CDCI3 ) and
deuterated dimethylsulfoxide (DMSO-dg) [Table 3.2, p.63] exhibit the same common
spectral features characteristic of cephalosporin analogues, i.e., the p-lactam ring protons and
the thiazinyl ring 2 -CH2  protons resonances. In cephalosporonate esters, the 6-H and 7-H
signals appeared as a single-proton doublet centred at 4.75 - 5.10 ppm and a single-proton
double doublet in the range 5.60 - 6.00 ppm, respectively. The 7-H dd signal is due to
coupling to 6-H (J=4-5 Hz) on one side and with the imino-proton (NH) on the other
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(J=8.2-9.3 Hz). Depending on the nature of the solvent, the NH doublet position varies, 
appearing at 6.10 - 6.40 ppm (J=9.0 Hz) in CDCI3 or at 9.12 ppm (J=3.24 Hz) in DMSO-fl?6 
[Table 3.2]. The 2 -CH2 signal shows the typical AB doublet pair in the range 3.10 - 3.70 
ppm (J=18-18.5 Hz) with only one exception, the 7-ADCA p-nitrobenzyl ester in D2 O-TFA 
where it appeared as a broad singlet at 3.34 ppm [Table 3.2]. From this Table the main *H 
NMR spectral features for the identification of the cephalosporonate esters are summarised as 
follows:
1. p-Nitrobenzyl esters, represented by the 7-amino and 7-(2-phenyl a:etamido) 3-methyl-4-p 
nitrobenzyl carboxylate A3 -cephem, and the esters of cephalothin an: desacetylcephalothin. 
The spectra of these esters are characterised by the following diagnose: features :
a) Low field A2 B2 doublet pair resonances, due to the aromatic protens of the p-nitrobenzyl 
group. The AB signal is clearly seen in the 7-ADCA ester spectrum in the range 7.26 - 8.25 
ppm (J=8.6-8.9 Hz); the position and coupling separation values depending on the solvent 
used [Table 3.2, p.63]. In spectra of the other esters the signal appeared close to, but resolved 
from, the other aromatic signals. The phenyl protons of the phemlacetamido derivatives 
show a five-proton multiplet in the range 7.20 - 7.40 ppm, while these of the p-nitrobenzyl 
group appeared further downfield as well resolved two 2-proton doubiets centred at 7.63 and 
8.22 ppm (J=8 .8  Hz) and separation 0.63 ppm (Fig. 3.8, p.61).
The 2’-thienylacetamido-esters give rise to two 2-proton doubles at 7.58 and 8.23 ppm 
(J=8 .8  Hz) for the p-nitrobenzyl group aromatic protons, and upfield : one-proton triplet and 
two-proton doublet at 7.00 and 7.28 ppm, respectively, for the thiophene ring. Generally, the 
aromatic protons resonance of the p-nitrobenzyl group are lower field than the other aromatic 
signals, due to the greater deshieding influence of the nitro group.
b) Methylene signal of the p-nitrobenzyl group (OCH2  A r): The ester of 7-ADCA shows a 
shaip two-proton singlet at 5.37 ppm (in DMSO-d6 ), a singlet overlapping the 7-H doublet at 
5.07 ppm (inD2 0 -TFA) and an AB doublet pair at 5.38 and 5.31 ppm (J=13.5 Hz) and a 
separation of 0.07 ppm(in CDCI3 ). The phenylacetamido derivative displays a two-proton 
doublet pair resonance at 5.26,5.36 ppm (J=13 Hz) in CDCI3 and a sharp two-proton singlet 
at 5.40 ppm (in DMSO-dg) for the methylene group. The cephalothin and 
desacetylcephalothin esters spectra (in CDCI3 ) exhibit the AB doublets resonance for the 
methylene protons of the p-nitrobenzyl group centred at 5.34 ppm 5.39 ppm (J=13.0 Hz), 
respectively. The former is distinguished by having very narrow chemical shift separation 
compared to that of desacetyl cephalothin (0 . 1 0  ppm).
2. Diphenylmethyl esters, represented by 7-phenoxyacetamido-3- methyl-4-diphenylmethyl 
carboxylate A3 -cephem. The main diagnostic features of its spectra (Fig. 3.9, p.61) are:
a) A complex aromatic signal in the range 6.90 - 7.50 ppm having a large integral (16 
protons); 15 from the three phenyl rings and 1H of the methine group (-CHPh2 ).
b) The relatively low field methine (CH) signal of the diphenyl methyl group, due to the 
combined deshielding effect of the two phenyl rings and the oxygen, obscured by the 
aromatic complex signal.
c) The methylene protons for the phenoxyacetamido-group of the ester give rise to a sharp 
two-proton singlet at 4.56 ppm (in CDCI3 ) and two-proton double doublet at 4.68 and 4.61 
ppm (J=13.5 Hz) in DMSO-d6, Table 3.2.
a^ )-C H 2CNHv ^
s. N .
NO
T 77 \ 75. C3 . J5v .
Fig 3.S : E xp an sion  o f  2 7 0  M H z 1H  N M R  spectrum  o f  7-phenylacetam ido-
3-m ethyl-4-p-n itrobenzylcarboxylate-A  -cephem  (C D C I3 ) sh ow in g  the aromatic region  
signals (7 .0  - 9 .0  p pm ).
(Experimental con d ition s as in section  3 .3 .1 )
O
Me
F ig 3.9 : E x p a n sio n  o f  2 70  M H z 1.H N M R  spectrum  o f  7-ph en oxyacetam id o-3- 
m ethyl-4-d ip h en ylm eth ylcarb oxylate-A 3 -ceph em  in C D C I3  t0  illustrate the aromatic region  
(6 .9  -7 -5  ppm ). S e e  tex t for details.
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3.4.4 1H NMR characterisation of various cephalosporin derivatives
Table 3.9 below summarises the common *H NMR spectral features (i.e. 2 -CH2 , 6 -H 












2 -CH2 3.00-3.90 d 3.0-3.90 d 3.10-3.70 d 3.45-3.95 d
(17-18 Hz) (17.5-19.0) (18.0-18.5) (18.0-19.0)
6 -H 4.85-5.35 d 4.84-5.15 d 4.95-5.10 d 5.20-5.30 d
(4.0-5.0) (4.0-5.0) (4.0-5.0) (4.0-5.0)
7-H 5.50-5.95 d 5.0-5.75 d 4.65-5.85,5.7- 5.90-6.0 dd
(4.0-5.0) (4.0-5.0) 5.9 dd(4-5, 8-9) (4-5, 8.0-8.5)
From the above Table slight differences were observed between the various 
cephalosporin derivatives. Furthermore, the esters and lactones can be differentiated by their 
specific *H NMR spectral features [Tables 3.2,3.3, respectively] as follows:
For esters
(1) The p-nitrobenzyl esters are characterised by the signal due to the methylene protons of 
the ester group. Depending on the solvent, it may appear as a two-proton singlet at 5.40ppm 
(in DMSO-dg), or as double doublet (in CDQ3 ) centred at 5.30 - 5.34 ppm with separation
13.0 Hz. In addition, the phenyl protons resonate as^pair of doublets centred at 7.57 - 7.64 
ppm and 8.20 - 8.24 ppm (separation 8 .8  Hz).
(2) The diphenylmethyl esters show very complicated aromatic resonance in the range 6.90 
- 7.60 ppm integrating for ten protons, in addition to the exceptionally lowfield singlet ( 
>6.90 ppm ) due to the methyl proton which is mostly obscured by the aromatic multiplet
For lactones
They are characterised by the two-proton singlet in the range 5.10 - 520 ppm due to 
the equivalent methylene protons of the lactone ring ( see Table 3.3 p.64, and Chapter 4 
section 4.4..4for full account).
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Tabic 3.2 : 1^1 NMR chemical shifts of cephalosporin esters
Copinound and 
manufacturer













3 .18 ,3 .50  d
(18.4)
6-1 I 5.09 d (4.8)
7-11 5.G6,5.69 dd 
(4.6,8.2)
6 -H 4.94 d (4.8)
7-115.78.5.81 dd 
(4 .8 ,9 .1 )
Ccphalothin-4-p-nitro- 
bcnzyl ester (Badt)
( lo n n u U v  p . 9 0  )
CDCL3  TMS 
270 0.00
3 .38 ,3 .57  d 
(18.5)
6 -II 4.98 d (4.9)
7-H 5 .85 ,5 .89  dd 
( 4 .V U )
Dcsacctylccphalolliin- 
4-p-nitrobcnzyl ester 
(Uniy o f Chicago) 
( f o r m u la  p . 3 0  )
4-p-Nilrobcnzyl ester 





3 .45 ,3 .66  d 
(18.0)
3.38, 3.62 dd 
(18.3)
6 -H 4.95 d (4.9)
7-H 5 .86 ,5 .89  dd 
(4 .9 ,9 .2 )











3.19, 3.45 d 
(18.7)
dd at 3.53
6 -II 5.00 d (4.8)
7-115.85,5 .88  dd 
(4 .8 ,9 .2 )
6 -II 5.15 d (4.6)
7-H dd 5.72
AromaLic protons M iscellaneous
I’hCI 12 7.25-7.31 m 
Ar-2’,6’ 7.69 d (8 .6 ) 
Ar-3’,5 ’ 8.24 d (8 .8 ) 
PhCH2 7.26-7.39 m 
Ar-2’,6’ 7.57 d (8 .8 ) 
Ar-3’,5 ’ 8.22 d (8 .8 )
Ar-2’,3’ 7.0  m (ihicnyl) 
Ar-4’ 7.28 m (thicnyl)
Av 7.11 7.57 d (K.KXrslev) 
Ar-2H 8.23 d (8 .8 )(cstcr)
Thicnyl 7.0 m, 7.28 m 
Ester 7.58 d (8 .8 )
8.23 d (8 .8 )
Ar-2’,6 ’ 7.69 d (8.9) 
A r-3',5’ 8.20 d (8.9)
Ar-(15H) 6.90-7.48 m
3-M e 2.06.S, ArCl l iCU  3.54df8.4; 
A»CH2 (csicr) 5.40s 
CONH 9.12 d (8.2)
3-M e 2.13s, ArCH2 CO dd 3.65 
ArCH2(cstcr) 5 .26,5.36d(13.2)
NH 6.12 d (9.2)
3 ’-M e2 .07  s A rC H 2 3.87 s 
3 -C / / 2  4.80, 5.14 d (13.6) 
AiCllyfcsUM) dd 5.34 
N il 6.32 d (9.1)
ArCH2 3.87 s, NH 6.39 d(9.0) 
3-CH 2  4 .0 3 ,4 .4 8  d (13.0) 
ArCH2 (cstcr) 5 .2 9 ,5.39d (13.0)
3-M e 2 .02 s, A 1C II2  5.37 s
3-M e 2 .12 s, PhOCH2  4 .56 s 
Ph2 CH obscured
Ar-(15H) 6.91-6.99 m 
7.27-7.54 m
3-M e 2.03 s, PhOCH2  dd 4.64  
NH 9.12 d (8.4), Ph2CH obscured
-6
3-






















4.67 d, 5.01 
and 535 de
A rofR Miscellaneous
3-Me 2.02 s 
3-Me 1.SS s
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b (for abbreviations see footnote under Table 3.1). 
c see text p. tfc for details.
6-H 4.89d (4.8)






531,5.94 d 7.14 s
(4.8)
6-H 5223d (5.1) 2*3’ 7.06-7.09 m
7-H 5.953.98 dd 4 ’ 7.48-7.50 m 
(5.1,8.4)
2 .8  =7-(2-phenylacetamido)desactoxy
3-Me 2.09 s 
Ar-CH2 238 dd 
7-NH 6.15d (8 .8) 
3-Me 1.91 s 
ArCH2 3343.72 d 
(14.6)
NOMe 4.08 s 
lactone CH-> 5.11s
ArCH2 3373.93 d 
(13.9) 
Lactone CH2 5.17 s 
7-NH 933d (8.4)
3.4.5 7-Amino desacetoxycephalosporanic acid (7-ADCA)
This compound is the precursor of many 3-methyl cephalosporins. It has a NMR 
spectrum [Table 3.3, p.64] that lacks signals below 5.1 ppm (as free acid in D^O-TFA), and 
may be identified from this unique feature. The usual 6 -H, 7-H 2nd 2 -CH2  AB doublet pairs 
are present. Spectrum showed the 6 -/ 7-H doublets centred at 4.9 and 5.06 ppm ( J=4.7 Hz), 
and those of 2 -CH2 at 3.3 and 3.4 ppm ( J=18.0 Hz), together with a three-proton singlet at 
2.02 ppm, due to the 3-Me group. On storage of the solution at room temperature for 10 
days, no change in the above spectral features was observed.
The sodium salt of 7-ADCA prepared from a mixture of the free acid and a small excess 
of NaHC0 3  in D2 O behaved anomalously. The doublet centred at 5.35 ppm, which is 
associated with 7-H, had only half the expected intensity while a second doublet with 
intensity corresponding to about half a proton was centred at 4.67 ppm. An apparent triplet 
was also present near 5 ppm made up of overlapping doublets. A single 4-line 2 -CH2 signal 
was present of greater AB chemical shift difference than found for 7-ADCA in D2 O/TFA, 
and a single Me resonance (1.88 ppm). Spectral appearance changed little on storage. These 
results may be interpreted in terms of the solution in D2 0 -NaHC0 3  being : a.) a mixture of 
the intact and P-lactam-opened product or a) a mixture of the two epimers of ring opened 
material in equilibrium. The absence of duplicate 2 -CH2 and 3-Me signals argues against 
either explanation. When the solution of 7-ADCA in D2 0 -NaHC0 3  was acidified with DC1 
its spectrum reverted to that of a single product with features : 7-H, 6 -H narrow doublets 
flanking HDO signal at 4.8 ppm, 2 -CH2  closely placed doublets centred near 3.15 ppm with 
inner lines of greater intensity than outer lines, 3-Me singlet -  1.8 ppm. This spectrum 
resembled that of 7-ADCA in D2 O-TFA prepared freshly, and also that of 7-ADCA in 
DMSO-d6 plus DC1 [Table 3.6]:
T a b l e  3 .6  : 1 H  N M R  c h a r a c t e r i s t i c s  o f  7 - A D C A  i n  D M S O - d g  a n d  a f t e r  a d d i t i o n  o f  D C 1
7-H, 6 -H 2-CH2 3-Me
7-ADCA in DMSO-d6 4.9Id (4.9 Hz) 3.56d (19.2) 1.97s
4.70d (4.9) 3.29d (18.3)
plus DC1 5.17d (4.9) 3.60d (17.4) 1.93 s
5.05d (4.9Hz) 3.50d (17.4Hz)
These results are evidence that the spectral appearance of 7-ADCA in D2 0 -NaHC0 3  is 
a result of the amino acid existing as a mixture/friono and di-ionized species at this pH which 









The same NMR phenomenon was observed in the case of 7-aminocephalosporanicacid 
(7-ACA) as solution in D2 0 -NaHC0 3  : doublet near 5.4 ppm, two overlapping doublets near
5.0 ppm, doublet near 4.7 ppm. .
3.4.6 13 C NMR features of cephalosporin salts, free acids and esters
1 0
C NMR is another NMR technique valuable for the characterisation of cephalosporin 
derivatives92,94’101-103. Its advantages over ^  NMR studies is the greater chemical shift 
range of 13C over 1H (JH : 0 - 10 ppm ,13C : 0 - 200 ppm) with the result that chances of 
resolving signals due to carbons in non-identical environments are high.
11During the course of study described in this section, many C NMR spectra of 
cephalosporin derivatives were recorded but comment is restricted to a few examples.
All the 13 C NMR spectra were run under proton decoupled conditions (see section 
3.3.1, p.38). The assignments of the 13C signals are based chiefly upon the expected 
chemical shift behaviour and on correlation with published data. One-bond and long-range 
coupling values to protons (obtained from coupled spectra) provide valuable evidence for 
carbonyl and other assignments, as will be discussed.
The following is an analytical scheme for interpreting the 13 C NMR spectra of the 
cephalosporin derivatives :
3.4.6.1 Common 13 C spectral features
1. The cephem ring carbons
The assignment of resonances for carbons directly bonded to hydrogen atoms (sp3 
type) were based on the DEPT technique (see section 3.3.1). The quaternary carbon 
frequences were identified by their absence in the 135* and 90* DEPT spectra:
(a) sp3 type : C-7 and C- 6  (CH positive from DEPT); C-2 (CH2 inverted from DEPT).
From previous studies on free acids and alkali metal salts in D2 O and esters in CDCI3 
and DMSO-df4,94,101-103, using the coupling magnitudes, and from the present
study, the chemical shift rank orders are compared below :
-6 7 -
Acids,salts range from previous range from present
and esters studies (in ppm) results (ppm)*
C-7 57.1 -64.2 57,0-61.4
C-6 55.5 - 63.4 54.4-58.0
C-2 24.3-31.6 23.0 - 30.3
(* All compounds of Tables 3.4, 3.5, and those in section 3.4.8, p.8 8  except for moxalactam).
The chemical shift values of the present study agree well with those reported. Values 
outside these ranges, which are seen in case of moxalactam (C-7 94.0 ppm, C- 6  82.2 ppm, 
C-2 64.8 ppm) are due to influence of the oxygen substituent. The 1 > values of C- 6  and
C-7 aid specific assignments. As C- 6  is flanked with the electronegative neighbours sulphur 
(in position-1) and nitrogen (position-4), it is expected to possess a larger1J value than those 
of C-7 and C-2, as reviewed by Hansen104. This is illustrated by the coupled spectra of 
cefixime ( 1 J(c//) C- 6  196 Hz, C-7 173 Hz) and ceftizoxime ( ^T(c//) C-6  near 176 Hz, C-7 
156 Hz) (Figs. 3.12, p.79, and 3.14, p .82, and Tables 3.10, p.80, and 3.11,p.8i, respectively). 
Many cephalosporin spectra display additional signals near 60 ppm, which can often be 
distinguished from the ring carbon resonance by their features in coupled spectra,e.g. 
NOCH3 of ceftizoxime 62.4 ppm (q, J= 145.4 Hz) and A1CHNH2 of cephalexin 59.3 ppm (d, 
J=157 Hz, no long range coupling).
(b) Sp2  type : These are the quaternary carbons attached to double bonds ( C-3 and C-4, 
C- 8  carbonyl) which give signals that are absent in the 135* and 90* DEPT spectra.
The discrimination of the C-3 and C-4 signals (in 13 C NMR) is a controversial 
problem103,105’106. Dipole-dipole relaxation time (T 1) measurements have been used to aid
assignments of C-3 and C-4 : if it is assumed that the molecule is reorienting in an isotropic 
fashion and that the relaxation mechanism is essentially dipolar, the relaxation time of a 
quaternary carbon is expected to decrease with an increasing number of [3-hydrogens109 (Fig. 
3.10 below):
la U3 \y■c—c — c-
I I I
H H
Fig.3.10 : Designation of protons in regard to carbon atom under consideration
Thus, C-3 in Fig. 3.10 has four P-protons and C-4 none; therefore, C-3 may be assigned 
upheld to the resonance of the less efficiently relaxed C-4, with the longer T i value. Neuss et 
ai.105,106 0 0 ^ 1 ^ 3  4  resonates at lower held than C-3 but cnly on the basis of
chemical shifts of model compounds. It was also observed that, in most cases, in 13 C NMR 
spectra of cephalosporin salts, the C-3 resonance is more intense than the lower held 
resonance of C-41C8,109, which is a very useful fact for distinguishing between these two
1 /VI
signals. Some argue that C-3 is more shielded than C-4, so is the higher f.eld signal . Tori 
et al. 101 reported that for esters comparison of the C-3 and C-4 signal intensities (in CDCI3 ), 
showed that the signal at the lower held was more intense than that of the higher held. When 
T 1 values were measured, the lower-held signal had the shorter T 1 value, and hence was 
assigned to C-3.
From present results, in spectra of cephalosporins with ionised 4-carboxylate functions 
[Table 3.4, p.74], ranges for C-3 and C-4 signals are 117.3-123.3 ppm (111.8 ppm for 
cefsulodin) and 127.0-131.4 ppm, respectively. The relative carbon assignments to both of 
these regions is confirmed by their proton-coupled spectra. Furthermore, the higher held
range is assigned to C-3 and the lower to C-4 (in case of salts) on the basis of a few T j 
measurements (e.g., ceftriaxone Na: 1.41 s for the 118.9 ppm signal, 3.48 s for the 130.2 ppm 
signal).
Our investigations on esters ( section 3.4.8, p. 88 ) show that C-3 becomes the lower field 
resonance, a conclusion supported by the multiplicities of C-3 and C-4 in proton-coupled 
spectra (e.g. 4-p-nitrobenzyl ester of cephalothin, Fig.3.18, p. 91: C-4 125.0 ppm, broad 
singlet, C-3 127.0 ppm, multiplet) and signal intensities. The fact that the C-3 resonance is 
more deshielded than C-4 is possibly due to contributions from the resonance foimJB, of 
structure below which is unfavoured in the salt:
2. T he carbonyl carbons
These are the 4 -CO2 X, 7-amido, and lactam ring (C-8) carbonyl carbons which are 
common to all cephalosprin derivatives.
Discrimination of the carbonyl carbon of the lactam ring (C-8) from the other carbonyl 
atom signals in cephalosporin spectra was also a problem. This is due in part to the difficulty 
of detecting the peaks at natural carbon-13 abundance, owing to their very low intensity and 
also to their proximity to each other in the carbonyl region of spectrum, i.e., 160-177 ppm. 
Other techniques were employed by some workers to assign these signals, such as single 
frequency selective heteronuclear decoupling (s.f.s.d.)110, off-resonance proton 
decoupling103 and T  j measurements101. Hence, C-8 was differentiated by considering the
fine structure in the proton— coupled spectra, and from the signal intensities (and their T \ 
values). C- 8  has one p and one y  proton, appearing as a triplet with long-range coupling ( J ~ 
6  Hz)105, C-10 (of CO2 X) has none, and splitting of the CONH line is mainly determined by
103the coupling with adjacent protons; furthermore, the CONH carbon was reported to have 
the shortest T  \ and be the most deshielded, C- 8  the less deshielded while CO2 X resonates 
between the two101,103.
Results from the study of the various cephalosporin derivatives, i.e., salts, acids, and 
esters (Tables 3.4, 3.5, and sections 3.4.7, 3.4.8 respectively) confirm that the lactam (C-8 ),
4-carboxylate and 7-amido carbonyl resonances fall in a chemical range of 160.0-170.0 ppm. 
The data in the following Table summarises the range for each, compared to those appeared 
in literature:
Literature data (ppm) 101 present results (ppm)
salts acids esters salts acids esters
7-amido 168-175 ' 165-170 169-174 164-176 169-170 168-171
4-C02R 164-171 163-171 162-163 164-169 164-166 161-162
8 -lactam CO 163-170 161-168 164-169 161-164 161-166 164-165
The carbonyl carbon resonances are easily identified from coupled spectra, supported 
by a few T 1 measurements. In all coupled spectra the lactam carbonyl signal (C-8 ) resonates 
as a narrow triplet due to coupling to C-7 and C- 6  protons. The 4-carboxylate carbonyl 
resonates as a broad singlet near 169 ppm for alkali metal salts in D2 O (ionised, deshielded), 
165 ppm for free acids (non-ionised carboxylate function), and 162 ppm for esters (due to 
resonance form B shown above). These variations in chemical shifts of the 4 -CO2 X carbon
- 7 1 -
resonance reflects the greater deshielding influence of COCT over that of CO2 H or 
CO2 R113, the 4-C=0 chemical shift of the salt being lower field than that of free acids and 
esters (as is illustrated by the struaires below ) :
deshielded









It is observed, in most cases, that the 7-amido C=0 resonates as the lowest field signal 
(in the range 170- 175 ppm) and forms a multiplet in coupled spectra.
Generally, in salts and acids, the 7-CONH resonates as the lowest field signal, the 
lactam C=0 the highest while 4 -CO2 X resonates between the two. In cases of esters : amido 
the lowest, 4 -CO2 R the highest and lactam resonating between the two.
3A.6.2 Specific13 C spectral features
1. Signals to higher field of 100 ppm
a) 3-Me type (identified by DEPT), e.g. cephalexin, shows a signal near 20 ppm appearing 
as a quartet in the coupled spectrum [l J(c//)~ 130 Hz].
b) 3-CH2X, another sp3 carbon (CH2, DEPT), which is differentiated from 2-CH2 signal by 
its lower field position (e.g., cefsulodin displays a 3 -CH2 resonance near 62.0 ppm).
c) Me signal, in 3-CH20C0Me, appearing near 21.0 ppm.
d) 7-OMe type, resonating near 53.0 ppm (moxalactam).
e) NOMe type, compared to other Me signals, resonates as the lowest field (e.g., ceftizoxime 
shows an NOMe resonance at 62.4 ppm, ceftriaxone 62.5 ppm).
Signals due to features of substituents at C-3 and C-7 complicate the spectrum.
2. Signals to lower field of 100 ppm
a) Aromatic signals : Low field signals due to the aromatic carbons occur in all spectra of 
the cephalosporins listed in Tables 3.4 and 3.5 (except 7-ADCA), and those in sections 3.4.7 
and 3.4.8, which provide diagnostic 13C signals. According to the nature of the aromatic 
carbon signals the type of ring can be identified as briefly summarised below :
i) The phenyl or thienyl type (as in cephalothin, cefsulodin and cephalexin), the sp2  carbons 
give rise to signals in the region 125.0 - 130.0 ppm and quaternary carbons 131.0 - 140.0 
ppm (except for the phenoxy type which display a Cq signal at 155.0 - 158.0 ppm).
ii) Ceftizoxime, cefixime and ceftriaxone [Table 3.4] have only one CH sp2  carbon in their 
thiazole ring which resonates near 113.0 ppm and the quaternary carbons in the range 140.0 -
148.0 ppm.
iii) Esters : the p-nitrobenzyl type shows resonances between 127.0 - 129.5 ppm for the CH 
sp2  carbons and 141.0 - 143.0 ppm and 147.0 - 148.0 ppm for the quaternary carbons. The 
diphenylmethyl type displays very complicated signals in the region 126.0-129.5 ppm (for 
the CH sp2  carbons) and near 139.4 ppm (for the Cq).
b) Other features, e.g., the less known heterocyclic systems (such as in cephamandole and 
ceftriaxone, Table 3.4) which required reference data to assign their carbon signals.
Tabic 3.4 ’. 13C NMR. cbaraclcrislics of some cephalosporin antibiotics0.
(F o rm u la e  in  T a b le  3 .1 ,  p .4 1 )
Compound Solvcni Ring Carbons
Reference C-2 C-3 C-4 C-6  C-7
Cephalexin D2 0-TFA 30.3 137.9 122.1 58.0 57.1
HOP (143) (IK?) (147)
Ccfmlroxil CD3 OO-TFA 30.9 135.5 124.4 60 .161.3
TMS (146) ( IKU) (15/)
Cefaclor CD3 OD-TFA 31.6 133.5 126.4 58.5 60.1
TMS (149) (180) (157)
Cephalothin Na D20  26.0 116.8 132.3 57.9 59.7
HOD (143) (181) (157)
Cefoxitin Na D20
non









165.9 ( f ’O .I I )
165.3 (lacuint)
C -r  132.3 3-Me 19.9 
C-7' In 111,1,130.3. 




165.K (C 02 11) 
165.4 (lactam)
c - r  123.6 
C-2‘,6' 131.1 






163.8 (C 02 H)
C -r 133.5 




168.5 (C 02 Nn)
165.1 (lactam) C-4’ 126.0(190)
C-r 136.3 
C-2'.C-3’ 127.8 
C-8 ‘(Mc) 20.8(131) 
C-5’ 36.7(133)






W .C O ’ I2K.0.I27.K 
(171)
C-4’ 126.2(189)
C - y  36.7(132)




Cefuroxiine Na D 2 0
HOD
26.0 117.4 131.9 57.7 59.4 




D2 0  26.3 116.9 132.3 57.8 59.3
HOD (145) (179) (158)
D2 0  27.1 118.6 131.6 57.9 59.2
HOD (143) (179) (157)
D2 0  27.3 120.3 133.6 57.8 59.7
HOD (144) (179) (157)
168.5 (C 0 2 Na) 
164.1 (amido) 
163.9 (laciam)
168.4 (C 0 2 Na)
164.8 (amido)
164.3 (laciam) C-3’ 171.0
175.8 (amido) 
168.0 (C 0 2 Na) 
164.7 (laciam)








C -r 141.2 
C-2’ 113.3(195)




C -2’ lo 127.6 
C-6 ’ 129.5 
C-7’ 74.3(150)
C -r  147.0(225)
C -2’ 50.1
C -7’ 64.8(154) 
C-8 ’ 159.4 
146.6(214)






C -4’ 168.9 




Tabic 3.5 : *3C NMR failures of some cephalosporin related compounds0




C-2 C-3 C-4 C-6 C-?
Carbonyls
7-ADCA D2 O-TFA 
HOD
29.9 117.9 142.3 54.4 57.5
' D20-NaIJC03 27.7 121.6 126.3 57.5 61.3
HOD 28.0 58.0 61.4









2.8 p 20  28.4 122.2 127.0 56.9 58.8
OSS O.OOppm
175.5 (amido) 
164.3 (C 0 2Nu) 
161.0 (laciam)





a For abbreviation see footnotes under Table 3.4; 
b 7-phenylacctamido-3-meihyl- A3 -cephalosporin; 
c 7-phenylacetamido-3-methyl- A3-cephalosporin.
R features R ’ features
(C-7 substituent) (C-3 substituent)
3-Me 19.0
3-Me 18.2
ArCH2 35.9 lactoneCH2 71.5
C-6’ to 125.2.126.5 
C-8’ 126.8 
C-5' 136.9
ArCH2 42.0 3-Mc 18.5
C-4* 127.5
C-2’,6 ’ 129.3
C -3 \5’ 129.0
C , - l ’ 134.7
ArCH2 43.2 3-Me 22.3
C-2’ to 130.3,
C-6’ 129.5,128.0 
C ,- r  136.4
-7
6-
A few detailed assignments of 13 C spectra of some cephalosporin salts and esters
follow. Examples have been selected in . most cases from cephalosporins of recent 
introduction (e.g. cefixime ceftizoxime, ceftriaxone and cefsulodin). Coupled spectra were 
used for:
1) specific assignment of C- 6  and C-7.
2) assignment of quaternary carbon (Cq) signals.
Relaxation time (T j)  measurements were used in a few examples to aid assignments of C-3 
and C-4 and the carbonyl carbons.
3.4.7 Detailed 13 C assignments of some cephalosporin salts
1. Cefixime Na
Assignments of 13 C signals was facilitated by published data on the close analogue, 
cefotaxime***:





^ 3 X H 2OCOCH3
0 2"Na+
Cefixime Na cefotaxime Na
The proton decoupled 13 C NMR spectrum of cefixime in D2 O (solubilised with NaHCC^) 
(Fig. 3.11) displayed the 12 low field (>100 ppm) and 4 high field signals required by the 
structure shown above. All signals could be assigned by reference to a coupled spectrum
(Fig. 3.12, p.79) and data for cefotaxim e [Table 3.10, p.80J.
n-MAR-39 08:29:2:
EXKOD 5GBCM
OB NiJC I X
OBFRO 67.EC MHz
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Fig. 3.11: Proton noise-decoupled 13 C NMR spectrum (at 67.i MHz) of cefixime Na in 
D2 O. (Experimental conditions as in section 3.3.1).






The data on cefotaxime are likewise of value for assignments of 13 C signals of
ceftizoxime. The 13 carbon signals were well displayed in the proton decoupled spectrum
(Fig. 3.13, p.82), 4 highfield of 100 ppm (due to NOCH3 , C-7, C-5 and 2 -CH2 ) and the rest 
lowfield. The ceftizoxime decoupled spectrum was also characterised by the low field signal 
of C3 -H (at 117.3 ppm) which is differentiated from the thienyl CH signal (at 113.1 ppm) 
from appearance of signals in coupled spectrum (Fig. 3.14, p.82); the former showed a
-7 8 -
Fig.3.12 : Expansion of the 13 C-1!! NMR spectrum of cefixime Na in D2 O showing :
a) the high field ( < 1 0 0  ppm) and b) low field ( > 1 0 0  ppm) signal multiplicities.
See Table 3.10 for details.
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177.0 nt 0C H 2 C 0 2H M e C 0 2H  177.2(Stothers)111
170.6 nd C-3’ C-3’171.0 (cefotaxime) 84
169.1 s 4-C02Na 4-C02Na 168.4 (cefotaxime) 84
164.4 nd 7-CONH 7-CONH 164.8 (cefotaxime) 84
163.4 nt lactam C=0 lactam 164.3 (cefotaxime) 84
148.1 s C-4’of 7- 
substituent
C-4’ 148.4 (cefotaxime) 84
140.2 nd C -l’ of 7- 
substituent
C -l’ 141.2 (cefotaxime) 84
132.0 Sd CH of 3- CH of 133.1 (Stothers) 111
(155 Hz) vinyl 2 -propene
129.8 brs C-4 of cep­
hem nucleus
118.5 brm C-3 of cep­
hem nucleus
115.1 t CH2  of 3- CH2  of 115.0(Stothers)111





C-2’ 113.3 (195) (cefotaxime) 84
72.7 S t(159) 0CH2 C02H
58.6 Sd (173) C-7






(N.B. signal at 160.0 ppm of coupled spectrum is an artifact).
* Chemical shifts to nearest 0.1 ppm, Jch values (Hz) in parenthesis. S=sharp, bi^=broad, 
d=doublet, t=triplet, m=multiplet, n=narrow, s=singlet; a cefixime signals (ppm), 
b (from coupled spectra).
doublet of narrow triplets due to one bond coupling to hydogen (3-CH) and long range 
coupling to 2 -CH2 , while the latter appeared as sharp doublet [^(c#) 191.7 Hz]. The 
complete 13 C signal assignments for ceftizoxime Na are listed in Table 5.11 (p.81).
Table 3.11 : Complete 13 C signal assignments for ceftizoxime Na (D2 O). (Formula p.78)
Chemical*1 Signal Assignment Reference
shift appearance
170.6 nd C-3’ of Thiazole ring C-3’ 171.0 (cefotaxime84)
168.3 nd A-CO^Na 4 -C(9 2 ^  168.4 (cefotaxime84)
164.6 nd 7-amido C=0 7-amido 164.S (cefotaxime84)
164.0 nt lactam C=0
OA
lactam 164.3 (cefotaxime )
147.8 brs Cq-4’ of 7- 
substituent
Cq-4’ 148.4 (cefotaxime84)
140.1 nd Cq-1’ of 7- 
substituent
Cq-1’ 141.2 (cefotaxime84)
131.2 brm C-4 of cephem 
nucleus
C-4 132.3 (cefotaxime84)
117.3 d ofnt C-3 of cephem 
nucleus
C-3 116.9 (cefotaxime84)
113.1 Sd C-2’ of Thiazole C-2’ 113.3 (cefotaxime84)
(191.7) ring (195)
62.4 q (146.1) OCH  3 (C-5’) OCH3 63.2 (147) (cefotaxime84)
56.3 brd (176.3) C- 6  of cephem 
nucleus
C- 6  57.8(179)(cefotaxime84)
23.6 to f  bim 2 -CH 2 of cephem 2 -CH 2  26.3
(143.2) nucleus (145) (cefotaxime84)
(for the abbreviations see footnotes under cefixime) 
a ceftizoxime signals (ppm)
13-N0/-88 00:52:05 
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Fig. 3.13 : The 67.8 13C NMR proton noise decoupled (normal and DEPT) spectra of 






























Fig. 3.14 : 13C-1H NMR coupled spectrum of ceftizoxime Na in D2 O. Insert: Expanded 
signals spectrum showing multiplicities due to C3 -H (at 117.3 ppm, narrow triplets) and 
thienyl CH (at 113 ppm as sharp doublet).
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3. Ceftriaxone sodium (in D20 )




The heterocyclic ring of the 3-substituent of ceftriaxone presents a problem for 
assigning carbons lowfield to 150 ppm; no reference data could be found to assign its carbon 
signals, and this task was achieved by considerations of carbon environments (expected 
chemical shifts behaviour). Other assignments were facilitated by the published cefotaxime 
data84, a coupled spectrum (Fig. 3.15, p.83) and 3"i measurements (Fig. 3.16, p.84). Table 
3.12 (p.85) lists the complete 13 C signal assignments for ceftriaxone Na. From the Table 
C-9’ is the most deshielded compared to the other carbons of the triazine ring (resonating at
164.1 ppm as singlet); it is the less efficiently relaxed of these ring carbons101, with the 
longer T j value (5.42 s). C-7’ has more y-hydrcgens and resonates at higher field (156.3 
ppm as a broad multiplet) with the shortest T j value (2.74 s). C-10’ (the triazine ring 
carbonyl carbon) resonates between the two (at 1:0.4 ppm as singlet). C-3 and C-4 were 
assigned on basis of their multiplicities in the coupled spectrum and their T \  values, C-3 
(having 4 (3-protons) more efficiently relaxed (T j=:.41 s) than C-4 (T  j=3.48 s).
130 in
50 30
> 100 ppm < 100 ppm
i
i s o I C O
Fig. 3.15 : The 67.8 MHz 13C NMR coupled specra, normal and expanded (inset) of 
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I N T E R C E P T
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L A S T Y
11
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J . 40M 49  i« c  
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Fig 3.16 : a) Partial spin-lattice relaxation (T \)  13C NMR spectrum of ceftriaxone Na in 
D2 O showing C-3 (*) and C-4 (0) signals, and b) linear regression plots for the calculation of 
C-3 and C-4 Tj values (in sec). v
(Experimental conditions as in section 3 .3 .1).
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170.4 nd C-3’ ofthiazole ring C-3’ 171.0 (cefotaxime84)
168.1 s 4-C(92Ato 4 -C0 2 M2 168.4 (cefc:axime84)
164.4 nd 7-amido C=0 (C-9) 7-amido 164.8 (cefotaxime )
164.1 s (T !=5.4s) C-9’ of triazine ring
163.4 nt lactam C=0 (C-8 )
160.4 s (T !=3.38s) triazine ring C=0 (C-10’)
156.3 brs (T ! =2.74s) C-7’ of triazine ring
147.8 s C-4’ of 7-substituent C-4’ 148.4 (cefotaxime'4)
140.3 nd C -l’ of 7-sustituent C -l’ 141.2 (cefotaxime54)
130.2 brs (T !=3.48s) C-4 of cephem nucleus
118.9 nt(r!=1.41s) C-3 of cephem nucleus
112.9 d C-2’ of thiazole ring C-2’ 113.3 (cefotaxime14)
62.5 q OCH 3 (C-5’) OCH 3 63.2 (cefotaxime84)
58.5 d C-7 of cephem C-7 59.3 (cefotaxime8"
(V i 53) nucleus
57.1 d C- 6  of cephem C- 6  57.8 (cefotaxime8-.
(^=175) nucleus
42.5 q NMe (C-8 ’)
33.6 t 3-CH2S
26.4 t 2 -CH 2  of cephem 2-CH 2  26.3(cefotaximel4)
nucleus
For the abbreviations see footnotes under cefixime. 
a ceftriaxone signals (ppm).




CH—C O N H \_____
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Assignments of C signals was facilitated by some reference data of related compounds, 
cephaloridine84 and benzamide111, in addition to a coupled spectrum (Fig. 3.17 below). Data 
are given in Table 3.13 (p.87).
. E F S U L C D I N . ( C o u p l e d )







Fig. 3.17 : The 67.8 MHz 13C NMR coupled spectra, normal and expanded (insert) of 
cefsulodin Na in D2 0. (Experimental conditions as in secdon 3.3.1).






168.6 nd C O N H 2 of 3-subs­ PhCONH2 168.2 (benzamide111)
tituent (C-l 4)
166.8 Ss 4-C02Na
166.4 brs 7-amido C=0 (C-9)
164.2 nt lactam C=0 (C-8 )
148.6 nt Cq-11 of pyridyl ring
145.2 brd C-9’, 13 of pyridyl C-7 M l 145.2 (cephaloridine84)
ring
135.2 nm C-4 of cephem C-4 138.0 (cephaloridine84)
ring
131.4 nm Cq-1 * of phenyl nucleus
129.2 d of nm C-10’,12 of pyridyl C-8 ’, 128.5 (cephaloridine84)
ring 1 0 ’
128.7 d of nm C-2’ to
128.4 d of nm C-6 ’ of phenyl ring
126.2 d of nm
1 1 1 .8 nm C-3 of cephem ring C-3 1 10.0 (cephaloridine84)
69.6 Sd C-7’ of 7-substituent
61.8 t 3-C H 2S 3-C H 2S  62.4 (cephaloridine84)
59.4 S d ^ 1 5 5 ) C-7 of cephem C-7 59.8 (cephaloridine84)
nucleus
57.2 d (each line C- 6  of cephem C- 6  57.6 (cephaloridine84)
nd)(J;176j nucleus
24.8 t of nm 2-CH 2  of cephem 2-CH2 24.6 (cephaloridine84)
a cefsulodin signals (ppm); for other abbreviations see footnotes under cefixime.
3.4.8 Detailed 13C assignments of cephalosporin esters
Interest
10
1) overall assignment of C signals.
2) assignment of relative chemical shifts of C-3 and C-4.
As already mentioned under common carbon-13 spectral features of cephalosporins 
(p.67), literature observations and present results showed that for the alkali metal salts of 
cephalosporins C-3 resonates at higher field than C-4 (e.g., cephalothin Na : C-3 at 118.8 
ppm, C-4 133.9 ppm103, the former having the shorter T j (1.79 s) compared to 5.13 s of 
C-4); cephamandole lithium (present results) : C-3 118.6 ppm (T  j 2.8 s), C-4 131.6 ppm 
(6.0 s). In addition to our investigations on esters (this section), there is evidence from pH 
studies of cephaloridine101 that C-3 becomes the lower field resonance when the 4 -CO2 H 
group is non-ionised (low pH). T  j data for cephalexin (free acid) are in support: T \ =2.54 s 
for 135.4 ppm resonance (C-3) and 4.36 s for that at 121.7 ppm (C-4).




A3-cephalosporin ester 3^ (in DIVISOR)
expected chemical shift behaviour, DEPT technique (for those directly attached to hydrogen 
atoms) and on the separation values of a coupled spectrum. Furthermore, the correlation with 
published data of some references (such as benzylpenicillin, cephalexin, and 4-nitrotoluene) 
provided valuable aids to assignments . From the Table the signal at 132.6 ppm showed a
0  • ^  9 '— '
15 H
Assignments of 13 C signals of 3^ 4 [Table 3.14, p.89] were based chiefly upon the
narrow quartet and was more intense than that at 121.2 ppm, so is assigned to C-3. The signal 
at 57.2 ppm appeared as a broad doublet in coupled spectrum with the larger separation 
t1 J(C//) 174.1 Hz] compared to that at 58.9 ppm which appeared as a sharp doublet and 
smaller separation t1 J(c//> 151.6 Hz], Therefore the former signal is assigned to C-6 and the 
latter to C-7. It is also noted that 4 -CO2 R resonates to higher field (161.6 ppm) than in 
ionised compounds (>164.0 ppm).
Table 3.14a : 13 C NMR characteristics of 7-phenylacetamido-4— p-nitro- 
benzyldesacetoxycephalosporanoate ester 3.4 (in DMSO-dg). (Formula p.8 8 )
Chemical signal assignment Reference
shift appearance
170.9 brs (+fine 7-amido C=0 7-amido 169.8 (cephalexin84)
structure)
la:tam 165.3 (cephalexin84)164.8 nt lactam C=0
161.6 brs 4-C02R
147.1 nt Cq-13 of ester group C-3 146.2 (4-nitrotoluene)
143.2 nm Cq-lO’of ester group
135.7 nm Cq-1 ’ of 7-substituent Cq-1’ 134.8 (penicillin G)
132.6 nm Cq-3 of cephem nucleus
128.9 d of nm C-11,15 of ester group C-l.C-5 130.0 (4-nitrotoluene)
128.6 d of nm C-2’,6’ of 7-substit. C-2’,6’ 129.8 (penicillin G)
128.1 d of nm C-3’,5’ of 7-substit. C-3’,5’ 129.3 (penicillin G)
126.4 d of nm C-4’ of 7-substit. C-4’ 127.7 (penicillin G)
123.4 d of nm C-l2,14 of ester group C-2,4 123.5 (4-nitrotoluene)
121.2 nm Cq-4 of cephem nucleus
CH2 60.1(Stothersu l )65.3 t (151.5Hz) CH 2  of ester group
58.9 sd (151.6) C-7 of cephem nucleus
57.2 brd (174.1) C-6 of cephem nucleus
41.5 t (131.0) ArCH2 of 7-substit. ArCH2 42.5 (133) (penicillin G)
29.1 tofnm 2-CH2 of cephem nucleus
3-Me 19.9 (cephalexin84)19.5 brq 3 -CH3
a For abbreviations see footnotes under Table 3.10; 
7-substit.=7-(PhCH2 CONH)
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2. Cephalothin-4-p-nitrobenzyl ester 3^ 5 (in CDCI3 )
4
■NO
With reference to cephalothin Na (in D2 O) data and a coupled spectrum (Fig. 3.18, 
p.91), the assignments of the 13 C signals of 3.5 are shown in Table 3.15 (p.92).
It is noteworthy that the overlap arms of C-H signals in the aromatic region of the 
coupled spectrum (Fig. 3.18) presents a problem in the specific assignment of the aromatic 
carbons. The C-6  (57.3 ppm, 174 Hz) resonance is assigned to higher field of C-7 (59.3 ppm, 
154 Hz) on basis of their1 J(c//) values. The C-3 signal was differentiated from C-4 from the 
intensities of their signals and multiplicities in coupled spectrum (in this case the C-3/ C-4 
chemical shift difference was unusually small).
3.4.8.2 Diphenylacetate type
The example studied was the 7-phenoxyacetamido-3-methyl-4-diphenylacetate- 
A -cephalosporin ester 3.6 :
o c h 2c o n h n
2o'
Due to the structural complexity of compound 3.6 (containing 29 carbons) several
7pm w^/V'/v Va
53
t t  c* c .  c r
62 58 56
148 130 126134
Fig. 3.18 : Expansions of the 67.8 MHz 13 C NMR coupled spectrum of JL5 (in CDQ3 ) 
showing a) the high field (<100 ppm) and b) low field signal multiplicities. See Table 
3.14 for details.







170.4 nm OCOMe OCOMe 1742 (cephalothin Na),
169.9 nt 7-amido C=0
164.8 nt lactam C=0 lactam 165.1 (cephalothin Na)
160.9 brs 4-C02R
148.0 nm Cq-13 ofe.gr. Cq-3 146.2 (--nitro toluene)
141.8 nm Cq-10’ ofe.gr.
134.6 nm Cq-1’ oft.r. Cq-1  136.3 (cephalothin Na)
129.1 d of nm C-l 1,15 ofe.gr. C-l,5 130.0 (4-nitrotoluene)
127.9 d of nm C-2’,3’ of C-2,3 127.8 (cephalothin Na)
127.6 d of nm thienyl ring
127.0 brm Cq-3 of c.n.
126.1 d ofnm C-4 ’ of t.r. C-4 126.0 (cephalothin Na)
125.0 brs Cq-4 of c.n.
123.8 d ofnm C-12,14 ofe.gr. C-2,4 123.5 (--nitrotoluene)
6 6 .6 to fn t (150) CH2  of e.gr. c f l  65.3(151.5)
62.9 t (each line 3-CH20 3-CH20  64.7 (cephalothin Na)
brs) (152) (152)
59.3 Sd(154.2) C-7 of c.n. C-7 59.7 (157 (cephalothin Na)
57.3 d(each line C- 6  of c.n. C- 6  57.9 (cephalothin Na)
bn) (174) (181)
37.1 t (130) CH2  of 7- CH2 36.7 (cephalothin Na)
substituent (133)
26.4 t of bim 2-CH2 of cephem 2-CH2 26.0 (cephalothin)
(142) nucleus (143)
20.7 q (129.3) C H 3  of 3- CH 3 20.8 (cephalothin Na)
substituent (131)
a For abbreviations see footnotes under Table 3.10; e.gr.=ester group, t.r.=thienyl ring,
c.n.=cephem ring. b 3.5 signals in ppm.
reference compounds (such as phenoxymethyl penicillin Na, benadryl HC1), in addition to a 
coupled spectrum (Fig. 3.19, p.95) and T \  measurements (Fig. 3.20, p.96), were employed 
for the assignment of the various 13 C signals (Table 3.16).






168.5 m (T !=4.36s) 7-amido C=0
164.0 nt (4.73s) lactam C=0
161.0 brs (4.67s) 4-C02R
156.8 nm (10.4s) Cq-1 ’ of 7-sub. C -l’ 155.6 (Stothers111)
139.4 m (4.98s) Cq-10’,16’ ofd.p.a. C-2,8 140.9 (benadryl)
139.3 m (2.91s)
134.0 nm (8.06s) Cq-3 of c.n.
( 6  lines)
129.5 d of nm C-3’,5’ of 7-sub. C-3’,5’ 130.5 (ph.m.pen.)
128.3 d o fn t C-13’,19’ ofd.p.a. C-5,11 128.7 (benadryl)
128.2 d of nt C-13’,19’ ofd.p.a.
127.8 d ofnm C - l l ’,15’,17’,2 r C-3,7,127.9 (benadryl)
of d.p.a. 9,12
127.0 d ofnm C-12’,14’,18’,20’ C-4,6,126.6 (benadryl)
126.8 d ofnm of d.p.a. C-3’,5’ 130.5 (ph.m.pen.)
122.4 m ( 6  lines) Cq-4 of cephem
(5. Msec) nucleus
1 2 2 .0 d of nt C-4’ of 7-sub. C-4’ 122.7 (ph.m.pen.)
(0.83sec)
114.6 dofnm C-2’,6 ’ of 7-sub. C-2’,6 ’ 115.2 (ph.m.pen.)
- 9 3 -
78.7 d(each line CHPh2 (C-9’) CHPh2 83.7 (benadryl)
brs)( 147.7Hz)
58.1 d(154)(Ti=0.72s) C-7 of c.n.
56.9 brd(174) (0.71s) C- 6  of c.n.
30.1 t of nm(144) 2 -CH2 of cephem
(0.31s) nucleus
19.9 Sq(129)(1.55s) 3 -CH3
a For abbreviations see footnotes under Table 3.15; 7 -sub.=7 -substituent,
d.p.a.=diphenylacetate group, ph.m.pen =phenoxymethylpenicillin. c.n=cephem nucleus 
b jk 6  signals in ppm.
In brief, the following was observed from the Table:
a) The T i data of C-3 and C-4 did not, for unknown reasons, correlate with their relative 
assignments, i.e., assignment of signal at 134 ppm to C-3 was not supported by relative T i 
value (8.06 s) compared to that of C-4 at 122.4 ppm (wiih T i=5.14 s). The 134 ppm signal 
showed more couplings than that at 122.4 ppm and was therefore assigned to C-3.
b) Using T  j values to differentiate between the three carbonyl carbons (amido, lactam, and 
4 -CO2 R ) (T 1 of Cq decreases with an increasing number of a  and p hydrogens104); thus, 
7-amido has two p hydrogens, 8 -CO lactam one, and 4 -CO2 R none; therefore the signal at 
168.5 ppm with the shortest T 1 value is assigned to 7-anido carbonyl carbon, that at 164.0 
ppm and 161.0 ppm have close T  \ values, but,the forme: appearing as narrow triplet in the 
coupled spectrum is assigned to the lactam, and that at 161.0 ppm (a broad singlet) to 
4-C02 R.
c) The T 1 value (0.83 s) of the signal at 122.0 ppm compared to that at 122.4 ppm (5.14 s) 
clearly confirm assignment of the higher field resonance to a CH carbon.
125130158162166












F ig . 3 .1 9  : T he 6 7 .8  M H z 13 C N M R  cou p led  spectrum  o f  in  CDCI3 . (Experim ental 
con d itions as in section  3 .3 .1)
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F ig. 3 .20  : Spin-lattice relaxation (7 " ,)  13C  N M R  spectrum  o f  3 .6  in C D d 3 . A rrow s indicate  
C -3 (*) and C -4  ( i )  signals. (E xperim ental conditions as in section  3 .3 . 1).
3.4.9 Ceph-2 -ene work
While searching the literature for methods for the removal of the p-nitrobenzyl acid 
protecting group a paper by a Lilly research group was found which described the use of 
sodium sulphide (Lammert et al.f 1978)89. The products resulting from treatment of the 











Since the reaction is carried out under alkaline conditions double bond migration is 
probably base catalysed, as shown :




Conversion of ceph-3-enes (i.e., A -cephalosporins) to ceph-2 -enes have in fact been 
reported by treatment of the antibiotics with aquecus pyridine and IN NaOH (Van 
Heyningen et al., 1968)34.
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The possibility of ceph-2-enes forming as one of the components of degraded 
cephalosporin antibiotics has not been investigated. For this reason, it was considered of 
interest to prepare authentic ceph-2-ene derivatives for use as reference standards in NMR 
stability investigations.
3.4.9.1 Synthesis of ceph-2 -ene 3.8
PhCH 2CONH<
CH
7-phenylacetamido-3-methyl-2-cephem-4-carboxylate 3.8 was synthesised in our
og
laboratones according to the method of Lammert et al. as described in Chapter two 
(section 2 .2 .3.6 ).
3.4.9.2 Characterisation of 3.8
a) ‘HNME
Assignments of the proton signals of 3.8 (Fig. 3.21, p.ICO) was facilitated by 
published data on: the sodium salt of 7-phenylacetamido-3-methyl-A2-cephalosporin 3.9 
(Mondelli et al.110) and 7-phenoxymethyl acetamido-3-methyl-2-cepnem-4-carboxylic acid 
3.10 (Lammert et al.S9):
H PhOCH2CONPhCH 2CONH-
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Table 3 .17  : *H N M R  characteristics o f  3 .8  (in  C D Q 3 +  D M S O -d g)* . (Form ula p .98 ).
C hem ical6 s ign a l assignm ent R eference
shift appearance (3 .1 0  in  C D Q ^ + D M S O -cU )
8.83 d (8 .0 6 ) 7 -N H N H  7 .9 0  d (9 .0)
7 .24 -7 .31 m Ph (5H ) P h  6 .8 6 -7 .4 8  m
6 .0 0 nm 2-H ( 2 -H  n o t reported )
5 .48 dd (3 .8 4 , 7-H 7 -H  5 .6 4  dd
8 .06) ( 5 .0 ,9 .0 )
5 .2 0 d (4 .0 ) 6 -H 6 -H  5 .3 5  d (5.0)
4 .65 brs 4-H 4 -H  4 .6 7  brs
3 .59 dd Ar-CH 2 O C H 2  4 .6 0  s
1.94 brs 3 -CH 3 3 -C H 3 1.98 s
a m =m ultiplet, nm =narrow  m ultip le!, d=doublet, dd=doublet d oub lets  
brs=broad sin glet, P h = P h en yl, A r= A rom atic. J v a lu es in  Hz in parenthesis, 
b _T8  signals in  ppm  from  T M S.
T able 3.18 : N M R  characteristics o f  3 .8  (+ N aH C 0 3  in E ^O )*. (Form ula p .98).
C hem ical6
sh ift
sig n a l
appearance
assignm ent R eference  
(3 .9  in  D 2 0 )
7 .3 3 -7 .4 0 m Ph (5H ) n o report
5 .95 nm 2-H n o report
5 .38 d (3 .9 ) 7-H 7 -H  5 .4 0  d (4 .0 )
5 .25 d (3 .9 ) 6 -H 6 -H  5 .2 7  d (4 .0)
4 .5 7 brs 4 -H 4 -H  4 .6 0  s
3 .69 dd A r-C H 2 A r-C H 2  3 .66 brs
1 .8 6 brs 3 -CH 3
a For abbreviations se e  foo tn o tes under Table 3 .1 7 ;  b 3J_ sign a ls (ppm )
3 .44.65 .05 .6
3/8 i nCDCLo / D M S O - d fi ti«o'
















Fig. 3.21 : 270 MHz NMR spectrum of 3.8 in CDG3 + DMSO-dg. (Experimental 
conditions as in section 3 .3 .1).
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b) 13C N M R
The 13 C data on 3.9 are likewise of value for the assignments of 13C signals of 3.8 
(Fig. 3.22, p. 102) as follows :




Q S m D 20)
174.4 7-amido C=0 7-CONH 176.0
170.9 lactam C=0 lactam 166.4
165.9 4-C02H 4-C02Na 175.2 
(unusually lowfield)
136.4 Cq-1’ of 
Ph ring
Cq-1’ 135.5
130.3 C-2’ to C-2’ to 130.3
129.5 C-6 ’ of C-6 ’ of 129.9
12S.0 Ph ring Arring 128.4
1 2 2 .2 Cq-3 of c.n. Cq-3 126.4
114.7 C-2 of c.n. C-2 111.8
61.7 C-4 of c.n. C-4 57.4
54.6 C-7 of c.n. C-7 60.4
53.9 C-6  of c.n. C- 6  53.4
432 Ar-CH2 Ar-CH2 42.8
22.3 3-Me 3-Me 22.2
a shifts are in ppm from TMS; b J3J3 signals (ppm); 
c Ph=Phenyl, Ar^ = Aromatic, c.n.=cephem nucleus.
-  1 0 1 -
t  5 - .  J c ' l  - 5 5  1 5  ■ 1 5  ■. 0  4 
£.<“C0 ICBCM
c^Nu'C n c
I'll BC (• /.Hi' Mil/
p o i n t  i u j <14
r <ECU 18050.5 Hz
SCAN! .1003 •
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Fig. 322 : 67.8 MHz C NMR proton noise-decoupled spectra (normal and DEPT) of 3.8 in 
CD3 OD. (Experimental conditions as in section 3.3.1).
3.4.9.3 *H NMR evidence of interconversion of 7-phenyIacetamido derivative 
of 3.7a to ceph-2-ene 3.8
PhCH2CONH
Table 3.20 : 1H NMR assignments^ of 3.7a and 3 ^
3.7a(inDMSO-rf6) 3.8 (in CDCl3 -fDMSO-d6)
Chemical signal assignment chemical signal assignment
shift appearance shift appearance
9.12 d (8 .2 ) NH 8.83 d (8 .1) NH
8.24 d (8 .8 ) ArH-10’,11’
7.69 d (8 .6 ) ArH-9’, 12’
7.25-7.31 m Ph (5H) 7.24-7.31 m Ph (5H)
5.68 dd (4.6, 7-H 5.48 dd (3.84, 7-H
8 .2 ) 8 .1)
6 .0 0 nm 2-H
5.40 s CH2 of
ester group
5.09 d (4.8) 6 -H 5.20 d (4.03) 6 -H
4.65 brs 4-H
3.54 d (8.4) CH2 of 7- 3.59 dd CH2 of 7-
substituent substituent
3.45,3.63 d (18.4) 2-CH2
2.06 s 3-Me 1.94 brs 3-Me
a for abbreviation see footnotes under Table 3.17.
*H NMR evidence of 3.7a interconversion to 3JUs provided by :
1- Absence of 2 -CH2 four line AB signal.
2- lowfield singlet (at -  6.0 ppm) assigned to vinylic proton at C-2.
3- new singlet (near 4.7 ppm) assigned to methine proton at C-4.
-1 0 3 -
3 .4 .9 .4  N M R  e v i d e n c e  o f  t h e  c o n f i g u r a t i o n  o f  c e p h - 2 - e n e s  3 . 8  ( a t  C - 4 )
Off-resonance proton decoupling and COSY experiments were employed to aid
solving the problem of configuration of the ceph-2-ene 3.8 at C-4.
It has been shown that the A -cephalosporins (compared to A ) were almost completely 
inactive as antibiotics. This was attributed to an unreactive p-lactam system112. Another 
possible factor of the inactivity of A2-cephalosporins must also be considered, and that is the 
absolute configuration of the 4-caiboxyl substituent
Van Heyningen et al.34 have shown (by chemical correlation, see below) that the 
carboxyls in penicillins (C-3) and A cephalosporins (C-4) possess the same absolute 
configurations (Fig. 3.23), and concluded that it is not the 4-carboxyl configuration but 
p-lactam stability that explains the feeble biological activity of A2-cephalosporin.
r c o n h ^ -
H COOH
A penicillin
RCONH^g g > S
H COOH
A A2-cephalosporin
Fig. 3.23 : Configuration of the carboxy group in penicillins (C-3) and A -cephalosporins (C-4).
  <5 i
The plan of the authors was to desulphurize phenoxymethylpenicillin 3.11 and obtain, 
after esterification, phenoxymethyl desthiopenicillin methyl ester 3.12. Similarly, they 
hydrogenated 7-phenoxyacetamido — A —desacetoxy — cephalosporanic acid to a 
tetrahydrothiazine and desulphurized it to 3.12, which possess identical NMR, IR, and UV 
spectra as that obtained from 3. J l. Furthermore, their X-ray powder diagrams coincide 
exactly. The authors subjected 3.12, from A2-cephalosporin, to acid hydrolysis and isolated 
valine. Although its rotation was low ([a] -245 *) compared to pure D-valine (-563 *)» the
- 1 0 4 -
rotation was strongly negative like D-valine (i.e. the product was predominantly the
  o
D-configuration). This proved that the carboxyls in penicillins and A -cephalosporins 









The purpose of the present work was to confirm (or otherwise) the above configuration at 
C-4 by NMR techniques (proton decoupling and COSY) i.e., by physical methods that avoid 
vigorous chemical reactions which may lead to stereochemical change.
1. 2D COSY experiment (of 3.8 in CDCI3 + DMSO-rf6)
The spectrum (Fig. 3.24, p. 106) was recorded on a Jeol JNM-GX 270 spectrometer, 
operating at 20.0*C, at a frequency of 3090.2 Hz, giving a digital resolution of 12.07 Hz. A 
14.0 jis pulse (PW1) was employed with a 0.083 sec acquisition time and a 1.00 sec pulse 
delay between pulses.
The diagonal points in the spectrum showed where the like signals meet, while the off- 
peak points indicate the coupled signals. The more intense the points the stronger the 
coupling. The low-field NH (at 8.83 ppm) showed strong coupling to the 4-line signal at 
5.48 ppm (due to 7-H). The 2-H signal at 6.00 ppm showed very clear coupling to the 3-Me 
signal at 1.94 ppm, and to a lesser extent (but clear) to the signal at 4.65 ppm (due to 4-H). 
Also the 4-H signal (at 4.65 ppm) showed similar long range couplings to both 3-Me (at 1.94 
ppm) and 2-H (at 6.0 ppm).
-  .  L .  .-I f .  -o  <N — I-. M  O  O  O  O  «T •» O  C  O  r  O
•• <7 c -  -on-. . c- • ■ . . 4 .10-0n  m . n o  . i '4C .' l i ' .vC .«»-W i|! 0  • -O C •> 04 •> -■> • • -  -  • • • o ... oUl N O -  ,0 0.., o O O *j c* r*
ft*®g£i i
3 - M e
4 - H2- H
NH
*P
F ig  3 .24  : 2 D -1 H /1H correlation  spectrum  o f  ceph-2-ene 3.8 in  C D Q 3 + D M SO -ds. 
(Experim ental con d ition s as in  section  3 .3 .1  and p. 105).
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2 . Off-resonance proton decoupling of 3.8 in (CDC^+DMSO-dg)
In the normal *H NMR spectrum (Fig. 3.21, p. 100) the signal at 6.1 ppm due to
2-H appeared as narrow triplet (i.e. small couplings evident), that due to 4-H (at 4.7 ppm) as 
broad singlet, and the 3-Me signal at ~ 2.0 ppm as broad singlet. Only low power was used 
since the couplings between 2-H, 3-Me, and 4-H are long-range and therefore small (Fig. 
3.25a-c, p. 108).
a) Selective irradiation at the frequency of 2-H (at 6.1 ppm) : the signals at 4.7 ppm and 
1.94 ppm appeared more shaiper, due to decoupling the 2-H from the 4-H and 3-Me protons 
(Fig. 3.25a).
b) Selective irradiation at the frequency of 4-H (at 4.7 ppm ): the signal at 6.1 ppm changed 
to a narrow doublet with similar separation as that of 3-Me at 1.94 ppm, which indicates the 
long-range coupling of 2-H with 3-Me (Fig. 3.25b).
c) Selective irradiation at the frequency of 3-Me (at 1.94 ppm) : the signals at 6.1 ppm and 
4.7 ppm appeared as narrow' doublets with almost equal J values, i.e., showing long-range 
coupling between 2-H and 4-H (Fig. 3.25c).
The above two experiments ( COSY and proton decoupling) provide clear evidence for 
long-range couplings (J~ 1 to 3 Hz) between the 2-H, 3-Me, and 4-H of the ceph-2-ene 3.8, 
and according to Stemhelll l j , protons separated by four bonds (e.g. the case of 2-H and 4-H) 
showing coupling constant magnitudes of 1 to 3 Hz usually have a planar zig-zag 
arrangement, or a W configuration:
This arrangement is only possible when 4-H has a [3-configuration. Hence, 4 -CO2 H of the 
ceph-2-ene derivative 3.8 must have the a-configuration, i.e., the same as that of natural ’• 
penicillin antibiotics (Fig. 3.23, p. 104). Therefore, this physical study confirms Van
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2-H 3-Me 4 -H 3-Me
Fig. 3 .25  : O ff-reson ance proton d ecou p lin g  spectra o f to in  C D C L 3 + D M S O -d 6 illustrating  
effect o f
a) se lective  irradiation at the frequency o f  2 -H  (at 6.1 ppm ),
b) se lective  irradiation at the frequency o f  4 -H  (at 4 .7 ppm ), and
c) se lec tive  irradiation at the frequency o f  3 -M e (at 1.94 ppm ) on  long-range coupling  
between 2-H , 4 -H  and 3-M e.
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CHAPTER FOUR
Stability and Degradation Investigations of (3-lactam Antibiotics
4.1 Introduction
Numerous studies of the degradation of (3-lactam antibiotics have appeared in the literature. 
Access to details can be obtained from the review articles referenced in the section. Many 
(3-lactam antibiotics are labile in aqueous solutions. Hydrolytic fission of the p-lactam ring 
produces an inactive drug.
4.1.1 Penicillins
An extensive degradative study of benzylpenicillin is described by Clarke et al.61. In 
aqueous solution, the penicillins are not only degraded by acid and base, but also by metal 
ions, penicillinase enzymes, oxidizing agents, alcohols, amines, and a wide range of other 
nucleophiles and electrophiles27,61.
The penicillins differ only with respect to the acyl side chain on C-6 ; the remainder of the 
molecule is the same in all penicillins except pro-drug formulations. In what follows only 
the degradation of benzylpenicillin will be considered.
4.1.1.1 Acid-base hydrolysis o f benzylpenicillin
The degradation has been found to be first-order with respect to benzylpenicillin in acidic, 
neutral and basic aqueous solutions50,114. The pH-rate profile showed that penicillin solution 
was moderately stable at pH 5 to 6 , but labile towards acid and alkali50,115. The overall rate 
of degradation of benzylpenicillin in aqueous solutions is proportional to temperature and 
found to obey the Arrhenius expression50  (i.e. Temperature dependence-activation reaction
u . [dlnK] E  _ __. _or energy, expressed by the equation---------- = ----- —, where K is the reaction rate in terms
[dt] R T 2
of concentration, T=temperature, E=energy of activation).
- 1 0 9 -
The instability of benzyl penicillin 4.1 in acidic aqueous solution is well known6' , and
its major degradation product, benzylpenillic acid 45, fully defined6'1. Other observed
degradation products include, benzyipenicilloic acid 4.2, formed when the (3-lactam ring
opens and benzylpenicillenic acid 4.3, detected by its intense UV absorption at 322
nm ll6 . l l7. It was later proposed1 that benzyipenicilloic acid, and its product of
decarboxylation in acidic solution (bezzylpenilloic acid 4.4), are also important degradation
products (see Scheme 4.1 below). Venous studies indicate that benzylpenicillenic add is
highly unstable, and is rapidly hydrolyzed not only to benzylpenillic acid150 but also to
benzylpenamaldic acid 4.649,117, benzyipenicilloic acids151 and 2-benzyl-4-hydroxyme'Jiyl_
11
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S e v e r a l  w o r k e r s  h a v e  m o n i t o r e d  d e g r a d a t i o n s  o f  b e n z y l p e n i c i l l i n  b y  h i g h - p e r f o r m a n c e
chromatography to study benzylpenicillin degradation at pH 2.7 and 37°C. In this study, 
benzyipenicilloic acid was not detected and this fact was attributed to its existence in 
equilibrium with benzylpenamaldic acid and its rapid decarboxylation to produce 
benzylpenilloic acid. A degradation Scheme was proposed (Scheme 4.2 below) based upon 
the order of appearance of the degradation products:
comprehensive series of decomposition products derived from benzylpenicillin. Kessler et
37liquid chromatography (HPLQ. Blaha and co-workers employed ion-exchange
Benzylpenicillin
Benzylpenicillenic acid




D-penicillamine + Benzylpenilloaldehyde + CCh
Scheme 4.2
ao
Vanderhaeghe and co-workers utilised cation-exchange chromatography to separate a
39al. examined the influence of ion-pair reagents on the degradation of benzylpenicillin at pH
2.5 and 37°C.
- I l l -
Degalaen and others62 have monitored the degradation of benzylpenicillin at pH 2.5 and 
37*C by *H NMR spectroscopy. Signal assignments were made by comparisons with spectra 
of standards recorded under the same conditions. Signals due to penillic, penicilloic and 
penamaldic acids appeared in the early stages of degradation. From the second day, lines due 
to penilloic acid steadily increased with concomitant fall in the intensities of signals due to 
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From the above NMR study it was shown that benzylpenicillenic acid is not a major
nn
intermediate, as proposed by Blaha , in the formation of benzylpenillic u*
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solutions45,50,119-121. In general, all the observations reported by these workers may be 
summarised as follows. Results indicated that the mechanism of alkali-catalysed degradation
that the alkali-inactivated product was benzyipenicilloic acid 4.2 which may exist as a
stereoisomers of ’natural’ benzyipenicilloic acid. It was concluded that epimerization at C-5 
was the major isomerization process but it is apparent from the reported data that 
epimerization at C- 6  is also possible.
Scheme 4.4 summarises the alkaline degradation of benzylpenicillin involving the 
cleavage of the p-lactam ring to produce benzyipenicilloic acid and its epimers.
of benzylpenicillin is of nucleophilic attack of OET on the P-lactam ring119. It was found
mixture of isomers45, i.e.,
H H H H H H H
H O P  H$l- 
4.2A(3S,5R6R)
COOH CC^H
R z  PhCH2CO-





H 02C ^  
5S ,6S Sch em e 4-4
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More recently Lipczynski (1988) reported a combined NMR-HPLC investigation of 
the degradation of benzylpenicillin in acidic and basic aqueous solutions. The author aimed 
to clarify’ the uncertainty about the details of the degradation of benzylpenicillin and the 
inter-relationships between the various degradation products, and to provide a kinetic study 
of the entire degradation process and reaction mechanisms consistent with experimental 
observations. The study reports employment of quantitative HPLC systems and NMR 
methods to optimise the separation and identification of benzylpenicillin degradation 
products. The degradation pathways proposed by the author are summarised in Schemes 4.5 
and 4.6 below.
Benzylpenicillin degraded in acidic solution to benzylpenillic acid 4.5, 
(3S,5R,6R)-benzylpenicilloic acid 4.2A and benzylpenicillenic acid 43. The dominant 
breakdown product of 4 ^  was found to be 4.2A, which is good evidence for 4.5 possessing 
(3S,5R,6R) stereochemistry', this not having been reported previously. Benzyipenicilloic acid 
in acidic solution was found to exist in complex equilibria with its C-5 and C- 6  
stereoisomers, benzylpenillic acid 4.5, and benzylpenamaldic acid 4^ 6; the dominant 
degradation pathways were epimerisation at C-5 and stereoselective decarboxylation to 
benzylpenilloic acid 4.4. Benzylpenicillenic acid 43  was found to be highly unstable in acid 
solution. The dominant breakdown products were benzylpenillic acid 4.5, the four possible 
(3S)-benzylpenicilloic acid stereoisomers 4.2 and benzylpenamaldic acid -M) (see Scheme 
4.5, p. 115). In basic solution benzylpenicillin was hydrolysed to 
(3S,5R,6R)-benzylpenicilloic acid 4.2A and also epimerised at C- 6  to 6 -epibenzylpenicillin 
which in turn was hydrolysed to (3S,5R,6S)-benzylpenicilloic acid 4.2C (Scheme 4.6, p.l 15).
85The author also reported the preparation of a number of the above-mentioned degradation 
products, which were used to investigate the kinetics and mechanisms of the individual steps 
in the degradation sequence by HPLC, and, together with UV and *H NMR spectroscopy, 
used to monitor the breakdown of benzylpenicillin and its degradation products in aqueous 
solution.
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B e n z y l p e n i c i l l i n
Benzylpenicillenic acid 4.3
Benzylpenillic acid 4.5 Benzyipenicilloic acid 4.2A 
(3S,5R,6R-)
Benzylpenamaldic acid 4.6
Benzyipenicilloic add 4.2 A Benzylpenilloic acid 4.4
(3S,5R,6R-)
• 8 5Scheme 4.5 : Degradarion of benzylpenicillin in acidic solution
(5R ,6 R)-B enzylpenirillin (5R,6S)-epibenzylpenicillin
(5R,6R)-Benzylpenirilloic acid 4.2A.
1
:(5R,6S)-Benzylpenicilloic acid 4.2C 
1
(5S,6R)-Benzylpenicilloic acid 4.2B^.r^(5S,6S)-benzylpenicilloic acid 4.2D
Scheme 4.6 : Degradation of Benzylpenicillin in alkaline solution85
4 . 1 .1 . 2  E n z y m a t i c  h y d r o l y s i s  o f  b e n z y l p e n i c i l l i n
Benzylpenicillin appears to be susceptible to all known p-lactamases, being converted to 
inactive penicilloic acid. These enzymes hydrolyse the p-lactam ring45.
R-CONH
P-lactamase
R -C O N H
♦ h 2o -> ^ — r ^ v M e




4.1.13 Aminolysis of benzylpenicillin
This reaction is of interest because the principal antigenic determinant of penicillin allergy is 
the penicilloyl group bound by an amide linkage to amino groups on proteins123a,b. This 
amide exchange reaction occurs readily and the susceptibility of penicillin to attack by 
nucleophiles has been attributed to strain in the p-lactam ring and the nonplanarity of the 
system which inhibits the usual amide resonance61.
Hamilton-Miller and co-workers44*3,6 followed the aminolysis (ND3 in D2 O) of 
benzylpenicillin by UV absorption and :H NMR spectroscopy. The changes in the 
absorption spectra ( ^ ^ 2 3 0  nm) and those of the *H NMR spectrum (upheld shift in the 
p-lactam proton signals and the increased non-equivalence of the gem-dimethyl groups), 















No evidence was given for the epimerization at C-5.
Page and associates124^  suggested that the aminolysis of benzylpenicillin proceeds 













R z  PhCH,CONH- Tetrahedral intermediate
The authors reported kinetic evidence of the tetrahedral intermediate involving a change 
in the rate-limiting step of the base-catalysed aminolysis reaction.
4.1.1.4 Hydrazinolysis of benzylpenicillin
towards the p-lactam carbonyl group. In their hydrazinolysis experiments, they used 25 Jil 
of aqueous benzylpenicillin Na (0.1 M), added to 2.5 ml of 0.005 - 0.2 M hydrazine in 
presence of increasing concentrations of buffer solutions prepared from various salts, pre­
incubated at 30°C, with thorough mixing. The disappearance of penicillin was followed 
spectrophotometrically at 235 nm. The authors suggested that the cleavage of the lactam ring 
proceeds through a similar way as that of aminolysis (section 4.1.1.3). They did not attempt 
to identify the degradation products to support their proposed mechanisms of hydrazinolysis.
4.1.2 Cephalosporin degradations
4.1.2.1 Simple degradation studies
Several studies of the degradation of cephalosporin antibiotics have been made which 
involve simple monitoring of decrease in the concentration of the antibiotic with time by use 
of HPLC and other analytical techniques. No product identifications were sought in these
Morris and Page (1980)124a,*> have shown that hydrazine is a very effective nucleophile
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studies. Cephalosporins of the type X, in general, easily undergo acid and base hydrolysis4 
(Scheme 4.7):
Acid hydrolysis results in the loss of the R substituent (a leaving group) at the 3-pos:aon 
and formation of an a ,  P-unsaturatec lactone. Base hydrolysis opens the p-lactam mciety 
and (simultaneously?) eliminates the R group at the 3’-position, with double bond migraion. 
Enzymatic deactivation of cephalosporins is believed to follow a reaction path similai to that
Jones et al. (1968)125 and Hall(1973)69 reported the use of a polarographic techriqi* to 
follow acid and base hydrolysis and p-lactamase degradation of some cephalosporins, i.e, 
cephalosporin C, cephalothin and cepoaloridine. The degradation mechanism followed dos€ 
pathways of Scheme 4.7. The polarographic method’s main limitations are the requiemmt* 




+  R H -f- H^O
O
X
R = good leaving group 
R'= benzyl and related groups
Scheme 4.7
of base hydrolysis, again with the loss of R group4. In general, the degradadot of
A *J
cephalosporins follow apparent first-order kinetics ’ .
leaving group at the 3-position.
Das Gupta4 0  employed UV and HPLC techniques to investigate the kinetics cf the 
hydrolysis of cefoxitin in aqueous solutions at 24*C and different pH value buffers, buffer 
concentrations and ionic strengths. The pH-rate profile showed that cefoxitin solution was 
moderately stable at pH 4-7, the major reaction being the hydrolysis of the p-lactam rirg by 
water, but very labile towards acid and alkali. The study reports the use of two different 
columns and mobile phases to confirm the reliability of the HPLC method over that cf the 
UV spectrophotometry. The proposed degradation pathways of cefoxitin are shown in 
Scheme 4.8 below:
OMe






\ < ^ C H 2OH
c o 2h  
K4  (occurs rapidly i:
C O O H
n
acidic m edium )
O M e ,O M e
HOOC HN
g ^ C H j C  O N H
Scheme 4.8
Increases in buffer concentration or ionic strength had very little effect in the 
decomposition rate at the various pH values.
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4.1.2.2 Degradation of 3 -acetoxymethyl derivatives to lactones
These derivatives may lose their acetyl function to give corresponding desacetyl 
derivatives which subsequently eliminate water to form the fairly stable lactones (Scheme 










The rapid lactonization of the desacetyl derivative to the lactone occurs only at relatively low 
pH.
—  A  7The chemical and/or enzymatic conversion of cephalosporin C 4.7a and of several
clinically useful 3-acetoxymethyl derivatives, cephalothin 4.7b36, cephaloglycin 4.7c1~£> 127
and cefotaxime 4.7d75,128, into the corresponding desacetyl analogues 4J! and lactones 4J9
100has been described (Fig. 4.1, p. 121). Two pathways have been proposed by which the 
nonenzymatic hydrolysis of these cephalosporins, or of any ester, may proceed. The more 
common path involves acyl-oxygen bond cleavage, but alkyl-oxygen bond cleavage may 
occur if the intermediate caibonium ion is particularly stable129.
a c
Yamana and Tsuji followed the aqueous acidic degradation of some 3-acetoxymethyl 
cephalosporin derivatives by HPLC and other techniques. The acetyl functions of the 
derivatives were found to hydrolyse eight times faster than their p-lactam moieties to yield 
the corresponding desacetyl intermediates, which were rapidly converted to the lactcnes. 
The authors proposed Scheme 4.10 (p. 121) for the eptire pH range; k i , k3 , and k5 correspond 
to the rates of P-lactam cleavage in the nucleus. In neutral and basic pH regions, the k4
r - n h n
''I
'N^ Y ^ s CHrOCOCH3
4-7
C O O H
R - N H
R
o  T : °
C r y
R —NHn. _____
o J , N^ < ^ C H 2-O H
4*8
COOH






r t a 2
s .  t fo c H 3H J r r
Fig. 4.1 : Chemical structures of some clinically useful 3 -acetoxymethyl cephalosporin 
derivatives and their corresponding desacetylanalogues and lactones.
RCONHv___
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reaction process is negligible, but became significant below pH 4.0. For example, for 
cephalothin the value of k4 , at pH 2 and 35'C, was 0.708 hr-1. No mechanism was suggested 
for the loss of the acetyl group to give the corresponding desacetyl derivative.
Mangia and co-workers71 reported a quantitative HPLC method for the determination of 
cephacetrile in bulk drugs and pharmaceutical formulations. They suggested the superiority 
of their method over the official microbiological and colorimetric method, in being more 
selective, rapid, accurate and free of interference by acetyl hydrolysis products. Furthermore, 
the desacetyl and lactone derivatives, arising from cephacetrile during storage, can be 
detected accurately upto 0 .1%.
The mechanisms for the aqueous formation of a desacetyl derivative from a
1 203-acetoxymethyl cephalosporin 4.7 have received much attention. Cocker et al. and 
Taylor131 suggested the existence of a resonance-stabilized allylic cation 4.10 (Fig. 4.1, 
p. 1 2 1 ) resulting from alkyl-oxygen bond cleavage, to explain sulphur and nitrogen 
nucleophilic displacement reactions at the allylic carbon in aqueous solution.
Hatfield et al. 132 suggested that 4.10 is also an intermediate in similar nonaqueous 
nucleophilic displacements. None of these workers, however, succeeded in isolating 4.10 or 
its nucleophilic reaction products. The only observed reaction was destruction of the 
p-lactam ring. Hence, Hatfield and co-workers proposed an acyl-oxygen bond cleavage 
pathway rather than an alkyl-oxygen bond cleavage or allylic cation 4.10, for the formation 
of the desacetyl derivative ^ 4^ and its subsequent cyclization product, lactone 4J), under 
aqueous conditions (Fig. 4.1).
72More recently, Indelicate et al. reexamined the aqueous solution chemistry of the 
C-3’-acetoxy group of cephalothin sodium 4.7b with isotopically labeled H ^ O  and
13 15?[2- C] acetate anion. They suggested, from the O incorporation studies, that the 
hydrolysis ( at pH 4.7 ) of 4.7b to the desacetyl derivative of cephalothin 4.8b proceeds via
two pathw ays : ~ 55-63% of the reaction occurs via alkyl-oxygen cleavage (C3 -CH2 -O R ) or 
allylic cation 4.10b (Fig.4.1, p.121) and the remaining via acyl-oxygen cleavage 
(C3 -CH2 O--R). They observed that the alkyl-oxygen cleavage pathway is a reversible 
reaction.
4.1.23  (3-Lactam ring opening
R-CONKn










This route (Scheme 4.11) is anticipated from studies of penicillin derivatives and should 
lead to analogues of penicilloic 4.2 and penilloic 4.4 acids together with their products of 
epimerization. The situation with cephalosporins is more complicated owing to the presence 
of another substituent on the nucleus at position 3. Unlike 4.2 and 4.4, the cephalosporin 
analogues are usually very unstable and can not be isolated because they undergo rapid 
decomposition133. To date cephalosporin analogues of 4.2 and 4.4 have only been isolated 
in the case of cefixime (Namiki et al., 1987)70; there is no NMR evidence for their 
existence. Two other exceptions134 known to this are, one being cephalosporins where the
3-substituent is linked within a y-lactone4 (Fig. 4.2a); the other comprises compounds where






Fig. 4.2 : a) a cephalosporin lactone; b) 3-(2:4-dinitrostyrene) cephalosporin derivative.
S a b a t h  a n d  c o - w o r k e r s  ( 1 9 6 5 ) 41 r e p o r t e d  t h a t  p - l a c t a m  c l e a v a g e  o f  c e p h a l o s p o r i n  C ,
cephalothin and cephaloridine with a P-lactamase was accompanied by the appearance of 
two equivalents of acid per mole of antibiotic, in case of the former two cephalosporins; o d s  
equivalent was attributed to the p-lactam hydrolysis while the other resulted from the 
liberation of acetate ion. Cephaloridine liberated, in addition to one equivalent of acid, one 
equivalent of base derived from pyridine (attached to C-3’). UV spectra of product solutions 
showed that the original 260 nm absorption disappeared as a 230 nm maximum appeared 
which, in turn, disappeared with time. The exact structures of the degradation products were 
not determined (see Scheme 4.12 below).
Scheme 4-12
Compounds such as cephazolin and cephamandole probably lose their 3 -substituent, but this 













Cephaloridine : ,p - —Ni Further fragmentation
of the'decomposition products is not yet firmly established.
Eggers and associates (1965)136 studied the reaction of cephaloram 4.12 with sodium 
benzyloxide in benzyl alcohol. The product 4.13, which has lost the acetoxy function, was 
suggested to arise by Scheme 4.13 illustrated below. The structure of compound 4.13 was 
verified by independent synthesis.
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R =  - C H ,P h Scheme 4*13
Studies by Hamilton-Miller et al. (1970)44<2,i on the aminolysis and enzymatic 
hydrolysis of cephalosporins have shed considerable light on the complex breakdown pattern 
of the cephalosporins. The degradation of 7-n-butyramidocephalosporanic acid 4.14 with 
ND3 -D2 O was monitored by NMR and UV spectra. Analysis of the data and comparison 
with model compounds led to the conclusion that the exo-methylene compound 4.15 was 
formed as a semistable intermediate. Compound 4.15 (Xmax 230 nm ) underwent further 













R ^ C H ^ C H ,
4.16 
Scheme 4-14
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However, aqueous aminolysis of the desacetoxv (a) and desacetyl (b) derivatives of 4.14, 
gave intermediate desacetoxy 4.17a and desacetyl 4.17b cephalosporoates 230 nm),
(Scheme 4.15).
p-lactamase treatment of desacetylcephalosporins, gave intermediates with 230 nm, 
which is a different result from the aminolysis. The investigators speculated that enzymatic 
treatment could have converted the hydroxyl groups of the desacetyl compound into better 
leaving groups resulting in behaviour similar to that of cephalosporins.
4.1.2.4 Elimination of a leaving group from the 3-position of a cephalosporin 
(Formation of 3-methylene derivatives)
It is well known4 2 ,137-139  that the antibacterial effectiveness of cephalosporin 
antibiotics is strongly influenced by substituents at the" 3-position. Furthermore, these 
substituents may have additional influence through their leaving group ability since it is
A  1 A A  L  i  0 * 3
known • a' • that nucleophilic p-lactam ring cleavage of cephalosporins that have a 
good leaving group in the 3-position, as many clinically important cephalosporins in fact do 
possess, is accompanied by elimination of the leaving group. Degradation products of this 
kind involve cleavage of the p-lactam ring coupled to migration of the N-CO bond electrons 
into the dihydrothiazine ring, shift of the endocyclic 3-4 double bond to the 3-exocyclic 
position and expulsion of the terminal group X as an anion (Scheme 4.16, p.127). The
X = OH 4.14 b
N D j - ^ O
4 . 17a  
4 . 17b
Scheme 4-15
process requires X to be a group which forms a stable anion, i.e., has good "leavability" 
properties.
RCONH.





S c h e m e  4 - 1 6
3-methylene cephem
Until 1984, both experiment1 4 0 -1 4 2  and theory42,57,143 have been interpreted in terms of 
p-lactam ring opening concerted with departure of the leaving group X in 4.18; i.e., no 
intermediate corresponding to 4.19, as shown in Scheme 4.17, has been observed in cases 
where X is a good leaving group such as acetoxy or pyridinium :
4-18
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Faraci and Pratt (1984)59 followed the reaction of a p- lactamase (TEM-2 type) with 
cephaloridine spectrophotometrically, at 260 nm. They reported a two-phase proton release 
reaction. They anticipated that one proton would be released during each step of Scheme
4.12 (p. 124), as it is well-known that two protons are released on hydrolysis of 
cephaloridine41. They concluded that, the departure of a good leaving group need not in 
general be concerted with P-lactam ring opening. No product identifications were sought in 
this study.
Recently, intervention of the intermediate (with the 3’-leaving group) during aminolysis 
of cephamycin and a consecutive reaction mechanism have been suggested on the basis of a 
carbon-13 NMR study144.
4.1.23 Attack by the a-amino group of the 7-amido side chain of cephalosporin
Cephalosporin derivatives with a-amino substituents in their C-7-amido side chain, such 
as cephalexin, cefadroxil, cephradine, and cefatrizine, undergo intramolecular anack by the 
a-amino group on the P-lactam carbonyl carbon with cleavage of the p-lactam ring and 











This route has been established in several cases by isolation of diketopiperazines of type 
4.20, and, in one case, an analogue with a 4-5 double bond 4 2 174 (p. 129). No product of this 
kind has, however, been isolated from simple degradation media.
74From an aqueous sodium carbonate solution of cephradine, Cohen et al. (1973) 
isolated the diketopiperazine-type compound, 4.21, as the major alkaline degradation product 
(Scheme 4.19, p. 129). The authors demonstrated the A4,5-double bond migration in the
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Scheme 4-19
or
Yamana and Tsuji (1976) followed the degradation of cephalexin by NMR
*7 a
spectroscopy according to Cohen et al. and by HPLC. In deuterium oxide-sodium
deuteroxide (D2 0 -Na0 D) at pD 8.0 and 60*C, the 3-methyl group in cephalexin showed a 
singlet ai 5 1.84, which gradually decreased in intensity as the degradation proceeded, and a 
new singlet for a secondary methyl group was observed at 1.22 ppm. When the degradation 
was performed in water at pH 8.0, the methyl proton signal appeared as a doublet (J=8.0 Hz). 
The authors suggested that, these NMR spectral changes for cephalexin indicated the double 
bond migration to the 4,5-position during the degradation and exhibited the same behaviour 
as for cephradine74. The HPLC studies also showed that, the chromatographic changes of 
the degraded solutions of cephalexin and cephradine at pH 8.0 exihibited the same elution 
pattern for all solutions.
Indelicate et al.6 5 ,6 6  isolated the A3,4- diketopiperazine type, 4.20, from the refiuxed 
benzene solution of the p-nitrobenzyl esters of cephalexin and cephaloglycin. The same 
authors66, together with Bundgaard73, and Yamana and coworkers3 6 ,1 4 5  have demonstrated 
that intramolecular nucleophilic attack by the a-amino moiety on the P-lactam is possible 
conformationally in cephalosporin molecules, causing an apparent increase in chemical
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reactivity and rate of hydrolysis of the p-lactam moiety, over compounds not containing an 
a-amino group in the 7-acylamido side chain. In contrast, penicillins with a-amino 
substituent, such as ampicillin, did not exhibit such a rate enhancement of the p-lactam 
opening by the direct intramolecular attack of the side-chain a-amino group . This was 
attributed to the steric hindrance of the gem-dimethyl group and the 3-proton to the attack of 
the a-amino group at the p-face as suggested by Indelicato et al.65,66.
Dinner et al. (1977)146 attempted to isolate products from basic aqueous degradation of
cefaclor 4.22a without success. However, a piperazine-2,5-dione 4.23a was isolated from the
fnacidic aqueous degradation of cefaclor , and they obtained 4.23b from the refluxed benzene 
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b : Cefaclor-4-p-NB Y = -C H ;K ^ O } -N 0 2 
ester
Scheme 4-20
However, elemental analysis of 4.23b indicated the absence of chlorine. The peak 
assignments for the *H and 13 C spectra (in D M SO -^) of 4.23b indicated a hydrogen 
substituted for chlorine. The authors146 proposed the following Scheme 4.21 (p. 131) to 
account for a nonconcerted loss of chlorine subsequent to opening of the P-lactam, either
in t r a - m o le c u l a r ly  b y  a n  a - a m i n o  m o i e t y  o r  b y  a n  e x te r n a l  n u c l e o p h i l e  :
co2r





Tsuji and coworkers (1981)64 described the degradation kinetics and mechanisms of
cefadroxil, in aqueous solution at pH 2.51-11.5 at 35’C and ionic strength 0.5. The 
degradation rates were determined by high-pressure liquid chromatography (HPLC). The 
compound was shown to degrade by three parallel reactions : a) intramolecular aminolysis by 
the C-7 side-chain amino group in the P-lactam moiety, b) water-catalysed or spontaneous
and weak alkaline solutions, the main degradation products were two piperazine-2 ,5-diones 
4.25 and 4.26 and 3-hydroxy-4-methyI-2(5H)-thiophenone 4.24 (see Scheme below), the 
former being formed from reaction (a), while the latter arose via the degradation pathways of
hydrolysis, and c) P-lactam cleavage by the nucleophilic attack of hydroxide ion. In neutral
-  1 3 1 -
products
The structural elucidation of 4.24, 4.25 and 4.26 was based on spectral data. The NMR 
spectrum of 4.24 showed three singlets at 2.09, 3.74, and 6.10 ppm; those of 4.25 and 4.26 
revealed two signals ascribable to methyl groups at 1.58 and 2.23 ppm in the reaction 
mixture, suggesting the existence of two different methyl groups, one attached to a secondary 
carbon atom and the other attached to a double bond (the former coupling with a vicinal 
proton). Signals at 4.05 and 5.41 ppm were assigned to the C-7 and C- 6  protons, showing 
long-range coupling with protons on C-2 and/or C-3.
Notes bn p-Iactamases
P-lactamases are enzymes of bacterial origin which hydrolyse the C-N bond in the
1 0/4
P-lactam ring of a penicillin or a cephalosporin . A classification of these enzymes from 
gram- negative bacteria into five main classes containing 15 different types of enzymes was 
proposed147. Some p-lactamases are highly species specific, such as those found in all 
strains of Pseudomonas aeruginosa41, whereas others, being mediated by an R factor such 
as R m a y  be found in several different species148. Some enzymes inactivate 
cephalosporins very much more rapidly than they inactivaie penicillins. Usually the activity 
and the concentration of these enzymes are primarily estimated from their effect on a known 
'concentration of benzylpenicillin and/or cephaloridine. Methods for assaying p-lactamase 
activity can be divided into two main groups. In one, the concentration of the unchanged 
substrate remaining is measured; in the other, the assay determines the concentration of 
breakdown products. In general, when the P-lactam ring of a penicillin is hydrolysed by a 
P-lactamase (Scheme 4.22 below), the corresponding penicilloic acid, which is a stable 





p-lactamase R -CO NH
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Scheme 4-22
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The situation with cephalosporins is more complicated owing to the presence of another 
substituent on the nucleus at position 3. The first product of P-lactamase attack on a 
cephalosporin is hypothetically a cephalosporanic acid (Scheme 4.23, p. 134), analogous to
Notes on p-lactamases
p-lactamases are enzymes of bacterial origin which hydrolyse the C-N bond in the 
P-lactam ring of a penicillin or a cephalosporin134. A dissification of these enzymes from 
gram- negative bacteria into five main classes containing 15 different types of enzymes was 
proposed147. Some p-lactamases are highly species specific, such as those found in all 
strains of Pseudomonas aeruginosa41, whereas others, being mediated by an R factor such
1A ftas Rj£M, may be found in several different species . Some enzymes inactivate 
cephalosporins very much more rapidly than they inactivate penicillins. Usually the activity 
and the concentration of these enzymes are primarily estimated from their effect on a known 
concentration of benzylpenicillin and/or cephaloridine. Methods for assaying p-lactamase 
activity can be divided into two main groups. In one, the concentration of the unchanged 
substrate remaining is measured; in the other, the assay determines the concentration of 
breakdown products. In general, when the p-lactam rinc of a penicillin is hydrolysed by a 
P-lactamase (Scheme 4.22 below), the corresponding penicilloic acid, which is a stable 
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A penicilloic acid
The situation with cephalosporins is more complicated owing to the presence of another 
substituent on the nucleus at position 3. The first product of P-lactamase attack on a 
cephalosporin is hypothetically a cephalosporanic acid (Scheme 4.23, p. 134), analogous to
penicilloic acid, but usually very unstable and cannot be isolated as it undergoes rapid 
decomposition.








For a comprehensive account of P-lactamase enzymes the reader is directed to reference
149.
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4.2 Aim of present work
Since the *H NMR technique yields detailed information about the degradation of 
p-lactam antibiotics of the penicillin class, we attempted to use the procedure to study the 
degradation of cephalosporins under various experimental conditions, i.e., alkaline 
hydrolysis, enzymatic hydrolysis, hydrazinolysis and acidic degradation. In the next section 
we describe the results of the 1H NMR study and endeavour to determine the structures of 
the degradation products with reference to previous studies in the field.
To complement the work with enzymes, the value of *H NMR spectroscopy in monitoring 
the action of P-lactamases on a group of penicillin antibiotics was also carried out. 'I'he 
results are presented separately on page 177 as a supplement to this Chapter.
4.3 Experimental
4.3.1 Instrumentation
1. The *H NMR spectra were recorded on a Jeol FT NMR GX270 spectrometer already 
described in Chapter three (section 3.3.1).
2. Readings of pH were carried out on a Philips PW 9410 digital pH meter.
4.3.2 Materials
1. 7-phenylacetamidodesacetoxycephalosporanic acid was obtained as described under its 
method of preparation (Chapter two, section 2.2.3.5).
2. Sodium salts of benzylpenicillin, cephalothin, cefoxitin, cephaloridine, cefuroxime, 
cefotaxime, cephazolin, diammonium salt of moxalactam, cefaderoxil, cefaclor, cephradine 
and cefatrizine, were obtained as described in Chapter two (Table 2.1). The compounds were 
used as received.
3. 99.8 % D2 O was purchased from Aldrich, England.
4. Hydrazine hydrate, 99% (AT/2 ^ ^ 2 - ^ 2  60 was obtained from Fluka AG chemicals, 
W.Geimany.
5. NaOD (40 % in D2 O), Goss Scientific Instruments, England.
6 . p-Lactamase enzymes; two types were used :
a) P-lactamase (ex. Bacillus cereus 569/H9), broad spectrum 
mixture, obtained from Genzyme Biochemicals, Kent, England, 
and b) broad spectrum p-lactamase mixture, obtained from Centre of 
Applied Microbiology and Research, Porton Down, Salisbury,
England.
Both enzymes were stored a t-5*C.
7. Deionised water was used where necessary.
8 . Carbonate and phosphate buffers prepared as follows :
0.2 M phosphate buffer of pH 9.6 (pD 10.0):
0.2 M deuterated NCI2 HPO  4  10 ml
0.25 M deuterated Na 3 PO  4 a quantity enough to adjust
pH to 9.6.
0.25 M Carbonate buffer pH 9.6 : Prepared by addition of 0.25 M deuterated Na2 C0 3  to
0.25 M NaHCC>3 to adjust pH to 9.6.
4.4 Results and discussion
4.4.1 Penicillins
1
4.4.1.1 Direct H NMR observations on hydrazinolysis of benzylpenicillin Na 4.27 
L iteratu re  results
Review of the available literature at the time revealed lack of any direct1H NMR study 
on the hydrazinolysis of benzylpenicillin. The only work of interest is that of Hamilton- 
Miller et al.44* on the aminolysis of benzylpenicillin. The changes in chemical shifts before 
and after the reaction are shown in Table 4.1 (p. 137).
H2CONH
4.27.
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Table 4.1 : Chemical shifts before and after aminolysis of 
benzylpenicillin* :
Substance 6 -H 5-H 3-H a,P-2-Me ArCH2
Intact 5.52 d 5.43 d 4.23s 1.55s, 3.64s
(4.0) (4.0) 1.49s
product 4.98 d 4.38 d 3.45s 1.55s, 3.68s
(7.5) (7.5) 1.23s
a s=singlet, d=doublet.
Of particular interest are the upfield shifts of the P-lactam proton signals, accompanied 
by an increase in coupling constant. There was also an upfield shift in the signal from the C-3 
proton and a slight downfield shift in the signals from the side-chain methylene protons. The 
authors reported that the spectrum became considerably more complicated after 24 hours, 
indicating that more than one species was present in the reaction mixture and suggested that 
epimerization had occurred at C-5. The structures of these degradation products were not 
determined, and no mechanism was suggested for their formation, (see our results with 
hydrazine/benzylpenicillin below).
1. Preparation of NMR sample
10 mg of benzylpenicillin Na salt 4.27 was dissolved in 0.5ml D2 O and 5 pi hydrazine 
hydrate (neat) was added. JH NMR spectra at room temperature (~ 24*C) were taken 
immediately and subsequently at appropriate intervals. The last three spectra (at day 8 , 13, 
and 37) after storage at 37*C.
2. Results and discussion
The initial spectrum (Fig. 4.3a, p. 139), recorded 5 minutes after the start of the 
experiment, showed evidence of rapid p-lactam ring opening, indicated by the complete
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absence of the intact 5-H/6-H signals (5.50, 5.40 ppm), accompanied by the appearance of a 
novel upfield set of two doublets centered at 4.92, 4.27 ppm with increased coupling 
constant, 8 .8  Hz. There was also an upfield shift of the C-3 proton signal (4.23 ppm moved to 
3.43 ppm) and the a-2-Me signal (1.49 ppm to 1.21 ppm). Furthermore, the AB quartet 
centered at 3.64 ppm, assigned to the non-equivalent benzylic CH2  protons of 
benzylpenicillin, changed to an intense singlet at 3.65 ppm.
80 minutes later, the high-field region of spectrum (Fig. 4.3b, p. 139) showed two extra 
lines at 1.88 ppm and 1.79 ppm, each integrating to about one proton. No other change was 
observed.
Fig. 4.3c shows the spectrum of the reaction mixture 24 hours after the start of the 
experiment. Little change occurred, apart from increases in intensity of the singlets at 1.88,
1.79 ppm (all the signals in the 1.90 -1.20 ppm region had the same intensity, i.e., 1.88,1.79, 
1.54 and 1.21 ppm signals) and the appearance of minor peaks at 1.50 - 2.50 ppm and 3.40 -
3.80 ppm regions.
The subsequent spectra, run 2, 5, 6  and 8  days later show insignificant changes, apart 
from the increased intensities of some minor peaks at 1.30 ppm(~ 0.4 H) and 3.71 ppm (- 0.4 
H); the 5-H signal at 4.26 ppm weakened (~ 0.7 H), and the singlet at 3.42 ppm integrated to 
about 0.7 H. These results may be interpreted in terms of rapid opening of the fi- lactam ring 




Changes in signals due to 3-H, 5-H, 6 -H and a-2-Me are remarkably close to those of
6 -H. The extra signals at 1.8  8  and 1.79 ppm cannot be explained at present They are unlikely 
to arise from 2-Me signals of an epimeric form of 4.28 because integrals of the 1.55 and 1.21
•s >vie
1^/MePhCHjCONH^j
the aminolysis product (Table 4.1) even in regard to the increased 3 J value between 5-H and
ppm singlets do not fall below 3 protons after appearance of the new signals. In addition, no 
other signals diagnostic of epimerization appear.
mo
Fig. 4.3 : 270 MHz JH NMR spectra of the hydrazinolysis of tenzylpenicillin Na. a: Initial 
(5 min), b: 80 min and c: 24 hrs after commencement. Integml distortions in (a) and (c) 
spectra due to suppression of HDO signal. See text for details.
4.4.2 Direct l H  NM R observations on the degradation of 
cephalosporin antibiotics
4.4.2.1 Degradation work on 7 -(2 -phenylacetamido)desacetoxy- 
cephalosporanic acid 4.29
C H ,— C O N V r  r ^ S
■CH
4.29
1. Reasons for choice of 4.29
The 7-(2-phenylacetamido) derivative of desacetoxycephalosporanic acid 4.29 was 
selected as the chief compound for degradation investigations for the following reasons :
(i) It is a close cephalosporin analogue of benzylpenicillin.
(ii) It has a non-leaving substituent at position-3.
(iii) Absence of an amino substituent to the 7-amido side chain (to avoid formation of 
ketopiperazine products).
2. Source of 4.29
Literature search
1 52Two methods were described in literature for the synthesis of 4.29 from 
benzylpenicillin sulphoxide.
The first method involves the heating of a mixture of the sulphoxide of benzylpenicillin, 
trimethylchlorosilane and a-picoline in chloroform for 20 hours at 83*C; after cooling the 
mixture was stirred with water and the pK adjusted to 7.5 with 4N KOH solution. The 
aqueous layer was separated, pH adjusted to 1.5 with 4N HC1, and extracted with 
ethylacetate. The organic solvent was then replaced by 1 -propanol and cooled to ~ O'C. 
Addition of water and a 1.25 M solution of potassium salt of 2-ethylcaproic acid in 
butylacetate gave a precipitate, which after filtering and drying, contained the potassium salt 
of A -7-phenylacetamidodesacetoxycephalosporanic acid (yield 47%), in addition to a minor 
yield of the A2 -isomer.
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The second method involves the reaction of the sulphoxide with dioxane, 
N,0-bis(trimethylsilyl)acetamide (BSA), a-picoline and a solution of a-picoline
o
hydribromide in dichloromethane yielding ~ 78% of the potassium salt of A -7-phenyl- 
acetamidodesacetoxycephalosporanic acid.
Material used in this work was obtained from the corresponding p-nitrobenzyl ester 
kindly supplied by Glaxo Laboratories. Details are given in Chapter two (section 2.2.3.5).
3. R esults and  discussion
(A) Effect of buffers alone
The 1H NMR chemical shifts of the spectra of reaction mixtures of 4.29 in either
0.25 M deuterated sodium carbonate buffer (pD 10.0) or 0.1 M deuterated phosphate buffer of 
pH 9.0, showed no indication of p-lactam ring opening, even after 4 hours. Apart from extra
minor signals in the 3-Me region (1.90-1.80 ppm), negligible change was observed,
suggesting that 4.29 is stable in buffered solutions over the pH range 9.6 -10.0.
(B) NM R analysis of products of 7-phenvlacetam ido-derivative 4.29 
hydrolyzed in carbonate buffer in the presence of p-lactam ase
1. P repara tion  o f 1H NMR samples
7-(2-phenylacetamido)-desacetoxycephalosporanic acid 4.29 (6.0 mg) was dissolved in
0.5 ml 0.25 M deuterated sodium carbonate buffer at pD 10.2 
and either a) few crystals of P-lactamase (Porton), 
or b) few crystals of P-lactamase (Genzyme), 
was added.
*H NMR spectra were taken immediately and subsequently at appropriate intervals 
(solution stored at 5*C).
2. Results and discussion
Pratt et al. (1986)153 followed the hydrolysis of desacetoxycephalothin 4.30, a close
analogue to 4.29, in 0.25 M Na2 CC>3 buffer (pD 10.0) in presence of either Rje m -2 (see 
p. 133) or the P99 p-lactamase, by *H NMR. They observed instant changes (< 1.0 min) in 
the initial spectrum to that of the ring opened product 4.31, as indicated by the upfield 
movements of the C- 6  and C-7 proton signals of the intact antibiotic (Scheme 4.24, Table 4.2 
below), and little change in the C-3’ signal:
P-lactanase
pD 10.0




Table 4.2 : Chemical shifts (ppm) before and after enzymic hydrolysis of 4.30
6-H/7-H 3-Me
4.30 (intact) 5.07,5.59 d 1.90 s
4.31 (enzymatic product) 4.51,4.59 d 1.84 s
No detailed H NMR data of product 4.31 were described to support its structuralv 1
identity; also no mention of the presence of epimers was reported.
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a) Hydrolysis of 7-phenyIacetamido-derivative 429in pD 10.2 + Porton enzyme
The NMR spectra of the degradation mixtures were analysed by observing any 
notable changes in the 2 -CH2 , 3-Me, and 6 -H/ 7-H signals of the products and by 
comparison with the *H NMR spectra of 429 (intact) in D2 O.
The initial *H NMR (Fig. 4.4a, p. 144), run immediately after buffer and p-lactamase 
addition, showed the complete absence of the 6 -H/ 7-H doublets of the intact molecule at
5.05 and 5.56 ppm, and appearance of new well resolved doublets centred at 4.52 and 4.60 
ppm ( J ~ 5 Hz), corresponding to the C-6  and C-7 protons of the P-lactam ring opened 
product. Also evident were a second pair of doublets which flanked the HDO signal, centred 
near 4.72 and 4.86 ppm (J ~ 3 Hz), i.e.,
6 -H 7-H J in Hz
Intact molecule of 4.29 
Ring opened product 
(enzymatic hydrolysis)
* Small separation change is evidence thai the 7-H, 6 -H configurations are retained.
The chemical shifts of C-6 /  C-7 protons of desacetoxycephalothin153 (p.142 and those of
or
the analogous protons of benzylpenicillin (5-H, 6 -H) also moved upfield when the 
p-lactam rings opened. The rest of the specuum, Fig. 4.4a, showed little change apart from 
the slight upfield shifts of the two doublets due to 2 -CH2  and the appearance of two (1 :2 ) 
singlets at 1.90 ppm (sharp) and 1.86 ppm (broad) with an integration (total)= 3 protons.
A spectrum recorded 90 min after the start of the experiment was similar to the initial 
spectrum and differed only in the appearance of fine structure on the lower field 2 -CH2 
doublet and a small change in the relative areas of the two signals near 1.90 ppm.
5.05 d 5.56 d 4.5 (cis)
4.52 d 4.60 d 5.0 (cis)*
4.72 d 4.86 d ~ 3.0
*PPM
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F ig .4 .4 a  : Part o f  the 2 7 0  1H N M R  spectrum  o f  the 7-phenylacetam ido derivative 4 .2 9  in  
buffer p D  10 + p-lactam ase (Porton) recorded im m ediately after preparation. T he broad band 
centred near 4 .8  ppm  is due to IIDO .
E i g h t e e n  h o u r s  l a t e r ,  t h e  f o l l o w in g  c h a n g e s  w e r e  o b s e r v e d  i n  t h e  s p e c t r u m  ( F i g .4 .4 b ,
i) the region close to the HDO band now showed a doublet pair centred near 4.55 and 4.66 
ppm in addition to the 4.52/ 4.60 ppm and 4.72/4.86 ppm doublets (these new signals were 
also apparent at low intensity in the 90 min spectrum),
ii) both halves of the 2 -CH2 signal were split into overlapping doublets,
iii) the A1CH2 signal also split into two overlapping doublets,
iv) the 3-Me region (1.90 - 1.85 ppm) now showed three lines : two closely placed lines at 
1.90 -1.91 ppm and a broad singlet at 1.86 ppm, with 1:2 relative intensities.
Nine days after the start of the experiment, the reaction mixture spectrum, was even 
more complex.
Although spectra could not be analysed in detail, since reference products of defined 
NMR parameters were not available, the results are clear evidence of enzyme-induced 
opening of the p-lactam ring and the rapid isomerization of the 7-R, 6 -R-analogue of 
benzylpenicilloic acid. After 90 minutes, signals due to a third product were evident, clearly 
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F ig .4 .4b  : A s for F ig .4 .4a  but recorded 18 hours after the start o f  the experim ent. T h e three 
d oublet pairs in the 7-11, 6 -11 region are designated a/a, b/b, and c/e.
b) Hydrolysis of 7-phenylacetamido-derivative 4.29 in pD 10.0 + Genzyme P 
-lactamase at 5°C :
The initial spectrum, showed little apparent change except for a new minor signal close 
to 3-Me signal at 1.90 ppm.
An hour later, the 6 -H, 7-H signals of the starting (intact) material 4.29 were still present 
but of reduced intensity, plus a new pair of doublets centred at 4.60 and 4.52 ppm (separation 
4.8 Hz). In the 2 -CH2  region of the spectrum, doublets due to the intact antibiotic were 
present (centred near 3.18 and 3.55 ppm) plus lower intensity doublets to higher field 
(centred near 3.08 and 3.42 ppm) as seen in the spectrum of material treated with the Porton 
enzyme. Three signals were displayed in the methyl region, one major at 1.90 ppm with a 
minor splitting, and a new broad signal at 1.86 ppm, having a 3-proton integration.
The following was observed in the spectrum recorded 17 hours after commencement:
i) The 5.55,5.05 ppm doublets, due to the 7-H/ 6 -H of the starting compound were absent.
ii) The 4.60, 4.52 ppm doublets were of increased intensity accompanied by a new set of 
low intensity doublets centred near 4.55 and 4.66 ppm ( the 4.72/ 4.86 ppm signals cf the 
Porton spectrum could not be resolved, possibly obscured by the HDO signal and side bands 
)•
iii) The 3-Me region showed two signals : one narrow at 1.90 ppm (no splitting), and the 
other broad at 1.86 ppm, with an intensity of 3:5, respectively.
iv) In the 2 -CH2  region (3.60-3.00 ppm), the 3.55,3.19 ppm doublets, due to the 2 -CH2 of 
the starting material were absent; two sets of signals centred at 3.40, 3.10 ppm appeared 
overlapping, with the lowfield doublets showing fine splitting.
In a spectrum run after a 9 day period all these features were apparent but with changes in 
relative intensities, Table 4.3, p. 148).
Table 4.3* :
7-H,6 -H 2-CH2 3-Me
Opened ring 4.60,4.52 d dd centred 3.40 1 .8 6  s,
(4.8) (18)
products 4.67,4.56 d dd centred 3.10 1.91s
(4.6) (18)
a s=singlet, d=doublet, J values in parenthesis.
Thus results comparable to those observed after use of the Porton enzyme were found.
Under the conditions of these experiments in which there was little control over 
quantities of enzymes employed, the Genzyme product was slower acting than the 
p-lactamase obtained from Porton.
(C) 1H NMR observations on the hydrazinolysis of the 
7-phenyIacetamido derivative 4.29
Pratt and Faraci (1986)153 examined the reaction of hydrazine with 
desacetoxycephalothin 4.30 (and other cephalosporin derivatives) at pH 9 and 5°C. UV 
spectra showed a hydrazine-catalysed, rapid (< 1 0  s) absorbance decrease at 260 nm, of 
similar magnitude to that observed in the P-lactamase-catalysed hydrolysis. Absorbance at 
A260 nm is characteristic of intact cephalosporins. The authors followed the reaction by *H 
NMR experiments and the initial spectrum changed instantly (< 1 min) to that of 4.32 
(presumed) whose upfield movements of the C- 6  and C-7 protons chemical shift support this 
structural assignment CTable 4.4, p. 149). They interpreted their results in term of Scheme 
4.26 reaction pathway. No detailed *H NMR analysis of 4.32 was described to support
this degradation Scheme
O - C H CONHk
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6 -H/ 7-Ha 3-Me
Intact 4.30 5.07,5.59 d 1.90 s
Hydrazinolysis product 4.32 4.55d, obscured 1.87 s
Enzymatic product 4.31 4.51,4.59 d 1.84 s
a (no separations reported); d=doublet, s=singlet.
Results and discussion:
The changes in 1H NMR spectra that occurred when 4.29 was allowed to react with 
hydrazine hydrate in presence of a deuterated buffered solution of 0.1 M sodium carbonate 
(pD 10.0) are shown below.
The starting spectrum of the reaction mixture, Fig.4.6a (p. 151, 10 min later), showed the 
following significant changes:
i) The 6 -H/  7-H signals of the starting compound were still present, but with much reduced 
intensity, accompanied by the appearance of a set of two doublets in the 4.40-4.65 ppm
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\region of separation ~ 9 Hz.
ii) Appearance of a new shaip singlet (integrated for about one proton) near 4.50 ppm.
iii) The methyl signal split into 3 lines ( with a 3 proton integration) at 1.89 ppm (sharp), 
1.86 ppm (broad, major) and 1.84 ppm.
iv) The 2 -CH2  signal shifted upfield, the outer peaks greatly weakened.
165 minutes later, the original signals from the p-lactam protons had vimzally 
disappeared, and the two doublets centred at 4.45, 4.61 ppm ( J=9.3 Hz) were now well 
resolved, except for the intensity of the lowfield doublet being slightly affected by the water 
broad peak centred near 4.80 ppm, and integrating for about 2 protons (Fig.4.6b). The 
disappearance of the original 2 -CH2 AB system (centred at 3.19, 3.56 ppm) and its 
replacement by two sets of overlapping double doublets centred at 3.09, 3.23 ppm (which 
still integrated for about 2  protons) seemed to be synchronous with the disappearance c: the 
original 6 -H/ 7-H signals. The ArCHi signal shifted slightly upfield and showed signs of 
further splittings. The three lines in the methyl region at 1.89 ppm (narrow), 1.86 ppm 
(broad) and 1.83ppm (broad) had relative intensities of 1:2:2, respectively.
The spectrum was much the same after 24 hours.
These results indicate that the initial product of hydrazinolysis is a single isomeric form 






The 3 J value between 6 -H and 7-H is notably greater than the value found in the intact 
antibiotic but comparable to the coupling found for equivalent protons of hydrazinclysis 
products of benzylpenicillin (see p. 137). On storage further resonance signals appeared,
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notably clear duplication  o f  the 2 -C H 2  sign a l ( 2  sets o f  A B  type ). T h is could be a result o f  
epim erization  o f  4 .3 3  at C-6 and C -7. E pim eric 6-H  and 7 -H  doublets could not be resolved; 
perhaps these are obscured by the broad H D O  signal near 4 .8  ppm .
J
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J Z 6 -H6-H -CH
F ig .4 .6  : Part o f  the 2 7 0  M H z 1H  N M R  spectra o f  7-phenylacetam ido derivative 4 .2 9  (in  
carbonate b u ffer  pD  10) in p resence o f  hydrazine hydrate :
a) recorded  im m ediately after preparation,
b) 165 m in  after the start o f  the experim ent.
(See text for  details).
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4.4.2.2 1H NMR study of degradation of cephalosporins with good leaving 
groups at C-3’
Cefoxitin
OMeH c  




Grabowski et al.(1985)144 reported a 13C NMR study of the aminolysis of cefoxitin 
(liquid ammonia at -50°C) which they claimed to be the first spectroscopic characterisation of 
the intermediate resulting from (3-lactam cleavage (4.34) prior to loss of the carbamic acid 









, Q ^ H:







4 - 3 5
Scheme 4 2 7
The authors stated that the intennediate 4.34 had a lifetime sufficient for 13 C spectral 
characterisation. Subsequent reaction yields 4-35 which is stable to the aminolysis conditions, 
and readily characterised by carbon-13 spectroscopy. Identification of 4.34 and 4.35 was 
based on the 13 C data, and the chemical shifts of cefoxitin and its aminolysis products are 
listed in Table 4.5 (p. 153).
T a b l e  4 .5  : 13 C  c h e m i c a l  s h i f t s  ( i n  p p m )  o f  c e f o x i t i n ,  4 . 3 4  a n d  4 .3 5  :
Carbon
atom
Cefoxitin 4.34° 4.35* Notes
C-2 26.05 28.39 30.04
C-3 114.30 101.74 131.33
C-4 134.05 139.60 172.09
C- 6 63.42 58.36 67.21
C-7 95.43 89.38 87.73
C-8 160.72 171.32 171.50
C-3’ 64.59 66.63 123.25 evidence of 
alkenic nature
a Numbering of 4.34 and 4.35 follows that of cefoxitin.
4.34 was identified by the increased shielding of C-3, now conjugated to an amine rather 
than an amide nitrogen, and large changes in shielding of C-4, C-6 , C-7, and C-8 , the latter 
having been converted to a primary amide carbonyl. Conversicn to4-35 produced some 30 
ppm deshielding of C-3 and C-4. The exo-methylene carbon recomes olefinic (C-3’) and 
appears downfield. Nevertheless, the structural identity of ihis intermediate has been
j  54.questioned .
Discussion of present work results:
1. Enzymatic hydrolysis of cefoxitin :
From the 1H NMR spectra of the reaction mixture of cefoxitin Na in 0.5 ml of 
deuterated water (D2 O) and few crystals of P-lactamase (Genzyne) at room temperature, run 
immediately and at appropriate intervals during 8 days of storage, the compound appeared to 
be substantially stable to enzymatic hydrolysis, as no signal changes occurred apart from 
appearance of minor peaks.
2 . Hydrazinolysis reaction on cefoxitin Na :
8 Mg of cefoxitin Na were dissolved in 0.5 ml 0.25M deuterated carbonate buffer 
solution at 5°C, then 5 |ll hydrazine (neat) was added to the alkaline solution in an NMR 
tube. *H NMR spectra were taken immediately and subsequently at appropriate intervals 
(stored at 5°C).
The initial spectrum (Fig.4.7a, p. 156), run 10 min after the start of the experiment, gives 
evidence of the rapid p-lactam ring opening, partial expulsion of the 3’-substituent and 
production of a structure with an exocyclic methylene group, indicated by the upfield shift of 
the signal due to the 7-OMe (3.52 ppm moved to 3.22 ppm), the much weakened double 
doublets at 4.64, 4.80 ppm and the appearance of two signals at 5.66, 5.71 ppm, with 
separation of 12.8 Hz similar to that of the non-equivalent 3-CH2 protons attached to an sp2 
carbon atom; the downfield shift indicates the olefinic nature of the exo-methylene at C-3.
21 Hours later (Fig. 4.7b, p.156), the signals at 4.64, 4.80 ppm were competely absent; 
signals at 5.14 ppm (due to C-6), and 5.65, 5.70 ppm (C3 ==CH2 ) had slightly weakened. 
The 7-OMe, 2 -CH2  and ArCH2 signal regions were more complicated, showing overlapping 
of peaks. The spectrum after 3 days of starting the experiment, was even more complex, 
showing appearance of new signals at 5.30, 5.40 ppm (as singlets), and a double doublet 
centered at 5.50 ppm. Signals at 5.14 ppm (s), 5.65 ppm (s) and 5.70 ppm were greatly 
weakened (trace only). Other signals, due to 7-OMe, 2 -CH2  and A1CH2 , were more 
complicated and difficult to interpret.
It is clear from the above *H NMR data of the initial spectrum of the reaction mixture, 
the cleavage of the p-lactam ring, and the intermediate 4.36 (Scheme 4.28, p. 155) prior to 
loss of the carbamic acid anion from position 3’, has enough lifetime for *H NMR to record 
the double doublet at 4.64, 4.80 ppm due to the residual 3 -CH2 OCONH2 . Subsequent 
reaction yields the(exo-methylene product 4.37 which is stable to the hydrazinolysis
condition for at least 20 hours, and readily characterised by 1H NMR spectroscopy. Later, 
epimerization at C- 6  appears to have occurred, and more than one epimer was present in the 
reaction mixture, as shown by the change in chemical shifts of signals due to 6 -H and 
C3 = C H 2  protons, and the overlapping of more than one set of peaks in the 7-OMe, 2 -CH2 
and A1CH2  regions.
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Fig. 4 .7  : 2 7 0  M H z *H  N M R  spectra o f  the hydrazinolysis o f  ce fo x itin  N a  : a) recorded  
im m ediately after preparation, and b) run 21 h is after com m en cem ent. S ee text for details.
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4.4.3 Effect of addition of NaOD-D20  on cephalosporins 
(uncontrolled high pH)
4.4.3.1 Preparation o f 1H NMR sample
20 to 30 mg of the cephalosporin was dissolved in 0.5 ml D20  at room temperature 
( 24*C) and the *H NMR spectrum of the aqueous solution recorded. A few drops of 
deuterated sodium hydroxide (NaOD, 40 %) were then added to the aqueous solution in the
1 r
NMR tube. H NMR spectra (at 270 MHz) were then taken immediately and at appropriate 
intervals.
4.4.3.2 Results and discussion
a) Cephalosporins with a good leaving group at C-3
These materials generally produce complex spectra but in most cases signals diagnostic 




A very complex spectrum resulted in presence of NaOD, but the following changes 
were noted:
i) disappearance of doublets due to 6 -H, 7-H (centred at 5.10,5.60 ppm, separation 4.9 Hz), 
and 3’-CH2  (at4.65,4.82ppm, 12.5 Hz).
ii) low field shift of the ArCH2  signals (dd centred at 3.86 ppm moved to 4.17 ppm, 
separation 16 Hz), and the upfield movement of the singlet due to OCOMe ( from 2.06 ppm 
to 1.84 ppm), the latter position is characteristic of acetate.
iii) appearance of 3 doublets centred at 5.30,5.40 and 4.58 ppm, with separations of 4.6 Hz.
iv) appearance of two signals at 5.55, 5.5.9 ppm (due to the exo-methylene protons 3=CH2 
at C-3).
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These changes indicate lactam ring cleavage, accompanied by the expulsion of the 





6 -H, 7-H 3’-CH2 2-CH2 OCOMe
Intact 5.22,5.83 d 4.72,4.89 d 3.41,3.69 d 2 . 1 0  s
(4.6) (12.5) (18.0)
Hydrolysis 5.14,5.46 d 4.22 dd 3.36,3.59 d 1.87 s




2.10 1.87 ppm5.83 5-46 5.22 5.1-
As shown in spectrum (Fig. 4.8, p.159) and the Table above, there is evidence for the 
P-lactam ring opening only, indicated by the upfield shifts of 6 -H/ 7-H signals; no exocyclic 
methylene signals were observed. The upfield movements of signals due to 3 ’-CH2 and 
OCOMe also indicate deacetylation of the 3’-substituent of the starting compound. It is not 
possible to decide from the spectrum if the p-lactam ring cleavage and deacetylation is a 
conceited reaction or otherwise. The spectrum of desacetylcefotaxime in D2 0-NaHC03 was 
similar to that of the NaOD-treated solution but different in having 7-H/ 6 -H signals at lower 
field (5.74 and 5.16 ppm respectively).
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Fig. 4.8 : 270 MHz NMR spectra of cefotaxime Na in a) D2 O, b) immediately after
addition of NaOD, and c) two days later, d) Expansion of the 3.4 -5.5 ppm region of 
spectrum (c).
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3 .  C e p h a l o r i d i n e  N a
The compound showed rapid P-lactam ring opening (upfield movement of the 6 -H/
7-H signals: 5.07,5.60 ppm, J=4.8 Hz to 4.50,5.30 ppm, separation 2.2 Hz) accompanied by 
removal of the 3’-substituent, a conclusion supported by the disappearance of the double 
doublet due to 3 *-CH2 at 5.27, 5.48 ppm plus the presence of a neutral pyridine molecule 
indicated by the upfield shift of its protons ( multiplets centred ai 8.02, 8.50 and 8.90 ppm 
moved to 7.30, 7.71 and 8.35 ppm ). The formation of the exo-methylene at C-3, was 
indicated by the pair of lines centred at 5.50 ppm with a separation of -  15.0 Hz and 
integrating for about two protons. Furthermore, it appeared from the small separation (2.2 
Hz) of the 6 -H, 7-H signals that the hydrolysis product had undergone epimerization at either 










A well-resolved spectrum (Fig. 4.9, p.161) was obtained after basification with NaOD. 
The duplication of signals indicates presence of more than one molecular species in the 
reaction mixture at the time*of recording the'spectrum, as shown below: 
i) An intermediate with a cleaved P-lactam ring, prior to loss of the carbamic acid anion
- 1 6 0 -
from position 3’, indicated by the upfield shift of the 6 -H, 7-H signals (doublets at 5.23, 5.83 
ppm, J= 4.6 Hz moved to 5.12,5.44 ppm, J=4.9 Hz) and the presence of the double doublet ( 
of reduced intensity ), due to 3’-CH2, shifted upfield (dd at 4.68, 4.87 ppm moved to 4.60 
ppm, lowfield doublet obscured by the HDO peak).
n) An exo-methylene product with cleaved p-lactam ring, indicated by the upfield 
movements of the 6 -H/ 7-H signals (d at 5.12,5.44 ppm moved to 4.69,5.38 ppm, separation 
3.7 Hz) and appearance of a pair of lines centred 5.58 ppm, integrating for two protons, due 
to the exo-methylene at C-3.
iii) Epimerization at C- 6  and C-7 is another possibilty, indicated by duplication of the 6 -H,







































































Fig. 4.9 : 270 MHz !H NMR spectrum of cefiiroxime Na in D20  + few drops of NaOD. 
Insert: normal spectrum in D2 0 . aC3 =CH 2 b7-H c 6 -H dC3 -CH2
Y = intermediate product (with cleaved ring and intact carbarnic acid in position-3).
Y = exo-methylene product (with cleaved ring and Jess of the carbamic anion from position-3).
- l b i -




The product obtained from the alkaline hydrolysis showed a complex spectrum, 
especially the 2.90-3.60 ppm region. Hydrolysis of the lactam ring with expulsion of the 
3’-substituent occurred, indicated by the upfield movements of the 6 -H and 7-OMe signals 
and the complete absence of the double doublet due to the 3 ’-CH2  of the intact antibiotic, 
with the formation of the exo-methylene at C-3, indicated by the two signals at 5.45, 5.52 
ppm.





6 -H, 7-H 2-CH2 3-Me
Intact 5.03,5.57 d 2.68,3.53 d 1 .8 6  s
(4.4) (18.0)
+NaOD 3.20,3.83 d 1.97 s
After addition of NaOD, a poor spectrum was obtained, showing cleavage of the
p-lactam ring, indicated by the disappearance of the 6 -H, 7-H signals. Degradation products,
esuch as a piperazine dione derivative, could not be identified since refemce compounds were 
not available.
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2. Cefaclor
Apart frcm evidence of p-lactam ring opening (absence of 7-H, 6-H signals), the 
spectrum recorded after addition of NaOD could not be analysed.






From the spectral changes which occurred after addition of NaOD, it is clear the 
hydrolysis of die P-lactam ring took place, indicated by the upfield movements of the 6-H,
7-H signals accompanied by a decrease in coupling constant value (4.98, 5.52 ppm, 
separation 4.4 Hz moved to 4.58, 5.29 ppm, separation 3.2 Hz) together with formation of an . 
exo-methylene signals (as two overlapping doublets at 5.51,5.52 ppm). Disappearance of the 
double double; due to 3’-CH2 (centred at 3.86 ppm) corresponded to the appearance of the 
two doublets overlapping at 5.51, 5.52 ppm (J=15.7 Hz). The duplication of signals due to 
3’-CH2(exo), 6-H, 7-H, ArCH and phenolic protons indicated isomerization of the 
degradation products.
As in all cephalosporins with a-amino substituents in the C-7 amido side chain, 
diketopiperazine formation is also possible but at this stage no evidence for this route was 
available.
4.4.4 Acid degradation of cephalosporins
4.4.4.1 Introduction
The formation of desacetyl and lactone derivatives as a result of acid hydrolysis of 
3-acetoxymethylcephalosporins has already been discussed in section 4.1.2.2, p.120. These 
cephalosporins may lose their acetyl function to give corresponding desacetyl derivatives 
which subsequently eliminate water to form the fairly stable lactones (Scheme 4.9, p.120). 
The lactonization occurs rapidly only at relatively low pH. This route is well documented in
The acidic degradation of the 7a-amino-containing cephalosporins (such as cephalexin
4.4.4.2 Source of compounds
Sodium salts of cephalothin and cefotaxime were kindly supplied by Eli Lilly and Roussel 
(U.K), respectively [see Table 2.1, p.25]. Cefotaxime (as free acid) and desacetylcefotaxime 
were also provided by Roussel. Desacetylcefotaxime sodium and desacetylcefotaxime 
lactone were obtaied from Hoechst (England).
the literature.36,75,126-129
RCON RCON"' S
- C O C H ,-----
CH2OCOCH; H,OH
COjH C 0 2H
R C O N H s
O
and cefaclor) has also been reviewed67,146 in section 4.1.2.5, p.128. A diketopiperazine-type
compound 4.20 was characterised as the major degradation product:
c o ;
4-20
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A -7-Phenyl—acetamido-desacetoxy—cephalosporin lactone was provided by Professor 
MJPage, Huddersfield Polytechnic. These compounds were used as received.
The following materials were prepared as described in Chapter two : cephalothin free 
acid, desacetylcephalothin and desacetylcephalothin lactone
With knowledge of the *H NMR features which distinguish intact 3-acetoxymethyl 
cephalosporin antibiotics from their desacetyl and lactone derivatives (see below), 
experiments were carried out to assess the potential of NMR in monitoring the degradation of 
cephalosporins of this kind under conditions of low pH.
4.4.4.3 Procedure
(pH < 2 but uncontrolled by a buffer)
The *H NMR spectrum of a cephalosporin (mostly Na salt) was run in DMSO-d6 
(D2 O usually added), then re-run after addition of 1-2 drops DC1 (pH attained < 2). The 
spectral changes were followed with time.
Addition of acid will bring about rapid conversion of the sodium salt to the free acid. 
This may be followed by deacetylation (to 3 -CH2 OH) and then lactonization. Deacetylation 
will produce acetic acid (CH3 COOH) which will have a *H Me signal that differs from 
acetylmethyl of the intact antibiotic (generally upfield of antibiotic signal).
DMSO-dg was chosen as it is a universal solvent for all likely products.
4.4.4.4 Cefotaxime series (in DMSO-d )^









2. Cefotaxime free acid
3. Desacetylcefotaxime
4. Desacetylcefotaxime lactone
Table 4.6 : NMR chemical shifts (ppm) of the above compounds I, 2, 3,and £  (in
DMSO-d6) :
Compound 7-H 6-H 3-CH2 NOMe 2-CH2 OCOMe
_1 5.60 dd 5.0 d 4.97,4.73 d 3.84 s 3.47,3.20 d 2.00s
(4.9,8) (4.9) (12.2) (17.2)
+D2 O 5.62 d 5.0 d 4.92,4.74 d 3.86 s 3.48,3.23 d 2.02 s
(4.9) (4.9) (12.2) (17.2)
2 5.80 dd 5.15 d 4.99,4.68 d 3.84s 3.63,3.49 d 2.04 s
(4.9,8.2) (4.9) (12.8) (18.2)
+D2 O 4.74 d 5.15 d 4.98,4.73 d 3.84 s 3.63,obscured 2.05 s
(4.8) (4.8)
3 5.56 dd 4.95 d 4.18,nr3.85dd 3.84 s 3.47,3.29dd
(4.7,8) (4.6) (12-13) (18.0)
+D2 O 5.63 d 5.0 d 4.23,4.03 dd 3.89 s 3.50,3.37 dd
(4.6) (4.6) (12.8) (17.4)
£ 5.94 dd 5.16 d 5.05 brs 3.85 s 3.79 dd
(4.9,8.2) (5.2)
+D2 O 5.9 d 5.18 d 5.04 brs 3.88 s 3.83,3.73 dd
(4.9) (4.9) (18.8)
Footnotes : s=singlet, brs=broad singlet, d=doublet, dd=double doublet nr=near, J values (Hz) in 
parenthesis.
+ D 2 0 =  few drops o f  D 2 O added to the cephalosporin solution in DM SO-dg.
Notes from Table 4.6 :
i) The 7-H, 6-H, 3 -CH2  and 2 -CH2 signals of desacetylcefotaxime £  are at higher fields 
compared to those of free acid 2 (most pronounced for 3-CH2  and valuable as an aid to 
differentiation).
ii) Cefotaxime lactone 4 is differentiated from cefotaxime free acid and desacetyl £ b y  the 
broad singlet nature of 3 -CH2  (exo); also 2 -CH2  is lower field of free acid and desacetyl 
signals with smaller AB chemical shift differences.
iii) The signals due to 7-NH and Ar-NH2 (>7.00 ppm) are absent after D2 O exchange; in 
addition, the 7-H signal changes from a double doublet to a doublet
iv) In the lactone £  the 2 -CH2  and 3 -CH2 protons are almost equivalent appearing as broad
singlets or narrow multiplets. This is presumably a result of the molecule being more planar 
than the parent antibiotic whereby differences between the environments of CH2 pairs are 
small.
The lactone derived from the cephalosporin 4.38 showed similar characteristics
to that of cefotaxime lactone. The *H NMR spectral (in DMSO-d$ + D2 O) data were as 
follows : 7-H/ 6-H 5.84, 5.10 ppm (d, 5.0 Hz), 3 -CH2 5.05 ppm brs, 2 -CH2 3.83, 3.74 ppm 
(d, 18.6 Hz) [3.79 ppm as brs in absence of D2 O], ArCH2 3.59,3.51ppm (d, 14.1 Hz).
The chemical shift data of Table 4.6, measured from spectra of solutions in DMSO-cfg at 
near-neutral pH may differ in solutions of lower pH (as in proposed experiments). This was 
checked by recording spectra in DMSO-d6 plus DC1; the spectral data (in ppm) were as 
follows:
Cefotaxime Lactone:
7-H 5.9 d, 6-H 5.2 d, 3-CH2 5.07 brs, NOMe 4.02 s, 2-CH2 3.89, 3.79 d 
(separation 18.6 Hz), i.e. little change apart from small chemical shift differences.
Desacetyl derivative:
Acidification of this derivative would be expected to lead to lactonization:
a) Freshly acidified solution : 7-H, 6-H minor doublet pair at 5.90, 5.23 ppm, major 
doublet pair at 5.74,5.16 ppm.
b) Two hours later: 7-H, 6-H 5.9/ 5.23 ppm and 5.74/ 5.16 ppm doublets were of similar 
intensities.




It may be concluded that the 5.9/ 5.23 ppm doublet pair is due'to the lactone and the 5.74/ 
5.16 ppm pair to the desacetyl derivative in the free acid state, as from Table 4.6 :
7-H/6-H 5.63/5.00 ppm.
c) 7 days later: the spectrum was essentially similar to that of the pure lactone:
7-H, 6-H 5.90,5.24 ppm doublets,
3*-CH2 5.07 ppm broad singlet,
2 -CH2  3.83,3.51 ppm doublets.
2-CH2 :
Both fresh and 2 hour aged spectra showed a pair of 4-line signals which could 
be assigned to 2 -CH2 of the lactone (3.89, 3.77ppm, d) and desacetyl derivative (3.68, 3.57 
ppm, d), compared to 2 -CH2  of desacetyl cefotaxime (3.50, 3.37 ppm, d) and cefotaxime 
lactone (3.83,3.73 ppm, d) of Table 4.6 (in DMSO-J6 +D 2  O).
Spectra of cefotaxime Na run in DMSO-d$ + DC1:
a) Freshly acidified solution (Fig. 4.10a, p.170):
The high intensity of OCOMe signal at 2.11 ppm showed that most of the antibiotic was 
intact at this stage. A lower intensity signal at 2.07 ppm was evidence of some loss of acetyl. 
7-H/ 6-H, 3 -CH2  and 2 -CH2  signals of the intact molecule were also prominent Minor 
signals of the lactone were resolved : 7-H 5.92 ppm (overlapped HDO band), 6-H 5.30 
ppm , 3 -CH2  at 5.12 ppm (as broad singlet), 2 -CH2  as double doublet centred near 3.87 ppm. 
No signals due to the desacetyl intermediate were detected.
b) After 60 minutes :
Signals due to intact antibiotic and lactone were approximately of equal intensities. The 
upfield shift of the OCOMe signal (from 2.11 ppm to 2.07 ppm) is a characteristic of acetate. 
The broad singlet at 5.12 ppm, integrating for tw o protons, was that of the methylene protons
BH I
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Fig. 4.10 : Partial JH NMR spectra of cefotaxime Na in DMSO-dg + DC1 : A) recorded 
immediately after acidification. Note scale error (add 0.2 ppm), and B) run 2 hrs later.
a: CT 7-H 
a’: lactone 7-H 
e : CT 2-CH2 
e’: lactone 2 -CH2 
CT = Cefotaxime
b: CT 6-H c: lac|>ne 3’-CH2 
b ’: lactone 6-H d: CT 3’-CH2 
f : CT 3’-Me 
F: Me of acetate group
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of the lactone ring. The chemical shift difference of the 2 -CH2 .of lactone are smaller (0.14 
ppm) than those of the intact antibiotic (0.17 ppm)
c) Two hours after acidification (Fig. 4.10b, p. 170) :
The lactone signals were of greater intensity than those of the intact molecule (~ 2:1).
d) 40 hours later:
The spectrum was essentially of lactone signals only. The acetate Me signal appeared as 
a singlet at 2.07 ppm. Those of the lactone molecule were : 2 -CH2  3.94, 3.80 ppm (double 
doublet, J=18.7 Hz), NOMe 4.07 ppm (singlet, 3H), lactone CH2 at 5.12 ppm (broad singlet, 
2H), 6-H at 5.30 ppm (doublet, J=5.0 Hz), 7-H 5.92 ppm (doublet, J=5.0 Hz) and ArH at 7.14 
ppm (singlet, 1H).
In a second trial (Fig. 4.11, p. 172), a spectrum of cefotaxime Na in DMSO-dg, D2 O + 
DC1 showed that the lactone preponderated in the freshly run solution. The acetate Me signal 
appeared as an intense singlet at 1.95 ppm, while lactone signals were as follows : double 
doublet centred at 3.85 ppm due to 2 -CH2 , lactone CH2  at 5.07 ppm as broad singlet, 6-H 
5.22 ppm (doublet, J=4.9 Hz), and 7-H at 5.91 ppm (doublet, J=4.9 Hz). It was specially 
fortunate that the HDO band did not obscure the signals in the spectrum.
The above acid products signals showed similar spectral characteristics to that of 
authentic lactone sample run in DMSO-d6 plus DC1: 7-H 5.9 ppm (doublet), 6-H 5.2 ppm 
(doublet), 3 -CH2  5.07 (broad singlet), NOMe 4.02 ppm (singlet), 2 -CH2 3.89, 3.79 ppm 
(double doublet, J=18.6 Hz).
A spectrum run 5 days later displayed lactone signals only.
In no case could the presence of the desacetyl intermediate be detected.
- 1 7 1 -
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Fig-4.11: Partial (expanded) *H NMR spectrum of cefotaxime Na in DMSO-d6, D20  + DC1 
showing the following signals :
a) lactone 7-H c) lactone 6-H e) lactone 3’-CH2 (CT 3’-CH2 obscured by HDO band)
b) CT 7-H d) CT 6-H f) NOMe g) lactone 2-CH2 h) CT 2-CH2
CT = Cefotaxime
PPM
1 I 1 ' • ' | « i" i i— |' i i i ~i— | i i -rr -j-r 
3 . 9  3 . 8  3 . 7  . 3 . 6  3 . 5
4.4.4JJ Cephalothin series (in DMSO-d^)
Table 4.7 below shows a comparison between the chemical shifts (5 ppm) of the 
following compounds:












Table4.7 : ^chem icalshifts (inppm) o f j , 2,3  andj4“ (inDMSO-dg)
Compound 7-H 6-H 3-CH2 2-CH2 OCOMe
_1_ 5.50 d 4.94 d 4.97,4.75 d 3.47,3.22 d 2.01s
(4.6) (4.6) (12.1) (17.2)
2 5.70 dd 5.10d 5.01,4.68 d 3.63,3.49 d 2.03 s
1 5.48 dd 4.90 d 4.18, 3.86 d 3.48,3.31 d
(4.9,8.4) (4.9) (12.4) (17.7)
_4 5.90 dd 5.20 d 5.17 brs 3.49 s
(5.1,8.4) (5.1)
a For abbreviations see footnotes under Table 4.6.
Relationships amongst this series are similar to those found for the cefotaxime group. 
Again the 3-CH2 and 2 -CH2 resonances of the lactone show the effects of a reduced CH2  
chemical shift difference in each case.
Spectra of cephalothin Na run in DMSO-dg-DCl
a) Freshly run
The spectrum was essentially that of the free acid. The intensity of the acetylmethyl 
signal at 2.05 ppm gave evidence of the small degree of degradation at this stage. The rest of 
the antibiotic signals had high intensities and minor resonances were not resolved. These 
signals were : 7-H at 5.70 (double doublet, 4.8 Hz), 6-H 5.10 ppm (doublet, 4.8 Hz), 3 -CH2
5.01, 4.68 ppm (as double doublet, 12.8 Hz), 2 -CH2 3.63, 3.49 ppm (double doublet. 18.2 
Hz). OCOMe as singlet 2.03 ppm. No signals due to desacetylcephalothin (as intermediate) 
were observed.
b) 6 days later
The 7-H 5.82 ppm (doublet, 5.0 Hz), 6-H 5.13 ppm (doublet, 5.0 Hz), 3 -CH2 5.07 ppm 
as broad singlet, 2 -CH2  double doublet centred 3.82 ppm signals of the lactone molecule 
were more intense than those of the intact antibiotic. A single methyl signal at 1.94 ppm (due 
to acetate) was present Minor 7-H, 6-H and OCOMe signals of the antibiotic were resolved.
c) 30 days later: Only lactone signals were present
Some experiments were carried out to detect de-acetylation of cefotaxime and 
cephalothin without subsequent lactonization by use of a pD 4.4 buffer in 1:1 DMSO-dg/ 
D2 O (by dissolving 30 mg of KH^PO 4  and 50 mg of N aqliPO^  in sufficient D2 O to 
produce 10 ml and adjusting the pH to 4.0 with glacial acetic acid).
The spectrum of cefotaxime free acid run immediately after dissolution in this buffer was 
that of a single product. Chemical shifts of signals due to 7-H (d, 5.71 ppm), 6-H (d, 5.1 
ppm) and 2 -CH2  (3.60, 3.35 ppm d) were close to those of both the intact antibiotic and its 
desacetyl derivative (Table 4.6, p. 166) with no evidence of the presence of lactone. However 
the presence of a four line signal centred near 4.81 ppm due to the 3 -CH2  protons and
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absence of a signal of this kind near 4.0 ppm gave evidence that loss of the acetyl group had 
not occurred.
This conclusion was confirmed by re-running the spectrum after the addition of authentic 
desactylcefotaxime when clear duplication of the 7-H and 6-H doublets was seen together 
with the appearance of a new 3 -CH2  signal centred near 4.2 ppm.
A similar result was obtained when a solution of cephalothin Na in the pD 4.0 buffer was 
examined. The gap between deacetylation and lactonization of 3-acetoxy methyl 
cephalosporins must therefore be a narrow one.
4.4.4.6 Notes on acid-degradation of other cephalosporins 
(in DMSO-d6 + DCl):
1. Cephaloridine Na
Only small changes were observed after addition of DCl. These involved the slight low 
field shift of the 7-H (from 5.56 ppm to 5.75 ppm), 6-H (5.05 ppm to 5.20 ppm), 3 -CH2 (the 
double doublet centred at 3.50, 3.10 ppm moved to 3.60, 3.40 ppm). The pyridyl signals 
showed very little difference after acidification ( 9.15, 8.60, 8.15 ppm to 9.05, 8.66, 8.22 
ppm) as further evidence of the molecule still being intact. The above low field shifts could 
be explained as the change of the molecule to that of the free acid. If cephaloridine 
eliminated pyridine (protonated) in the presence of acid, it should yield a lactone identical to 
that formed from cephalothin, No evidence of lactone formation was obtained.
2. Ceftazidime Na
It behaved similarly to cephaloridine. No signals due to the lactone were detected even 5 
days after addition of DCl.
3. Cefsulodin Na
No change other than slight lowfield shift of signals. The molecule remained intact.
4.4.4.7 13 C NMR diagnostic features of lactones
The 13 C NMR spectra of lactones derived from cefotaxime, cephalothin and the 
7-benzylamido derivative 4.38 (p.l6$ were recorded in DMSO-dg. Spectra were similar to 
those of the parent cephalosporins but could be distinguished by the 3-CH2 resonance. The
3 -CH2  resonance moves to lower field when the lactone ring forms, as shown below :
3 -CH2 free acid (ppm) lactone (ppm)
Cefotaxime 63.8 72.0




" Investigation of ability of NMR to monitor 
the degradation of penicillin antibiotics by p-lactamase 
enzymes (see p.135)."
Treatment of a penicillin antibiotic with a p-lactamase enzyme would be expected to 
open the P-lactam ring to give the corresponding 5R, 6R penicilloic acid. On storage the acid 
of 5R, 6R configuration should then isomerize to the 5S, 6R diastereoisomer and possibly to 
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Epimerization is known to proceed at C-5 (not C-6) because deuterium exchange does
not occur at C-6 when the reaction is performed in D2 O, a fact which supports
interconversion via the imine tautomer 4.39121.
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The reactions of Scheme 4.29 may be readily monitored by 1H NMR by recording 
spectra of benzylpenicillin in D2 O (Fig.4.12a) treated with a small amount of NaOD/ D2 O. 
Spectra are shown in Figure 4.12, p. 179.
a) 5 min after addition of alkali
No intact antibiotic remains (absence of 5-H, 6-H signals) and the spectrum is that of the 
5R, 6R penicilloic acid.
b) 60 min after start (Fig.4.12b)
Low intensity signals due to 5-H and 2-Me2 of the 5S, 6R penicilloic acid are now 
apparent. These exceeded the intensities of corresponding 5R, 6R signals at 5 hrs (Fig.4.12c), 
and at 24 hrs. After 24 hrs SR signals predominated by a factor of about 8.
Some NMR experiments, chiefly qualitative, of the effect of (3-lactamase enzymes on 
several penicillin antibiotics were next carried out.
The procedure was to dissolve an arbitrary amount of a sample of P-lactamase (obtained 
from Genzyme Biochemicals Ltd) in D2 O and to add a small volume (equal in all cases) to a 
solution of the antibiotic (20-30 mg in 0.5 ml D2 O). The enzyme and antibiotic solutions 
were stored at 5’C when not in use. Viability of the enzyme solution was assessed by 
determining its action on the NMR spectra of benzylpenicillin.
In the first experiment, a spectrum of benzylpenicillin sodium in D2 O was recorded. A 
few drops of a solution of enzyme obtained from Genzyme were added to the solution in the 
NMR tube and spectra recorded at intervals. No buffer system was present
The 5 minute spectrum (Fig.4.13a, p. 180) shows that a mixture of intact antibiotic and 
5R, 6R benzylpenicilloic acid are present Unexpectedly the chemical shifts of the 
penicilloic acid (notably 5-H, 6-H and 3-H) were distinctly lower field than corresponding 
signals observed for the acid generated in D20-NaOD [Table 4.8, p.181]. This must be a pH
* v
effect The acid will exist as a dianion at high pH (D-O-NaOD) whence the carboxylate 
functions exert maximum sliielding influences on nearby protons (Scheme 4.30, p. 181).
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Fig.4.12 : 270 MHz !H NMR spectra of benzylpenicillin Na in D2 O A) 5 min after addition 
of NaOD, B) 60 min after start of experiment, and C) 5 hrs later.
RR = 5R, 6R-benzylpenicilloic acid SR = 5S, 6R-benzylpenicilloic acid.
a 6-H b 5-H c 3-H dPhCH2 e2-Me2 f HDO
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F ig .4 .1 3  : *11 N M R  spectra o f  b enzylpen icillin  N a  +  p-lactam ase (G e n z y m e ): A ) recorded  
5 m in  after addition o f  en zym e, B ) 9 hrs after start o f  experim ent, and C) 4  days later, 
(sam e annotations as fo r F ig .4 .1 2 ) . S ee text p .178, 181 for details. *•
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Table 4.8 : Some of the *H NMR data (in ppm) of benzylpenicillin (intact) and its immediate 




Compound 6-H 5-H 3-H
Intact 5.5 d 5.43 d 4.22 s
(3.85 Hz) (3.84)
Enzymatic 5.36 d 4.64 d 3.93s
product (4.95) (4.95)
Alkaline 5.01 d 4.20 d 3.38 s
product(+NaOD) (6.0) (6.0)
d=doublet, s=singlet, J values in Hz in parenthesis.
After 45 minutes the spectrum was principally that of the 5R, 6R penicilloic acid; all 
penicillin signals had disappeared.
After 9 hrs, the spectrum was that of a mixture of 5R, 6R and 5S, 6R epiners with 
excess of the former (Fig.4.13b).
In the 24 hr spectrum the epimeis ratio was approximately 1:1.
After 4 days, the 5S, 6R diastereoisomer was the major component of the mixture. 
Signals due to a third product were now apparent (see narrow doublets near 5 ppm and the 
2-Me2 region which shows 7-8 lines instead of the 4 indicative of a binary mixture, 
Fig.4.13c, p.180).
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Methicillin Na was the next example to be studied.
 yOMe
/Cyy  CONH^ ^Sv^jvie
TDMe
4- 40  °
The spectrum of material (provided by Beecham laboratories) that had been stored at 5*C 
for several years was consistent with the P-lactam structure 4.40 but showed low intensity 
doublets (near 5.03 and 5.28 ppm) and singlets (1.49 and 1.66 ppm) indicative of the 
presence of a small amount of one of the diastereoisomeric penicilloic acids.
After addition of the Genzyme enzyme little spectral change was seen after 5 hrs 
(Fig.4.14 below) while even after 24 hrs signals due to the intact antibiotic remained 
predominant.
These results concur with the proven resistance of methicillin to penicillinases155.
eX
S I  S I  S S  S . 4 i!i ile 'i.'/Vi:.f c.a c./J c.
Fig.4.14 : 270 MHz JH NMR spectrum of 4.40 5 hrs after addition of p-lactamase from 
Genzyme, showing the stability of the antibiotic to the enzyme.
X=intact antibiotic signal, Y=penicilloic acid signals.
(For abbreviations see annotations under Fig.4.12, p.179).
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The 1H NMR spectrum of a sample of flucloxacillin Na (4.41) in D2 O indicated that the 
sample was pure (5-H, 6-H doublets 5.5,5.6 ppm, 2-Me2 singlets 1.45 and 1.49 ppm). After 
addition of the Genzyme enzyme little change was seen after 10 minutes but a 90 minute 
spectrum (Fig.4.15, p. 183) showed lower intensity doublets near 4.7 and 5.3 ppm and two 
new lines in the 2-Me2 region (1.36 and 1.57 ppm). .After 29 hrs, signals due to the intact 
antibiotic remained the major resonances and there was some evidence of epimerization of 
the initially formed penicilloic acid (new doublets nearHDO resonance,.two new lines in the 
2 -Me2 region).
Results of an experiment using oxacillin Na were similar. Both these isoxazole 
derivatives are of proven resistance to penicillinases155.
U  i /
T Tr T TV
l.S
Fig.4.15 :270 MHz 1H NMR spectrum of flucloxacillin Na + Genzyme enzyme 90 min after
commencement of experiment
X= intact antibiotic signals, Y=penicilloic acid signals.
(For abbreviations see annotations under Fig.4.12, p. 179).
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The 1H NMR spectrum of a sample of flucloxacillin Na (4.41) in D2 O indicated that the 
sample was pure (5-H, 6-H doublets 5.5,5.6 ppm, 2-M?2 singlets 1.45 and 1.49 ppm). After 
addition of the Genzyme enzyme little change was seen after 10 minutes but a 90 minute 
spectrum (Fig.4.15, p.183) showed lower intensity doublets near 4.7 and 5.3 ppm and two 
new lines in the 2-Me2 region (1.36 and 1.57 ppm). After 29 hn, signals due to the intact 
antibiotic remained the major resonances and there was some evidence of epimerization of 
the initially formed penicilloic acid (new doublets nearHDO resonance,.two new lines in the 
2 -Me2 region).
Results of an experiment using oxacillin Na were similar. Both these isoxazole 
derivatives are of proven resistance to penicillinases155.
1.4 1.4t.J l.J.4 4 .4  4.J 4.4 1.4 l.l
Fig.4.15 : 270 MHz *H NMR spectrum of flucloxacillin Na + Genzyme enzyme 90 min after
commencement of experiment.'
X= intact antibiotic signals, Y=penicilloic acid signals.
(For abbreviations see annotations under Fig.4.12, p.179).
- 183-
The next two examples of phenethicillin and ticarcillin present additional complexity in 
that they are marketed as diastereoisomeric mixtures epimeric about the a-carbon of the 
6-amido side chain:
Phenethicillin K
The 270 MHz *H NMR spectrum of the sample showed 2 sets of 5-H/ 6-H doublets in 
the 53-5.6 ppm region and 4 lines in the 2-Me2 region in addition to the duplication of other 
resonances (Fig.4.16a, p. 185). A spectrum recorded 15 min after addition of the Genzyme 
enzyme (Fig.4.16b) displayed the same features but changed in the following respects :
1) the highest field doublet of the 5-H/ 6-H signal (in the 5.4-5.3 ppm region) was more 
complex showing overlap with one or more additional signals.
2) a new pair of doublets were present 4.65 ppm.
3) the 2-Me2 region now showed two new lines (at 1.34 and 1.39 ppm).
A spectrum recorded two hours after the start of the experimem showed the following 
features:
1) 5-H/ 6-H signals due to the intact antibiotic were absent while those due to the principle 
penicilloic acids were well resolved near 5.4 and 4.65 ppm. The low intensity doublets near
5.2 and 5.3 ppm are probable due to the corresponding epimers.
2) In the 2-Me2 region, lines due to the intact molecule were absent while four lines of the 
principle penicilloic acids were prominent plus low intensity lines due to epimers.
H COphenethicillin
#  H H H
O -C O N vl =.
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F ig .4 .1 6  : T he 2 7 0  M H z N M R  spectra o f  phenecillin  N a  a) in D 2 0 ,  b) 15 m in  after 
addition o f  G en zym e en zy m e and c) recorded 2  hrs after the start o f  the experim ent.
X =intact d iastereoisom ers, Y = 5R ,6R  p en icillo ic  acids Y ’= 5 S ,6 R  p en icillo ic  acids 
* C H M e h  PhO CH  ( F ° r other abbreviations se e  annotations under F ig .4 .12, p. 179).
A 24 hrs spectrum showed the same features but intensities of signals due to epimers had 
increased relative to the original penicilloic acids.
Under approximated equivalent conditions it is clear that phenethicillin is far more 
susceptible to the Genzyme enzyme than methicillin, flucloxacillin and oxacillin.
Ticarcillin Na
The spectrum of the sample in D2 O showed a complex signal in the 5-H/ 6-H region
analysed into a high field doublet and a low field pair of doublets the inner lines of which
overlapped the doublet which corresponded with that at high field. The 2-Me2 region 
displayed three lines, the central being made up of two closely overlapping lines (Fig.4.17a, 
p. 187). These features confirm the diastereoisomeric nature of the material.
Spectral changes apparent 5 min after addition of the Genzyme enzyme were as follows:
1) appearance of an apparent triplet (overlapping doublets) centred near 5.3 ppm, assigned 
to ring opened products.
2) presence of four extra lines in the 2-Me2 region (Fig.4.17b).
A 24 hr spectrum (Fig.4.17c) had the following features :
1) 5-H/ 6-H signals due to intact antibiotic were absent
2) 5-H/ 6-H signals due to the initial penicillioc acids and their epimers were well resolved 
(overlapping doublets near 5.36 ppm and 5.25 ppm, 5-lines to high field of HDO band near 
4.8 ppm).
3) eight lines in the 2-Me2 region none of which corresponded with those of the intact 
antibiotic.
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Fig.4.17 : The 270 MHz JH NMR spectra of ticarcillin Na a) in D2 O, b) 5 min after 
addition of Genzyme enzyme, and c) 24 hrs after start of experiment.
X=intact diastereoisomeis, Y=5R,6R penicilloic acids Y’=5S,6R penicilloic acids 
g ArGH. (For other abbreviations see annotations under Fig.4.12, p. 179).
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Spectra run at the time intervals of 60 min 2nd 8 hrs although poorly resolved, clearly 
indicated the absence of 5-H/ 6-H signals due to the intact antibiotic.
Susceptibility of ticarcillin to the Genzyme enzyme is demonstrated by these results 
together with evidence of epimerization of the initially produced P-lactam ring-opened 
products.
CHAPTER FIVE
Investigation of binding of cephalosporins and 
degradation products to serum albumins
5.1 Introduction
The binding of drugs to plasma proteins is of remarkable biological significance, as it 
influences the distribution of drugs in the body and their access to sites of action, metabolism 
and excretion1 3 158. Drug distribution is represented schematically in Figure 5.1 below. 
Therefore, an understanding of the nature of this binding is clearly fundamental to the 
prediction of the therapeutic and toxic effects of drugs.










Fig.5.1: Schematic diagram of effect of protein binding on drug pharmacokinetics.
Drug-protein interactions cover a wide range of binding mechanisms, from the highly 
specific binding of a drug to a Teceptor-site’, for instance, physostigmine inhibition of 
acetylcholinesterase action, to the relatively non-specific interaction between various 
compounds and the plasma proteins159. This specificity of binding at receptor sites is logical 
since an enzyme needs only to have an action on the substrate it is designed for, and a 
pharmacological receptor would be of reduced value if a wide variety of substances caused
an effect. Apart from tendency to favour lipid-soluble molecules, plasma protein binding is 
remarkably non-specific. It occurs with drugs that are aromatic (such as suphonamides) or 
heterocyclic (streptomycin), anionic (penicillins) or cationic (phenothiazines), water-soluble 
(sodium salicylate) or lipid-soluble (barbiturates), and with those that have polar (amino 
acids) or neutral (bilirubin) groups. Almost all drugs are bound reversibly to proteins 
throughout the body. The amount of drug bound is a function of the concentration of the 
drug, the affinity of the drug for the binding sites, and the capacity of the binding 
sites160' 161.
When drug molecules are bound to plasma proteins, they are pharmacologically inert. 
However, binding of drugs to serum proteins in vivo has major clinical significance when 
levels of free drugs are reduced to values below the effective concentrations160,162. 
Furthermore, bound drug molecules can not gain access to the sites of biotransfoimation or 
excretion, and because protein binding is reversible, the bound drug serves as a reservoir 
which releases unbound drug when needed. As it is generally accepted that only free, 
unbound drug can exert phaimacological activity162, the binding of drugs to serum proteins 
can have a considerable effect on their potency and duration of action. One example of these 
effects is the highly protein bound trypanicidal drug Suramin which remains in the body for a 
considerable time, but enough is released from the bound form to exert a trypanicidal action 
for 3 months or more after administration of a single intravenous dose160,163.
A number of endogenous substances, such as fatty acids, bilirubin, hormones etc., are 
bound to plasma proteins, competing for the same limited number of protein sites as for 
drugs, and therefore affecting the binding of these drugs. Also the ability of one drug to 
displace another depends on the competition for common binding sites. A compound which 
is strongly bound will displace a weakly bound one. This can have a marked phaimacological 
effect The action of some drugs may be mediated, increased, or decreased by other drugs or 
endogenous compounds by displacement from protein binding sites. In some cases, such a
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displacement could be advantageous, but in other cases it may be dangerous . For instance, 
a reduction of only 0.6% in serum binding of dicloxacillin by sulphaethylthiadiazole 
increases the concentration of unbound dicloxacillin at its locus of action by 20-40%164. 
Cases have been reported in which phenylbutazone has caused profound bleeding in patients 
under treatment with the anticoagulent drug warfarin165. Also, displacement of bilirubin 
from plasma albumin in newborn infants by acidic drugs such as salicylates, causes
163Kemicterus (brain damage) .
The most important contribution to drug-plasma protein binding is mace by serum
1 5 7  158albumin which comprises about half of the total plasma proteins • , and because it
interacts with a wider variety cf drugs, due to its comparatively large surface area09, than do
1 5 7other plasma proteins, it is used frequently in model investigations of drug binding . The 
albumin molecule consists of a single polypeptide chain with a molecular weight of about 
69,000. At the plasma pH (7.4), it has a net anionic charge (the isoelectric point being at pH 
4.9)166. Albumin has high capacity (i.e., several binding sites of one type), but low affinity 
for binding most cationic drugs. However, many acidic drugs bind strongly to albumin; many 
of them are bound with high affinity but the binding sites may have only a low capacity
I fn 1 /jo
(<10) , and in most cases rot more than two primary sites . Many drugs also bind to
lower affinity (secondary) binding sites, which often number less than ten.
It has been suggested that there are potentially only three distinct sites for most drugs 
on human albumin158,169,170. These have been characterised by the use of fluorescent 
probes169 and are designated sites I, II, and HI. Site I is also referred to as the warfarin- 
binding site, site n  as the indole and benzodiazepine binding site, and site HI as the digitoxin 
site.
The binding affinity depends strongly upon the molecular structure of the drug. It 
appears that the terminal and side chain carboxyl and hydroxyl groups of the amino acid 
residues of the albumin, which are predominantly ionized at the pH of plasma, are likely to
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be involved in the binding of drugs157. It is generally considered that albumin can attract 
drugs by forces of association between ionic charges, polar and non-polar groups, through 
the establishment of, ionic, charge transfer, hydrophobic, van der Waals or hydrogen bond
171linkages . More than one of these forces can be involved in a single combination. In most 
cases the binding force seems to be principally electrostatic, involving the squeezing out of 
the intervening water layers, as both the drug and protein are surrounded whcfty or partly by 
water molecules. This interaction as a whole is sometimes described as hydrophobic 
bonding, involving conformational changes in the drug and the albumin 
molecules157-159,172.
5.2 p-Lactam antibiotics and plasma protein binding
As the majority of infections occur in the tissue rather than the vascular system, the 
protein binding of antimicrobials is of considerable importance in the assessment of their 
efficacy. A relationship between the proportion of drug bound and the penetration into tissues
173has been studied . Generally, it appeared that a highly bound antibiotic (>80%) penetrated 
poorly into the tissue. Although there is a controversy over the relevance of protein binding
1 HAin antibiotic therapy , it appears that there is to some extent a linear relationship between 
penetration of free drugs into tissues and protein binding160,173.
The cephalosporins form a chemically and pharmacologically homogeneous group,
but they are known to bind with different affinities, i.e. strong, medium and weak binding, to 
175serum proteins . The consequences of this binding on bacteriological activity, rate of renal
176 177excretion, and body distribution of these drugs have received considerable attention ’ .
For example, Barza et al. 176 have shown that the serum concentration of the P-lactam 
antibiotics are proportional to the rate constant of elimination of the drug, and the volume of 
distribution. Only free antibiotic manifests antibacterial activity; e.g., cephalothin in serum in 
a concentration of 1 0 0  Jig/ ml exhibits an antibacterial effect similar to that of 1 0  |ig/ ml in 
water. Thus a high degree of serum binding may nullify the apparent advantages of higher
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serum levels of some agents. Another important consequence of protein binding is related to 
the fact that only free drug is able to cross the "aqueous pores" of the capillaiy
199endothelium .
The binding of cephalosporins by human and bovine serum albumin has been 
investigated by several authors with different techniques. It is evident from Table 5.1 
(p. 194), which summarises the literature data, that the results reported show considerable 
variation. A  general review of studies on the binding of cephalosporins to plasma proteins
177has been published by Nightingale , who reported the binding expressed as a %. This data 
is presented in Table 5.2, below. A more detailed description of the techniques used to 
measure binding in the present and other work follows in section 5.2.
T ab le  5 .2  : B in d in g  da*.a o f  so m e  ce p h a lo sp o r in s  fo r  H SA  as ob ta in ed  
fr o m  N ig h tin g a le  r e v ie w 177
C o m r o u n d  T ech n iq u e B m d in °  ca ta
 ____________________________ ( in  %)
C ep h alex in M isc e lla n e o u s <  10
C ep hrad ine M isc e lla n e o u s 8 - 3 0
C ep hazolin E q u ilib r iu m  d ia ly s is 7 3  -  84
U h r a filir a t io n 74  -  8 6
O th ers 8 0  -  9 0
C ep h a lo th in U ltr a f iltr a t io n 6 5
C ep h a lo r id in e M isc e lla n e o u s 8 -  31
Briand and coworkers173 examined the binding of seven cephalosporins to human 
serum albumin (HSA) with equilibrium dialysis and proton NMR. From their results, Table
5.1, cephalexin does not bind to HSA, and the binding of cephradine is very weak (Ka ~ 300 
M-1). Cephapirin, cefoxitin, and cefotaxime have only moderate affinity for HSA (Ka 
around 1000-2000 M-1). Strong binding was seen for cephamandole and cephazolin (Ka 
greater than 5000 M-1). These values showed some agreement with previously published
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T ab le  5.1 : B ind ing d a ia  fo r  cep h a losp orin s a s  o b ia in ed  b y  p rev io u s
in v e s t ig a io r s  u s in g  d ifferen t tech n iq u es :
C p d a b lood  T echnique B in d in g  d ata  R eferen ce
fraction __________________________________ n. Kc.' ( M 1)__________________
CEP U ltra fillra tio n 5 0  7c 177
U ltra fillra tio n 6 5  % 162
BSA F lu orescence p rob e 2.2. 1.2 x 10 3 180
BSA F lu orescence p rob e 3 .0 . 7 .0  x 103 185
HSA F luorescence p rob e 2 .0 .  0 .8 5  x 1 0 3 180
H SA F luorescence probe 3 .0 . 3 .3  x 1 0 3 186
CEZ U llra filtra tio n 74 % 162
H SA E q u ilib riu m  d ia ly s is 0 .7 .  2 0 0 0 175
BSA F lu orescence probe 3 .0 . 8 .1 9  x 103 185
H SA F lu orescence probe. 3 .0 . 6 .3 6  x 10 3 186
HSA F luorescence prob e 1 .4 . 3 .6 7  x 105 179
CEM HSA E q uilib riu m  d ia ly s is 2 .2 . 9 1 0 175
BSA F luorescence probe 3 .0 . 8 .9 8  x 103 185
HSA Fluorescence p rob e 3 .0 . 6.6 x 10 3 186
H SA F luorescence p rob e 1 .4 , 8 .11  x 105 179
CED U llra filtra tio n 31 % 177
U ltra filtra tion 2 0  7c 162
BSA F luorescence probe 2 .2 , 0 .5 9  x 1 0 3 180
BSA Fluorescence prob e 3 .0 . 5 .3  x 1 0 3 185
H SA Fluorescence p rob e 2 .0 . 0 .5  x 1 0 3 180
H SA F luorescence probe 3 .0 , 2 .8 6  x 1 0 3 186
H SA F luorescence p rob e 1 .4 . 8 .1 1  x 1 0 5 179
CEL U ltra fillra tio n 15 % 162
H SA E q uilib riu m  d ia ly s is 0 .0 .  < 1 0 0 175
BSA F luorescence p rob e 2 .2 . 0 .4  x 1 0 3 180
H SA Fluorescence probe 2 .0 . 0 .4  x  1 0 3 180
H SA F luorescence probe • 1 .4 , 8 .5 7  x 10 5 t79
CET H SA E q uilib riu m  d ia ly s is 3 .3 . 7 1 0 175
H SA Fluorescence p rob e 1 .4 . 4 .8 1  x 1 0 5 179
CER BSA F luorescence p rob e 3 .0 . 7 .9 8  x 1 0 3 185
H SA F luorescence p rob e 3 .0 . 4 .3 7  x 1 0 3 186
CEF H SA E q uilib riu m  d ia ly s is 2 .0 . 6 0 0 0 175
H SA F luorescence p rob e 1 .4 . 6 .6 8  x 105 179
a c p d = c o m p o u n d . C E P = cep h a lo th in . C E Z = cep h a zo lin . C E M = cefo ta x im e .
C E D = ce p h a lo r id in e . C E L =cep halex in . C E T = c e fo x it in . C E R = cefu rox im e. 
C E F = ce fa m a n d o le .
results174,176-178. Five of these cephalosporins were examined by Csiba (1985)179, using 
the fluorescence probe technique. According to the latter, cefotaxime and cephamandole were 
bound more weakly to albumin.
Craig and Welling162 evaluated the serum-protein binding of cephalosporins 
according to other authors. The examined methods were based on ultrafiltration and 
equilibrium dialysis. The binding of four cephalosporins in order of rank were, cephalexin 
15%, cephaloridine 20%, cephalothin 65%, and cephazolin 8 6 %. The orders were not 
identical to those obtained by Csiba.
180Veronese and coworkers utilised the fluorescent probe technique to determine the
binding data of three cephalosporins for serum albumins from different species, namely,
human, bovine, rabbit and chicken. Only minor variations in the binding properties were
found. The constants for fluorescent probe, ANS, are in agreement with those reported by Jun 
181et al. , but disagree with those of Csiba (see Table 5.1). According to Veronese, the number
of binding sites in the protein molecule is about two for bovine and human serum albumin,
which is also similar to the values reported by Chignell (1969)182, Sudlow et al. (1973)183,
and Muller and Wolbert (1976)184. The association constants for cephalosporins fell into
3  1different groups, cephalothin showed a stronger binding affinity (1.0 X 10 M- ), whereas 
weaker bindings were observed for cephaloridine and cephalexin (Kfl =0.55 X 10 and 0.4 X 
103 M-1, respectively). These data are in good agreement with those reported by
1 7 7  1 7 9Nightingale ; but showed wide variations with those reported by Csiba , who observed 
that weaker binding does take place with cephalothin (Table 5.1).
185Kim et al. determined, by a fluorescent probe technique, the binding affinity of six
1S6cephalosporins to bovine serum albumin (BSA). In another report , they obtained the 
binding values of the same cephalosporins to,. HSA, using the same technique. They 
demonstrated close similarity in binding values of the cephalosporins to BSA and HSA, i.e., 
stronger bindings for cefotaxime and cephazolin, and weaker bindings for cephaloridine and
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cephacetrile (see Table 5.1, p.i94>- The number of binding sites are similar for both BSA and 
HSA (n=3).
187—189The pioneering NMR studies by Jardetzky and coworkers exemplify the
advantages of NMR methods in studying the interactions involved in inteimolecular 
complexes. In particular, proton relaxation rates (spin-spin, I / I 2 , and spin-lattice, l/Tj) 
provide information about the portion of the ligand which interacts with the macromolecule.
Our literature search revealed only a few NMR studies of the interactions between serum 
albumins and p-lactam antibiotics. Fischer et al. 189 utilised the transverse (spin-spin) 
relaxation measurements technique to examine the binding of benzylpenicillin to bovine 
serum albumin. They demonstrated that there were changes in relaxation rates large enough 
to be measured. They were able to show that the phenyl group plays the major role in the
175binding. Briand et al. studied the interaction between human serum albumin and some 
cephalosporins (cephradine, cephamandole, cefoxitin, and cefotaxime) by using the 
transverse relaxation rate, l / I j ,  technique. They postulated that the major binding site for 
cephalosporins with high HSA affinity (cephamandole and cephazolin) is the electron-rich 
heterocycle fixed on the methylene at position 3. In those with moderate affinity (cefoxitin 
and cefotaxime) the binding to the protein involves the heterocyclic substituent of the 
acetamide chain carbon atom (C-7).
5.3 Techniques used to measure drug-protein binding
Various experimental techniques have been employed to study drug-protein interactions, 
mainly to elucidate the extent of binding199’191. These are listed in Table 5.3 (p.198), with 
brief notes on their advantages and disadvantages. Chignell(1972)191 has reviewed a number 
of these techniques. Further information can be derived from the references given in the 
Table. All the available methods utilise one of four basic principles (Goldstein, 1949)192 :
(i) The concentration of free drug may be diminished in the presence of a binding protein.
(ii) The drug may show measurable changes in its properties, on binding.
(iii) Measurable alteration in the protein’s properties may occur on drug binding.
Civ) The drug’s interaction may be studied by its ability to displace a ’probe compound’ 
from protein-binding site(s).
The most commonly used techniques for studying cephalosporin-protein binding include
ullrafiltration, equilibrium dialysis, and fluorescence spectroscopy. With respect to the two
former techniques, usually the protein-bound amount of the drug cannot be measured directly
but is calculated from the difference between the unbound and the total amount.
Ultrafiltration involves the use of special membranes. These are filled with albumin solutions
containing the cephalosporin and centrifuged for a period of time. The unbound drug
concentration in the filtrate is then determined (e.g., using gas chromatography). The binding
parameters of the drag bound to albumin can then be obtained by the Scatchard plot (section
5.3.1). This method was utilised by Craig and Welling to study the binding of four
cephalosporins (cephalexin, cephaloridine, cephalothin, and cephazolin) to serum albumin,(
Table 5.1, p. 194). The main disadvantage of this technique is the possible loss of drag due to
10'?adsorption to the membrane. Equilibrium dialysis involves the use of an isotonic 
phosphate buffer. Drag solutions in the buffer and plasma samples were placed on each side 
of equilibrium dialysis cells. At equilibrium the concentration of the drag in the buffer 
solution equals the concentration of the free amount in the protein-drag solution194. This
1 7 5technique was used by Briand et al. to examine six cephalosporins, cephazolin, 
cephamandole, cefotaxime, cefoxitin, cephalexin, and cephradine, CTable 5.1). Although no 
loss of drag occurs in this technique compared to the previous, but prolonged equilibration 
time may cause protein denaturation, in addition to the effect of the buffer in disturbing 
equilibrium by dilution.
•v
Displacement methods employing fluorescence spectroscopy (one of the techniques used 
in the present work) have proved to be of increasing value and more popular than the other
-1 9 7 -
158
T a b l e  5 . 3  P r i n c ip a l  m e t h o d s  o f  s t u d y i n g  D r u g - P r o t e i n  B i n d i n g
T e ch n iq u e A d v a n ta g e s D isa d v a n ta g es Selected
references
E q u ilib r iu m
d ia ly s is
A ccu ra te  rep ro d u cib le  
q u a n tita t iv e  d a ta . M ost  
used  te c h n iq u e .
U ltr a f iltr a t io n  Rapid. C lo s e ly  ap prox­
im ate in  v iv o  
s itu a tio n .
U ltr a c e n tr i-  N o m em b ra n e  b ind in g.
l‘u °a tio n
Gel c h r o m a to ­
grap h y
E lec tro p h o resis
F lu o rescen ce
sp ec tr o p h o to ­
m etry
S ep aration  o f  sev era l 
b in d in g  p r o te in s  
p o ssib le  '
Q u a lita tiv e  d a ta . Can  
separate m u lt i-p r o te in  
m ix tu r e s  an d  o n ly  sm a ll  
sa m p les  req u ired
S en s it iv e  tech n iq u e.C a n  
m o n ito r  flu orescen ce  
ch an ges in b o th  drug/ 
p rotein  on  b in d in g . 
P ro v id es b o th  q u a n ti­
ta tiv e  an d  q u a lita t iv e  
in fo r m a tio n . O n ly  m icro-  
q u a n tit ie s  o f  m ateria l 
requ ired .
Q u a n t ita t iv e  in fo rm a tio n  210
o n ly ,  su b je c t  to  error fr o m  
b in d in g  to  m em brane.
P ro lon ged  eq u ilib ra tion  
t im e  ca u s in g  bacterial 
co n ta m in a tio n  and 
p ro te in  d en a tu ra tio n .
Q u a n t ita tiv e  data o n ly .  B in d -  211
ing to  m em b ran e. E q u i­
lib ra tio n  d istu rb ed  b y  
p rote in  con cen tra tion .
P ro lon ged  ex p er im en ta l t im e . 212
Q u a n tita tio n  m ore d ifficu lt .
C an n ot u se  protein  m ix tu r e s .
A d so r p tio n  to  ge! m a y  d is tu r b  213
e q u ilib r iu m .D ilu t io n  o ccu rs.
Q u a n tifica tio n  d ifficu lt. N o n -  214
p h y s io lo g ic a l . In terp reta tion  
d ifficu lt  d u e  to b ind ing to  
su p p ort m ed iu m .
Can n ot be u sed  if in te ra c tio n  215
cau ses n o  sp ectra l ch an ge. N o n -  
p h y s io lo g ic a l . Need to  c o m p e n ­
sa te  fo r  co m p o u n d ’s  a b so rb ­
ance. Q u an tifica tion  can  
in v o lv e  le n g th v  c a lc u la tio n .
NM R S en sit iv e  to  ch an ges in  
m o lec u la r  g e o m e tr y
In te rp re ta tio n  m ay be d iff ic u lt . -188 
E q u ip m en t exp en sive . N o n  
p h y s io lo g ic a l.
techniques in protein-binding studies. They involve the ability of some drugs to displace 
model fluorescent probe molecules from protein-binding sites. Therefore, it can give
1 58information on specific-site interactions .
The chemical interaction of cephalosporins with serum albumins was also examined
b y f e w  workers using NMR resonance methods, i.e., relaxation time (Ti & T2 )
measurements. These techniques provide information on structural features of the studied
drug which contribute to the formation of a complex with protein. It seems difficult to judge
the validity of results obtained by the relaxation measurements, partly because of the
difficulty of making accurate and reproducible measurements of relaxation times since many
1factors contribute to them .
The transverse (spin-spin, T2 ) relaxation technique is briefly defined as the redistribution 
of the absorbed energy within the spin system to return to equilibrium . It involves the 
measurement of changes in the linewidths at half heights of the resonance signals arising 
from the various hydrogen-containing parts of the drug molecules on adding serum albumin. 
The part involved in protein-drug binding shows relatively larger broadening of its signals.
175Briand and coworkers utilised this technique in the identification of the drug sites 
involved in cephalosprin-protein interaction. They calculated the transverse relaxation rate 
values from the expression, 1 [Ti = 7tAvi/2 , where Avj/2 , the full-linewidth at half-maximal 
height, is the mean of several spectra recorded at a 90* excitation pulse and an acquisition 
time of 2 .6  s.
The longitudinal (spin-lattice, T i) relaxation process involves the loss of energy from the 
excited nuclear spins to the surrounding molecular lattice induced by the modon of magnetic 
(or electric) fields195. Two methods were employed for the Tj measurements:
a) The inversion recovery method (which is discussed, with some detail in section 3.3.2, as 
it is the one chosen for the present work), and
b) the progressive saturation technique, in which a series of 90* pulses separated by a time
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delay T (<5Ti) are applied, i.e. the sequence is (90* — T)^, avoiding the long pulse delay of 
the inversion recovery method.
In method (b) the magnitization will not have time to recover in between pulses, and an 
equilibrium state will eventually be established195. A plot of In against T will
produce a straight line with a gradient -1/T\. Since only a 90* pulse is employed, the peaks 
are never inverted. In practice, the normal approach when performing progressive saturation 
measurements is to obtain data at two different x-values and calculate Tj from the ratio of 
the two intensities.
Not a single study was found in the literature for the use of Ti measurements technique 
in the investigation of binding of cephalosporins to serum albumin
Ti " inversion recovery" and spectroflucrometry "probe displacement" methods are 
used in the present work.
5.3.1 Theory of Scatchard Plot for calculation of binding parameters
It is assumed that a protein molecule possesses a number of binding sites for a fluorescent 
probe or drug. If these binding sites have the same affinity for the drug, and are able to act 
independently (i.e., the binding of a drug molecule to one site does not influence the affinity 
for the next site), then the law of mass action can be applied to each site individually, and can 
describe the relationship between binding and the concentration of free drug at 
equilibrium157,158 :
k l[P]f  +  [D]f  s  ■■■—^  [DP]  (5 .1 )
where [P ]y is the molar concentration of unbound protein,
[D If  is the molar concentration of free drug,
[DP ] is the molar concentration of drug-protein complex present, 
and k i and k^ are the rate constants for association and dissociation, respectively, of the 
complex.
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At equilibrium, the rates of association and dissociation of the complex are equal, that is :
k i [ D ] f i P ] = k 2 [DP] 
therefore, for each of the binding sites:




where Ka is the association or affinity constant of the drug for the 
protein (which is a measure of the affinity of the drug for the 
protein, with a single binding site).
If there are n independent binding sites, then n [P ], will be the total concentration of 
binding sites for the drug, (and since the total concentration of protein [P ], equals 
[P]/+[D P]),
n[P ] t = [DP] + [P]f
which can be arranged to give
[P]f = n[P] t - [ D P ]  (5.4)
Substitution of equation (5.4) into (5.3) yields
[DP]Kn =
which may be rearranged,
divide by [P],
n[D]f -
[D]fi_DP] _  [DP] 
[/*], “  Ka[P],
Ka[P], [PI
[DP] f j _  
[/>], [ KaPI
[DP] . 1 +[D]f K ^
[/>]« K,
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t o  g i v e
[DP] nKa[D]f
[/>], "  \ + K a[D]f  (5' 5)
[D PI .Now, if r  equals moles of drug bound per mole of protein =  , then, equation (5.5)
[P  Jr
may be rewritten as
nKa[D)f
r = (5. 6)1 + K a[D)f
Hence, on the basis of the law of mass action, it can be deduced that if there are ’n ’ binding 
sites per protein molecule, each of which has its own (intrinsic) association constant ’Kai ’ 
and if there is no interaction among the bound ions, then the average number of moles of
bound drug per mole of protein (r) and its dependence on [D]f  is given by196:
r
(S> Kai[ D] f  
r — T .................... 0 =1 >2 ,.....n)
h ^ K * m f  ( 5 7 )
where K ai is the association or affinity constant for a binding site i.
It has been suggested by Scatchard (1949)197 for the special case that the Kai’s are equal
i.e. all sites are equivalent, equation (5.7) can be rewritten in terms of a single binding 
constant Ka as
nKa[D]f
r  1 +Ka[D]f  (5‘ 8)
where n is the number of binding sites per protein molecule,
[D ]f is the concentration of free drug, 
and K a is the affinity constant of the drug for the protein.
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Rearrangement of equation (5.8) gives the Scatchard equation in its most simple form :
V
[£>]/
= nKa -  rKa (5. 9)
A plot of the experimental data in terms of j  - versus r (which is known as a ’Scatchard





Fig.5.2 : A  theoretical Scatchard plot from eq.5.9 (for single class o f  binding site)158,160.
From the Scatchard plot, the affinity constant (Ka) of the ligand for the protein can be 
calculated from the gradient of the graph since
[gradient] = - K a (5.10)
and the number of binding sites (n) obtained from the intercepts of the line with the r-axis 
(primary sites).
A linear Scatchard plot will only be obtained if a single class of binding sites is involved, 
each site being totally independent of the others. Deviations from linearity are taken to 
indicate the involvement of more than one type or class of binding sites or the modification 
of one protein-binding site by drug interaction at the second site. In practice, Scatchard plots 
are frequently nonlinear158.
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Klotz (1946)198, in studying the binding of proteins to small molecules, inverted the
law of mass action solved for r to give :
1 ^  l+Kc[D]f  
r nKa[D]f
n + ( (5.11)
is known as ’Klotz Plot’ (Fig. 5.3, below), with an intercept ofA graph of — against
1 and a slope o f  . This has the disadvantage of concealing deviations from the ideal
nKan
laws, and of tempting the drawing of straight lines where there should be curvature; it also
F i g . j o  : i s j o i z  pioi ^ror single ciass or omaing sue;
The Scatchard plot is known to be the most commonly used procedure for the analysis 
of data on protein-binding, and we have found it convenient to plot our data as suggested by 
Scatchard197.
Scatchard theory allows calculation of the affinity constant of the drug in the absence of 
any interfering compound. An adaptation of equation (5.8) can be applied where there is a 
competing compound:
1 ^ 8tends to excessively underemphasise the results obtained at low dmg: protein ratios .
Hence, it is generally less widely used.
intercept=-Ka
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nKa[D]f
r  1 + Ka[D]f  + K a-[C] (5 ' 12)
where [C ] is the concentration of the competing compound, 
and K j  is the affinity constant of this compound for the protein.
As above, equation (5.12) can be rearranged to give
K.a
(«-'•) (5.13)[D]f  1+ K A C )
A Scatchard plot will therefore allow the calculation of the affinity constant of the 
competing compound for the protein (Ka>), assuming that the affinity constant of the drug 
(Ka) is known, since :
[gradient] = Ka
1 + K j [ C \
and therefore,
Ka' = -
r Ka-[gradient]  N 
[gradient][C] (5.14)
This is the method adopted for the calculation of the affinity constants of the cephalosporins 
for the serum albumins in the present study.
5.3.2 Measurement of drug-protein binding by spectrofluorimetry
5.3.2.1 Spectrofluorimetry theory
Fluorescence spectroscopy is an important tool in the study cf the binding of drugs to 
proteins.
The photoluminescent method of fluorescence is closely related to molecular absorption 
spectrophotometry. After molecules have absorbed radiant energy and been excited to a 
higher electronic state, they must lose their excess energy in order to return to the ground
 o
electronic state. Fluorescence is >the immediate emission On the order of 10 sec) of light 
from a molecule after it has absorbed radiation, lost some of its excitation energy by
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vibrations; thus emitted light is always of longer wavelength than that of the exciting light. 
The phenomenon arises from a singlet-singlet transition (where all of the electrons in the
The fluorescence of a given drug molecule may be characterised by several parameters 
including :
i) the wavelength of maximal excitation and emission (spectra). The former is obtained by 
setting the emission spectrometer to an emission wavelength of the sample and then scanning 
a range of wavelengths with the excitation spectrometer. By adjusting the excitation 
spectrometer to an excitation wavelengths for a sample and causing the emission 
spectrometer to scan, the emission spectrum of the sample will be recorded.
ii) the quantum yield (Q), which is a measure of the efficiency of fluorescence and is defined 
as the ratio of the number of photons emitted to the number of photons absorbed ( a photon is 
a quantum of light energy), e.g., Q is zero for nonfluorescent substances.
v
iii) the fluorescence lifetime, is the time of the fluorescence decay after extinguishing the 
light source.
lOImolecule have their spins paired) ’ . A schematic energy-level diagram for a diatomic
molecule is shown in Fig.5.4 below.
energy
loss o f vibrational 
 by collision
Intemuclear distance between 
the two ate ms
Fig.5.4 : A schematic energy-level diagram for a diatomic m olecule200.
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iv) the degree of polarization, here the fluorescence of the excited molecules (having their 
absorbing dipole vectors parallel to the direction of polarized light) will also be polarized to a 
degree depending on how much Brownian motion has randomized the orientation of these 
molecules during the excited state lifetime.
These parameters are very sensitive to changes in the molecular environment, e.g. 
interaction with macromolecules.
53.22  Choice of technique for fluorescence measurements for studying drug binding
As mentioned in section 5.3.2.1 there are several approaches for studying drug-protein 
interactions. Fluorescence spectroscopy has been applied under three different conditions:
a) when the drug itself is fluorescent,i.e., any drug that is highly fluorescent both before and
201after binding to a macromolecule.lt has been reported that the binding of the 
anticoagulant warfarin to HSA results in a sixfold increase in the fluorescent yield of the drug 
and a small shift in its fluorescence emission maximum to shorter wavelengths.
b) when quenching of protein fluorescence occurs on binding of a drug. Quenching is due to 
energy transfer from excited-state tryptophan residues to the bound drug. This is illustrated 
by the effect of thyroxine on serum albumins202.
c) when the drug itself is not fluorescent but can displace fluorescent probes. This is the 
method of choice in the present work. It involves the use of fluorescent probes, such as 
l-anilinonaphthalene-8 -sulfonic acid (ANS), which after binding to a macromolecule, can be 
used to detect changes in the various structural parameters of the macromolecule.
The use of fluorescent probes has provided insight into the mechanisms and sites of 
binding of small molecules and has been shown to be a convenient tool for competition 
studies of small molecules for protein binding sites203. '■
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A fluorescent probe is defined as a compound that undergoes changes in one or more of
2 0 4  2Jj3its fluorescence properties when bound to certain protein . The observation that certain
probes bind to a number of highly hydrophobic protein sites led to the proposition that these
compounds might be useful in investigation of the hydrophobic nature of protein204-206. An
additional observation suggested that the fluorescence intensity of the probes in protein
181solution is decreased by the introduction of certain drug molecules . This is taken as an 
indication that competition between drug and probe does occur and that the drug falls into 
the same type of binding category as characterised by the probe, i.e., binds tc hydrophobic 
binding sites on protein181. ANS is the most commonly used fluorescence probe to detect
17Sbinding at the hydrophobic sites of proteins . Competition with a drug for these sites 
reduces the fluorescence intensity of the probe-protein complex.
The fluorescence emission spectrum of an aqueous solution of probe in the absence of 
serum albumin will show a very low fluorescence intensity, but upon binding :o the protein 
molecule the intensity will be strongly enhanced. A change in the nature of fluorescence, i.e., 
the wavelength of emitted light may also occur. The extent of increase of the probe 
fluorescence upon addition to serum albumin is used to calculate the binding constants for 
the albumin-probe complex. The decrease in probe binding caused by a drug and the 
subsequent decrease in fluorescence of the probe-albumin complex could be used to calculate 
the binding affinity of the drug for the protein.
53.2.3 Theoretical background to fluorescence measurements of drug binding using 
the probe displacement technique
The fluorescence intensity of a probe, e.g. ANS, which is bound to serum albumin, is a 
function of the probe concentration, i.e .:
[ANS]b = P x f  (5.15)
where [ANS ]$ is the concentration of the probe, ANS, bound to protein,
/  is the intensity of the fluorescence produced,
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a n d  P  i s  a  c o n s t a n t .
The constant, P , is termed the "constant of proportionality" or "the proportionality 
factor". Hence, if the value of this constant is known, the amount of probe bound to protein, 
[AA/SJa, can be calculated directly from the fluorescence intensity, according to equation 
(5.15).
To obtain the value of the proportionality constant, P , a solution of probe, ANS, is 
titrated with a large, 1 0 0 -fold, exess of protein solution, at which concentration it is assumed 
that the probe completely bound by protein. It can be seen that as the concentration of protein 
rises, the fluorescence intensity increases to maximum ( fmax). At this maximum all the ANS 
is bound to protein, i.e., [AMS]*, =  [ANS],. Hence, knowing the concentration of the probe 
and the value of / max, the proportionality constant, P, can be calculated from equation (5.15) 
to give
[ANS]g
p  = —f   (S. 16)
J max
It should be noted that the observed relative fluorescence intensity, f ot must be corrected 
for the " inner filter effect". This is an attenuation in the intensity of the exciting and emitted 
beams due to absorption by the sample itself191. The correction is made by multiplying the 
uncorrected fluorescence intensities by the correction factor, x, which is defined as the antilog 
of the average of the effective optical densities, which are the absorbances at the excitation 
and emission wavelengths, measured in a 1 cm pathlength cell multiplied by half the width 
of the fluorescence cell202. Hence, for the 1 cm pathlength fluorescence cells used, this factor 
becomes:
Ap-r + A em
x  = antilog(  -------) (5.17)
where x  is the correction factor,
Agx is the absorbance at the excitation wavelength, 
and A em is the absorbance at the emission wavelength.
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Thus, the corrected fluorescence, / ,  is defined by
f = x x f 0 (5.18)
where f 0  is the observed fluorescence intensity obtained 
directly from fluorimeter reading.
53 .2 .4  M athem atics and  application of S catchard  analysis
The fluorescence enhancement of the probe, ANS, upon additicn to human ( or bovine) 
serum albumin, can be determined, and the data used to calculate the binding constants for
the albumin-probe complex, from a Scatchard plot. The decrease in fluorescence of the
albumin-ANS complex in the presence of cephalosporins, can te used to calculate the 
binding constants of the drug-protein complex.
The fraction of probe bound, [AMS]&, is calculated using the equation (5.15). After the 
value [AMS ]b is found for each point along the titration curve, the concentration of free 
probe, [AMS ]y, can be calculated if the total concentration of the prcbe is known since,
[ANS ], = [AMS ]b + [ANS ] f  (5.19)
and therefore,
[AMS ] f  = [ANS ], -  [ANS]b (5.20)
r  can be defined mathematically by,
[ANS]b
r = V ^ T n T  (5- 21)
(r is the number of moles of ligand bound per mole of protein)
rThe binding constants (n and Ka) can now be determined from a Scatchard plot o f ----------
[A M S ]/
versus r. Ka' for cephalosporins are then measured from equation (5.14, p.205).
53.3 Measurement of drug-protein binding by NMR spectroscopy
5.3.3.1 Theoretical basis of NMR relaxation measurements
Relaxation time can be defined as the decay time characterising the return of the 
nuclei excited by the absorption of radiation to an equilibrium state . It correlates with 
structural features of molecules, and particularly with their motion.
For purposes of the relaxation experiments to be described in the following sections, a 
high resolution proton magnetic resonance spectrum can be thought to represent as many 
spin systems as there are lines in the spectrum. A spin system can be defined as an assembly 
of nuclei characterised by two energy levels (denoted as a  for the lower and p the upper 
level). When attention is focused on a given spin system, all other nuclei and electrons in the 
sample are collectively refered to as the lattice. In the presence of electromagnetic radiation 
of a particular frequency, the spin system absorbs energy from the radiation field, with a 
consequent increase in the population of the upper state and a corresponding decrease in the 
population of the lower stale. If this absorbed energy is sufficient to equalize the population 
of the two states, the system is said to have undergone saturation. The return of an either 
completely or partially samrated system to equilibrium consists of two simultaneously 
occurring relaxation processes:
1) the spin-spin (or transverse) relaxation, T  2 .
2 ) the spin-lattice (or longitudinal) relaxation, T  j .
Fig. 5.5 (p.212) illustrates the mechanisms of the two relaxation processes. If the state of 
a spin system is described by its magnetization vector, A/, which is the vertical sum of all 
nuclear magnetic moments comprising the system, i.e., the bulk magnetization vector, then 
after an applied RF pulse (through an angle 0  degrees) has been removed, the perturbed spin 
system will begin to relax back towards its equilibrium condition (in which M  is aligned 
along the Z-axis).
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Component of M in the X ’Y ’ plane
tegins to fan out and loses phase 
coherence (T2 processes)
M z relaxes back along 
the z-axis to its original 
value M q (T 1 )
Fig.5.5 : Mechanisms of the two relaxation processes, T \ and T ^195.
The spin-spin relaxation process involves the fanning out of the component of M  in the 
X’Y’ plane, i.e., it loses coherence with the redistribution of energy among the spin system 
and there is no detectable signal along the Y’ (or the X’)-axis. In the spin-lattice relaxation 
process, the magnetization remaining along the Z-axis relaxes back, along the Z-axis, to its 
original value M°,  by means of exponential decay characterized by the relaxation time.T 1 .
53.3.2 Measurement of relaxation time, T \ bythe inversion recovery m ethod 195,207
The method involves the application of a 180* pulse to invert the magnetization to the 
Z-axis. Hence, immediately after the pulse, the magnetization vector M z equals -M°z. Mz 
will now begin to relax back along the Z-axis towards its equilibrium value M  °z via the 
spin-lattice relaxation process (see Fig. 5.6, p.213).





M y  detected by
spectrometer
Fig.5.6 : The rotating frame picture o f  the 180*-T-90* pulse experiment.
As most spectrometers do not detect signals along the Z-axis, after the 180* pulse, a 
second 90* pulse is applied after a delay of % sec which tips the magnetization onto the 
-Y’-axis, where it can be detected, i.e., the full sequence is : 180* - delay T - 90* pulse. At the 
end of the cycle the magnetization lies along the -Y’-axis and so, before a second 180* pulse 
can be applied, it is necessary’ to allow a period 5T j sec (where T \  is the longest in
A
molecule) to allow the magnetization vector to relax back to M  (It is also assumed that 
during a 5Ti  delay, the transverse magnetization "7V' is allowed to decay completely9). 
Hence, a pulse delay (PD) equal to 5T i must be inserted between each cycle, giving the 
overall sequence (180* - T - 90* - PD)n, where n is the number of times the cycle is repeated. 
The timing of the pulses and delays is normally formed automatically by the computer. At 
the end of the experiment the accumulated FID (Free Induction Decay) is transformed and 
the intensity of the signal ( which is a function of T \  ) determined. This can be expressed 
mathematically as :




where Mz is the component of M  along the Z-axis t sec after the application of the 180* 
pulse, M ° z is its equilibrium value, and T \  is the spin-lattice relaxation time.
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Rearranging equation (5.22) gives
Mz - M \ =  -2 M °ze x p ^ -  (s. 23)
1 1
Hence, taking logs,
ln(MI - M 0z) = ln(2M0l)- Y -  (5. 24)
Hence, a plot of In (Mz - M ° z) against X will give a staight line with a gradient of - — .
T  l
In practice, a series of cycles with different values of x are carried out and the value of 
M qz determined by using one cycle in which x > 5T\.  A graph of ln(A/z — M °2) is then 




1) Fluorimetric measurements were made at 24*C with a Shimadzu microcomputer- 
controlled recording spectrofluorophotometer model RF-540 (Kyoto, Japan), equipped with a
150 W xenon lamp, a monitoring photomultiplier R212-09, and a photometric 
photomultiplier R452-01 tube. Measuring conditions can be stored and printed with a 
Shimadzu data recorder unit model DR-3. The entrance slit for the excitation light and the 
exit slit for emission light were both 10 nm. The relative fluorescence intensities of bound 
ligand were obtained directly from fluorometer readings of uncorrected excitation and 
emission wavelengths.
2) Optical densities were measured in a Peridn Elmer Lambda 3 UV/VIS spectro 
photometer. Absorption readings were taken at the excitation and emission wavelengths 
(both previously determined from fluorescence spectra of a solution of serum albumin and 
probe).
3) pH measurements were made in a Kent EIL 7020 pH meter.
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4) Stirring, during fluorometric titrations, was achieved with a small magnetic flea by means 
of a magnetic stirrer.
5) SGE microlitre syringes, Scientific Glass Engineering PTY. Ltd., Ringwood, Australia.
5.4.1.2 Materials 
The following materials were used without further purification :
1 . Cephalosporin derivatives studied were: cephalothin Na, cephazolin Na, cefatrizine, 
cephalexin, cefotaxime Na, desacetylcefotaxime, and cefotaxime lactone, (list of suppliers in 
Chapter Two, Table 2.1).
2. Bovine serum albumin (BSA) : Albumin, Bovine powder fraction V, 96-99% albumin, 
Sigma Chemicals Co., USA. A molecular weight of 68,000 was assumed for this lot.
3. Human serum albumin (HSA) : Albumin, Human No. A-1887, fraction V, molecular 
weight 69,000. Sigma Chemicals Co., USA.
4. 8 -Anilino-l-naphthalenesulfonic acid, ammonium salt (F.W.=316.38), melting point 
242-244’C. Aldrich Chemicals Co., England.
5. Highly purified water (Milli-Q water systems, Millipore S. A, France).
6 . All other chemicals were of reagent grade and used without further purification.
5.4.123 Preparation of phosphate buffer of pH 7.4 and ionic strength (I) of 0.154 at 
room temperature
The buffer was prepared by mixing appropriate amounts of 0.1 M disodium hydrogen 
orthophosphate (Na 2 HPO 4 ) and 0.1 M potassium dihydrogen orthophosphate (KH 2 P O 4 ) 
to pH 7.4. The ionic strength was adjusted to 0.154 by 0.9% sodium chloride according to the
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following equation :
/  = 0 .5 £ C ; X Z 2i (5.25)
where C\ is the molar concentration of the ion species i, 
and Zi is the valency of ion species i.
5.4.1.4 Experimental conditions
(i) All solutions were freshly prepared in phosphate buffer.
(ii) The serum albumin powder was dried overnight under vacuum before use.
(iii) The serum albumin solutions were stored, foil wrapped in refrigerator overnight, 
before they were used for binding studies, so all the molecules had become fully hydrated 
and had taken up a stable conformation, and to allow the fluorescence to stabilize.
(iv) Titrations with ANS were carried out at both low and high serum albumin 
concentrations.
(v) All titrations performed at ~ 24’C.
(vi) The following concentrations were used for the titrations :
a) for ANS : 1 x 1(T3 M.
b) for serum albumin: 1 x 10"5M an d l x KT^M.
c) for cephalosporins: 5 x lO^M.
(vii) The binding data were the mean of at least two measurements.
(viii) In order to avoid variations in the buffer pH, probe and albumin concentrations, all 
the cephalosporin solutions for a particular group of titrations were made at the same time. 
These solutions were used within 24 hours to avoid errors due to any degradations of the 
cephalosporins.
5.4.1.5 Methods
The binding of the probe, ANS, to serum albumin was determined by measuring the 
increase in fluorescence following titration of the protein solution with the probe as described
by Brand et al.203 and Hsu, Ma, and Jun208 and modified as described below.
Fluorescence measurements were made at 478 - 480 nm using an excitation wavelength of 
419 nm at high (1 X 10- 5 M) serum albumin concentration, and at 487 nm using an excitation 
wavelength of 419 nm at low (1 X 10- 6  M) serum albumin concentratioa All measurements 
were carried out at (~ 24°C). Solutions of serum albumin were prepared in buffer. The probe, 
ANS, was in buffer at a concentration of 1 X 10-3 M.
The above-mentioned instrumental conditions set-up (performed by fluorimetric scans for 
probe-protein solutions) were kept constant throughout all titrations carried out as in Table
5.4 (p.218).
1) For determination of proportionality constant (.P)
The constant P  was determined from titrations A and B CTable 5.4, p.218) as follows:
3 ml of the probe solution was pipetted into a fluorometer sample cell of one cm 
pathlength. A small magnetic flea was then introduced into the cell. Initial measurements of 
fluorescence and optical densities were then taken, separately. Successive addition of protein 
solution, in increments of 3, 5, 10 and 20 pi, was continued until obtaining an almost 
constant fluoresence intensity reading. The contents of cell were allowed to stir for at least 40 
sec after each addition of protein solution increments and before any measurements were 
taken. Additions were made by means of SGE microsyringes.
To minimise any photodecomposition of solution during fluorescence titrations, the 
contents of the sample cell were exposed to light of the excitation wavelength only during 
the actual measurement of fluorescence intensity. Furthermore, the instrumental setting 
conditions were kept constant throughout the titration.
The above titration of probe with serum albumin was used to determine the limiting 
fluorescence when this concentration of probe was completely bound. This value was then 
used to calculate the proportionality factor (eq.5.4, p.201), and accordingly, the 
concentrations of free and bound probe in a reverse titration of serum albumin with probe.
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Table 5.4 : Titrations of ANS/ HSA (or BSA) in absence and presence of cephalosporin 
derivatives
A) 3 ml of 1.0 X 10-5M ANS was titrated with a solution of 1.0 X 10_3M BSA Cm 1.0 X 
10"5M ANS).
B) 3 ml of 5.0 X lO ^M  ANS was titrated with a solution of 5.0 X lO ^M  HSA (in 5.0 X 
10~6M ANS).
C) 3 ml of 1.0 X 10-5M BSA was titrated with a solution of 1.0 X 10-3M ANS Cm 1.0 X 
10_5 MBSA).
D) 3 ml of 2.76 X 10_6M BSA was titrated with a solution of 1.0 X 10"3M ANS (in 2.76 X 
10‘ 6M BSA).
E) 3 ml of 1.0 X 10-6M HSA was titrated with a solution of 1.0 X 10“ 3 ANS (in 1.0 X 
lO^M  HSA).
F) 3 ml of 5.0 X 10^M  cephalosporin (in 2.76 X 10-6M BSA) was titrated with a solution 
of 1.0 X 10“3M ANS (in 5.0 X lO^M cephalosporin in 2.76 X 10^M BSA).
G) 3 ml of 5.0 X lO^M cephalosporin (in 1.0 X lO^M  HSA) was titrated with a solution of
1.0 X 10~3M ANS (in 5.0 X lO^M  cephalosporin in 1.0 X lO ^M  HSA).
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The solutions of the probe were made up in a solution containing the same concentration 
of HSA or BSA (and cephalosporin) as in the solution being titrated so that these 
concentrations would not vary during the titration. Similarly for titrations A and B, the 
protein solutions were made up in ANS solution.
2) For determination of binding parameters of ANS to serum albumin (from 
titrations C to E)
The fluorescence of ANS is enhanced on binding to serum albumin, and the emission 
maximum is blue-shifted (from 512 nm to 480 nm). The fluorescence intensities of the 
protein-probe complex as a function of probe concentration (1 X 10_JM) were measured at 
the protein concentrations, (1 X 10“6 M) and (1 X 10- 5 M) in phosphate buffer. The titration 
steps were similar to those used for determination of P, except that the titrant this time was 
the probe solution : 3 ml of each protein solution was titrated with successive additions of 3, 
5,10 and 20 |il of probe solution. Enhancement of the probe’s fluorescence upon addition to 
serum albumin, was determined, and these data were used to calculate the binding constant 
for the albumin-probe complex.
3) Displacement of ANS from serum albumin by cephalosporin derivatives 
(titrations F and G)
Cephalosporin binding was determined by repeating the titrations of 3 ml low protein 
solutions with probe in the presence of 5.0 X lO^M  cephalosporin. The decrease in 
fluorescence of ANS-albumin complex in presence of cephalosporins could be used to 
calculate the binding constants of the drug.
(N.B. The instrument was zeroed before use with reference solvent).
5.4.1.6 Calculation of [ ANS ]*
The total ANS concentration is calculated as follows : In the titration of solutions of 1.0 X 
10_5M serum albumin with 1.0 X 10-3M ANS, assuming x |ll is the increment of ANS 
added to the 3 ml of protein solution in the fluorescent cell, then, after this addition, the total
- 2 1 9 -
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The solutions of the probe were made up in a solution containing the same concentration 
of HSA or BSA (and cephalosporin) as in the solution being titrated so that these 
concentrations would not vary during the titration. Similarly for titrations A and B, the 
protein solutions were made up in ANS solution.
2) For determination of binding parameters of ANS to serum albumin (from 
titrations C to E)
The fluorescence of ANS is enhanced on binding to serum albumin, and the emission 
maximum is blue-shifted (from 512 nm to 480 nm). The fluorescence intensities of the
—3protein-probe complex as a function of probe concentration (1 X 10 M) were measured at 
the protein concentrations, (1 X 10- 6 M) and (1 X 10- :M) in phosphate buffer. The titration 
steps were similar to those used for determination of ?, except that the titrant this time was 
the probe solution : 3 ml of each protein solution was titrated with successive additions of 3, 
5, 10 and 20 }il of probe solution. Enhancement of the probe’s fluorescence upon addition to 
serum albumin, was determined, and these data were used to calculate the binding constant 
for the albumin-probe complex.
3) Displacement of ANS from serum albumin by cephalosporin derivatives 
(titrations F and G)
Cephalosporin binding was determined by repeating the titrations of 3 ml low protein 
solutions with probe in the presence of 5.0 X lO^M cephalosporin. The decrease in 
fluorescence of ANS-albumin complex in presence of cephalosporins could be used to 
calculate the binding constants of the drug.
(N.B. The instrument was zeroed before use with reference solvent).
5.4.1.6 Calculation of [ ANS ]f
The total ANS concentration is calculated as follows : In the titration of solutions of 1.0 X 
10-5M serum albumin with 1.0 X 10-3M ANS, assuming x }ll i^'the increment of ANS 
added to the 3 ml of protein solution in the fluorescent cell, then, after this addition, the total
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volume in the cell = (3000 u.1 + x pi); and as x pi of 1.0 X 10 3M ANS=(x X 100) jul of 1.0
5.4.2 NMR
5.4.2.1 Instrumentation
The determination of relaxation times (T  i) were performed on a Jeol GX270 FT NMR 
spectrometer operating at 270 MHz with 28 |is (180*) and 14 ps (90*) pulses, 3001 Hz 
spectral width and acquisition time of 2.73 s. Magnetization decay obtained in the detection 
mode was accumulated on 16 K memory and sensitivity enhancement of 0.1 Hz was applied 
before the Fourier transformation.
5.4.2.2 Materials
The materials used were the same as in section 5.4.1.2, in addition to the following :
1) Cephaloridine and cephalexin (Glaxo, U.K.), and cefadroxil (Latina, Italy).
2) Benzylpenicillin Na (Glaxo, U.K.).
3) Deuterium oxide (D2 O), 99.9 Atom%D, MSD, Montreal, Canada.
5.4.23  Experimental conditions
1. Unless otherwise specified, all experiments were conducted in deuterated 0.05M
phosphate buffer, pH 7.4 and 1=0.154, at room temperature (see section 5.4.1.3 for
preparation of buffer, using D2 O instead of distilled water). The pH values of the buffer are
C7*V) 90Qactual meter reading and are corrected for deuterium isotope effects, i.e., pH meter^ 0.4 .
2. Drug concentrations are all expressed as molar (M), and protein concentrations are given 
in percent weight per volume (% w/v).
X 10 5 M. Therefore, the total ANS concentration in the cell will be
(5.26)
With low protein concentration (lO^M )
(5. 27)
3. All drug solutions were freshly prepared in the deuterated buffer before use. Drug-protein 
solutions were made up by adding the freshly prepared drug solution to weighed amounts of 
serum albumin immediately before the spectra were recorded.
4. The final concentration of protein was in the range 0 - 10 % w/v (0 - ~ 1.5 X 10-3 M), 
based upon a molecular weight of 69,000.
5. All measurements were made within 5 hours. No change was observed for periods as 
long as 8  hours.
6 . Deuterium in the solvent was used as a lcck signal.
7. Solvent elimination : The presence of a large peak at 4.8 ppm due to the residual HOD 
can cause considerable problems because it obscures part of the spectrum and restricts 
dynamic range. The solvent peak was eliminated by gated secondary irradiation such that the 
decoupler was on only during the pulse delay (homo- gated decoupling)195.
S.4.2.4 Methods
The longitudinal relaxation times (Ti) of solutions of cephalosporins in 0.05 M deuterated 
phosphate buffer were determined either in absence or presence of added serum albumin.
As already mentioned in section 5.3.3.2 the mesurements of Ti were performed by 
using the (180* - T - 90* - PD)rt sequence. In our experiments, a series of cycles with 
different values of T, ranging from 0.005 to 25 sec and an average PD value of 25 sec, were 
carried out. At the end of the experiment the accumulated FID was transformed; the T  ^  
values of the protons were determined by least-squares regression of the relation
ln(Afz -  A /°z) = ln(2M°z) - and the results were output directly on the teletype. The
T  l
spectra were output as a ’stacked plot’.
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5.5 Results
5.5.1 Spectrofluorimetry
The results documented here were the mean values of at least two measurements. The 
standard deviation for the fluorimetric measurements was less than 7 % of the mean.
The excitation and emission spectra of a) 1.0 X 10- 3  M ANS, b) 1.0 X 10- 3  M ANS in
1.0 X 10- 5  M HSA, measured in pH 7.4 phosphate buffer are shown in Fig. 5.7 (p.225). The 
enhancement of the fluorescence intensity of ANS on binding to serum albumin appears 
clearly, accompanied by a blue shift of the emission wavelength maximum from 512 nm to ~ 
488 nm.
5.5.1.1 Interactions with HSA
A) Determination of the proportionality factor, P
The value of (P) was determined from titration B (Table 5.4, p.218), and was used in the 
treatment of the results from other titrations. The concentration of ANS used was 5.0 X 
10- 6 M, and f mlx w&s 73.5 (as obtained from Fig. 5.8, p.226); hence, according to equation 
(5.16, p.209),
s o y  i n-6 
P = - - - - - - - =  6.80X 10"*Af±0.21
73.5
This P  value was only correct for the sensitivity settings used during its determination 
titration; it represented the mean value of four separate measurements.
B) Binding of ANS to HSA
Table 5.5 (p.227) lists the mean complete data as obtained from the fluorimetric and 
UV/VIS absorption titrations of 1.0 X 10- 6  M HSA with a solution of 1.0 X 10- 3  M ANS 
(titration E in Table 5.4, p.218), in addition to the calculated values of the free, bound and
rtotal ANS concentrations, r  an d   — .
[AMS]/
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The binding constants of ANS for HSA were calculated from the Scatchard plot (Fig.
Y"
5.9a, p.230) of versus r, as reported in section 5.4.1.5, where Ka is the affinity
constant of ANS for HSA, and the number of moles of ANS bound per mole of HSA (r) is an
expression of the number of binding sites, n , on a molecule of HSA,
hence,
Ka -  slope o f  curve 
°-9 4 -X106 M - 1
0.28
= 3.36X106M~l 
and n (intercept of the line on r-axis) = 1.37
C) Displacement of ANS from HSA by cephalosporins
Table 5.6 (p.228) presents data for corrected fluorescence intensities of ANS in absence 
and in presence of examined cephalosporins : cephalothin Na, cephazolin Na, cephalexin, 
cefotaxime Na, desacetylcefotaxime, and cefotaxime lactone.
Competition between ANS and the cephalosporins for the binding sites in proteins (as 
evidenced by the decrease of fluorescence intensities of ANS in presence of the examined 
cephalosporins, Table 5.6), can be quantitated by the calculations reported below.
An example calculation of the binding constants of cephalothin for HSA is presented 
below:
The binding parameters (Ka> and n) for cephalothin Na were determined from the data in 
Table 5.7 (p.229) and the Scatchard plot illustrated in Fig.5.9e (p.230), and according to 
equation (5.14), the affinity constant (Ka') of cephalothin for HSA was calculated from the 
gradient of the graph (Fig. 5.9e) as follows :
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r .. 2.01—1.70 V 1  n 5gradient o f  line = ^ —X 10 M
6  J 0.5-0.4
= 3.1X105W 1 
Ka = 3.357X 106M-1 (as determined in previous section) 




= 1.966 xlO 4
The number of binding sites (ri) was obtained from the intercept of the line with the r-axis, 
n=  1 .1
Fig. 5.9 (p.230) reports the Scatchard plots obtained for ANS alone and in the presence 
of examined cephalosporins. The intercepts on the abscissa are almost identical (n = 1.0 - 
1.4) for the five examined compounds thus indicating a competition between ANS and the 
drugs at the same, or adjacent, sites. Furthermore, the slopes of curves are different for the 
different compounds under study and the calculated relative binding constants are 
summarised in Table 5.8 (p.231), with comparison to those obtained by other workers.
- 2 2 4 -
Ordinate scale x 2
S en sitiv ity  high
^ m ax512n m
4 3 0 . 0
: i.» „ ij,
O rdinate sca le  x l 6
Xmax 487 nm
Sen sitiv ity  h igh
4
•ocl<N
Fig.5.7 : Fluorescence emission spectra of A N S  (at excitation wavelength of 418 nm), 1 x 10 3 M. in phosphate 
buffer (0.05 M) pH 7.4 and I 0.154 in absence (a) and in presence (b) of 1 x 10- 6  M HSA.
T n c t r n m o n f a l  cptfinorc o r e  in/4ir»ofoa in
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J 8.78 .009 1.017 8.93 1.0 .61 0.39 .61 135
6 13.55 .010 1.018 13.8 2.0 .94 1.06 .94 0.88
G 16.75 .011 1.019 17.07 3.0 1.16 1.84 1.16 0.63
12 19.08 0.0115 1.02 19.46 3.98 1.32 2.65 1.32 030
15 21.03 0.012 1.021 21.47 4.98 1.46 332 1.46 0.42
18 22.63 0.0125 1.022 23.12 5.96 1.57 439 1.57 0.36
21 23.98 0.0133 1.022 24.52 6.95 1.67 528 1.67 0.32
24 25.20 0.014 1.023 25.78 7.94 1.75 6.19 1.75 0.28
27 26.25 0.0143 1.024 26.87 8.92 1.83 7.09 1.83 026
30 2723 0.0145 1.024 27.88 9.90 1.90 8.00 1.90 0.24
* > 28.63 0.015 1.025 2933 11.53 1.99 9.53 1.99 0.21
-0 29.90 0.0155 1.025 30.65 13.16 2.08 11.08 2.08 0.19
45 31.00 0.016 1.026 31.80 14.78 2.16 12.62 2.16 0.17
50 31.93 0.018 1.027 32.81 16.40 2.23 14.17 223 0.16
60 33.85 0.019 1.030 34.85 19.61 237 1724 237 0.14
SO 36.78 0.022 1.033 3191 25 97 2.58 2339 2.58 0.11
fo=observed fluorescence intensity, f=correoed fluorescence intensity = fo x P, X=corrcrion factor, 
b Xex=419 nm, absorbance at Xem487 nm = 0.006 (constant)
< [ANS]=1 x 10“3M,
[HSA ] ,= !  X lO ^ M , P=0.068 x  lO ^ M















3 8.78 .009 1.017 8.93 1.0 .61 0.39 .61 135
6 13.55 .010 1.018 13.8 2.0 .94 1.06 .94 0.88
9 16.75 .011 1.C19 17.07 3.0 1.16 1.84 1.16 0.63
12 19.08 0.0115 i.o: 19.46 3.98 1.32 2.65 132 0.50
15 21.03 0.012 1.021 21.47 4.98 1.46 3.52 1.46 0.42
18 22.63 0.0125 1.C22 23.12 5.96 1.57 439 1.57 0.36
21 23.98 0.0133 1.022 24.52 6.95 1.67 5.28 1.67 0.32
24 25.20 0.014 1.(33 25.78 7.94 1.75 6.19 1.75 0.28
27 26.25 0.0143 ' 1.024 26.87 8.92 1.83 7.09 1.83 036
30 27.23 0.0145 1.024 27.88 9.90 1.90 8.00 1.90 034
35 28.63 0.015 1.025 2933 11.53 1.99 9.53 1.99 0.21
40 29.90 0.0155 1.025 30.65 13.16 ' 2.08 11.08 2.08 0.19
45 31.00 0.016 1.026 31.80 14.78 2.16 12.62 2.16 0.17
50 31.93 0.018 1.C27 .32.81 16.40 2.23 14.17 233 0.16
60 33.85 0.019 1.C30 34.85 19.61 2.37 1734 237 0.14
80 36.78 0.022 1.G33 3131 25 97 238 2339 238 0.11
fo=observed fluorescence intensity, f=correc^d fluorescence intensity = fo x P, X=corrcdon faaor, 
b Xex=419 nm, absorbance at Xem4S7 nm = 0.006 (constant) 
t [ANS]= 1  x 1(T3 M,
[HSA ] ,= 1  x lO^M , P=0.068 x lC rS l
Table 5.6 : Corrected fluorescence intensities of ANS in absence and in presence of examined 
cephalosporins0
fil ANS [ANS ], Corrected fluorescence intensity (arbitrary unit)
addedb 1CT6 ANS CETH CEZ CEX CEF DesCEF CEFlact
3 1.0 8.93 3.41 5.83 7.01 7.16 6.59 4.96
6 2 .0 13.80 5.27 8.91 10.6S 10.95 9.70 8.71
9 3.0 17.07 6.72 11.17 13.23 13.82 11.78 11.65
12 3.98 19.46 8.07 13.04 15.19 15.97 13.35 . 13.87
15 4.98 21.47 9.43 14.59 16.8- 17.83 14.80 15.90
18 5.96 23.12 10.16 16.05 18.27 19.27 16.04 17.54
21 6.95 24.52 1 1 .2 0 17.19 19.41 20.52 17.19 19.06
24 7.94 25.78 12.13 18.24 20.57 21.56 18.03 20.30
27 8.92 26.87 13.45 19.18 21.71 22.70 18.97 21.52
30 9.90 27.88 13.70 20.14 22.54 23.53 19.81 22.56
35 11.53 29.33 14.74 21.49 24.00 24.89 20.98 24.09
40 13.16 30.65 15.89 22.63 25.17 26.14 21.94 25.44
45 14.78 31.80 16.85 23.68 26.22 27.20 23.00 26.69
50 16.40 32.81 17.81 24.74 27.27 28.15 23.87 27.74
60 19.61 34.85 19.84 27.00 29.26 30.07 25.60 29.85
70 22.80 36.54 21.55 28.78 30.86 31.55 27.11 31.62
80 25.97 37.97 23.18 30.37 32.26 32.94 28.31 32.99
1 0 0 32.26 40.25 25.85 33.04 34.63 35.14 30.41 35.30
1 2 0 38.46 42.10 28.10 35.37 36.50 36.94 32.32 37.21
140 44.59 43.71 30.06 37.36 38.19 38.40 33.80 38.75
a CETH=cephalothin, CEZ=cephazolin, CEX=cephalexin, CEF=cefotaxime, 
DesCEF=desacetylcefotaxime, CEFlact=cefotaxime lactone, b ANS concentranon=l x 10“  ^M
Table 5.7 : Data for the calculation of the binding parameters of cephalothin for HSA from a 
r
Scatchard plot of vs r
_____________  [ANS]f
Corrected
fluorescence [ANSL lANSJb lANSJf r
intensity,F x 1 0 " 6 x 10” 6 x 1 0"6
P x  F
1 .2 0 .2 0.0816 0.1184 0.0816 0.689
1.76 0.4 0.1197 0.2803 0.1197 0.427
2.26 0 .6 0.1537 0.4463 0.1537 0.344
2.72 0 .8 0.1850 0.6150 0.1850 0.301
3.20 1.0 0.2176 0.7824 0.2176 0.278
3.60 1.2 0.2448 0.9552 0.2448 0.256
4.00 1.4 0.2720 1.1280 0.2720 0.241
4.40 1.6 0.2992 1.3008 0.2992 0.230
4.70 1.8 0.3196 1.4804 0.3196 0.216
5.10 2 .0 0.3468 1.6532 0.3468 0 .2 1 0
5.76 2.4 0.3917 2.0083 0.3917 0.195
6.40 2 .8 0.4352 2.3648 0.4352 0.184
7.00 3.2 0.4760 2.7240 0.4760 0.175
7.52 3.6 0.51 M 3.0886 0.5114 0.1656
8.04 4.0 0.5467 3.4533 0.5467 0.158
8.80 4.6 0.5984 4.0016 0.5984 0.150
9.50 5.2 0.6460 4.5540 0.6460 0.142
10.16 5.8 0.6909 5.1091 0.6909 0.1352
10.78 6.4 0.7330 5.6670 0.7330 0.129
11.36 7.0 0.7725 6.2275 0.7725 0.124
1 2 .2 0 8 .0 0.8296 7.1704 0.8296 0.116
13.00 9.0 0.8840 8.1160 0.8840 0.109
13.80 10 .0 0.9384 9.0616 0.9384 0.104
15.20 12 .0 1.0336 10.9664 1.0336 0.094
16.44 14.0 1.1179 12.8821 1.1179 0.087
17.70 16.0 1.2036 14.7964 1.2036 0.081
2 0 .0 0 2 0 .0 1.3600 18.6400 1.3600 0.073
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Fig.5.9 : Scatchard plot of ANS for HSA in absence (a) and in presence of the 
examined cephalosporins (b-e).
ANS= 8 -anilino -1-naphthalenesulphonic acid, ammoniurp salt, CET=cefotaxime Na, 
CE2^=cephazolin, CETH=cephalothin, CEX=cefalexin.
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Table 5.8 : Summary of binding parameters of studied cephalosporins to HSA (with 
comparison to those of other workers)
Cephalosporin Present work 
Ka oi Ka- <M~l ) 
n
Csiba179 Kim186 Veronese180
ANS 3.36 x 106
1.37
1.38 x 106 
1.4
1 .2  x 1 0 6 
2 .1
Cephalothin 19.7 x 103 
1.1
4 x 105 
1.4
3.3 x lO 3 
3.0
0.9 x 103 
2 .1
Cephazolin 5.37 x 103 
1.1
3.7 x 105 
1.4
6.36 x 103 
3.0
Cephalexin 1.72 x 103 
1.1
8 .6  x lO 5 
1.4
0.4 x 103 
2 .1
Cefotaxime 2.83 x 103 
1.2
8 .1  x 1 0 5 
1.4








10.05 x 103 
1.7
5.5.1.2 In teraction  with BSA
A) Determination of proportionality factor, P
The value of the proportionality factor (P) was determined from Fig. 5.10 (p.233) as 
follows:
- 2 3 1 -
fm a x
= 1 0 X 1 0 ~5 = 1.06X10~7M 4 0-13 
94.7
B) Binding of ANS to BSA
The binding parameters (Ka and n) for ANS were determined from the Scatchard plot 
(Fig. 5.1 la, p.235), as follows :
(35.0-20.2) l/v 5  K, = gradient = (2 3_ 19?) XlO5
= ^ g -x lO 5 = 4 .49xl06Af"1
and the number of binding sites Qi) obtained from the intercept of the line with the r-axis,
i.e. n = 3 .2
C) Displacement of ANS from BSA by cephalosporins
The data in Table 5.9 (p.234) illustrate the decrease in the fluorescence of ANS in 
presence of studied cephalosporins. When Scatchard plots were made from the binding data 
obtained for ANS in the presence of the cephalosporins, almost straight lines were obtained 
with the initial slopes measured. The intercepts of lines with the abscissa were nearly 
identical (n ~ 3), indicating competition between the probe and the drugs for the same 
binding sites. The decrease in ANS binding and the subsequent decrease in fluorescence of 
the piobe-protein complex at lower protein concentration (2.76 x 10- 6  M) was used to 
calculate the binding constants (Ka*) of the studied cephalosporins [Table 5.10, p.236], 
according to equation (5.14).
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Fig.5.10 : plot of corrected fluorescence inensity.of A N S v s  






Table 5.9 : Corrected fluorescence intensities of ANS in absence and in presence of studied 
cephalosporins
JIl ANS [ANS ]/ Corrected fluorescence intensity (arbitrary unit)
addedb 10~5 ANS CER CETH CEZ CEF DesCEF
3 0 .1 10.15 9.97 9.10 - 9.20 9.01 9.46
6 0 .2 19.10 18.14 16.70 17.40 17.20 19.03
9 0.3 28.25 25.74 23.90 25.10 25.00 26.74
12 0.4 36.50 32.90 30.70 32.60 32.20 34,69
15 0.5 44.20 39.72 37.80 38.90 39.20 41.84
2 0 0 .6 6 55.65 49.42 43.10 49.50 49.30 52.30
25 0.83 64.80 56.95 54.10 58.00 58.20 59.51
30 l.CO 72.10 63.12 62.90 64.00 64.90 67.00
40 1.32 81.10 71.11 73.20 73.50 73.30 75.87
50 1.61 87.10 76.38 79.10 79.60 79.80 82.00
60 1.96 91.10 80.25 84.10 82.60 83.70 86.67
80 2.60 95.00 85.30 88.50 8 8 .2 0 89.43 93.15
1 0 0 3.23 99.00 88.98 92.10 92.20 93.45 95.89
1 2 0 3.85 1 0 1 .0 0 91.55 95.70 93.60 95.88 97.14
a CER=cefauizine, CETH=cephalothin, CEZ=cephizolin, CEF=cefotaxime, 
DesCEF=desacetylcefotaxime, b ANS concentration=l x 10 M
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,Fig.5.11 : Scatchard plot of ANS for BSA in absence 0 )  and in presence of the 
examined cephalosporins.
- 2 3 5 -
Table 5.10 : summary of results of the binding data of ANS and the studied cephalosporins 
for BSA (compared to those of other workers).
Compound Present work 
Ka or Kd  (AT1) 
n
Veronese180 Kim185
ANS 4.50 x lO 6 
3.2
0.9 x 106 
2 .2
2.08 x 1 0 6 
3.0
Cefatrizine 9.60 x 103 
2 .8
Cephalothin 5.18 x 103 
2 .6




Cephazolin 4.41 x 103 
3.0
8.19 x lO 3 
3.0




Desacetyl cefotaxime 2.13 x 103 
2 .8
-2 3 6 -
5.5.2 NMR
5.5.2.1 Benzylpenicillin
The proton NMR spectrum of benzylpenicillin in D 2 O consists of six groups of peaks 
arising from : i) a singlet (7.32 ppm, 5H, aromatic), ii) a doublet (5.48 ppm, 1H, 6 -H), iii) a 
doublet (5.40 ppm, 1H, 5-H), iv) a singlet (4.20 ppm, 1H, 3-H), v) an AB double doublet 
(centered at 3.63 ppm, 2 H. PI1CH2 ), and vi) two' singlets at 1.55, 1.47 ppm due to the 
nonequivalent methyl groups.
A typical example of the effect of albumin on the benzylpenicillin spectrum is shown in
Fig.5.12 (p.238). The protein appears under of the whole spectrum in a diffuse manner. On
addition of albumin, a decrease of T 1 of most protons of the penicillin molecule with
18 9increase in protein concentration was observed. Fischer et al. assumed the possibilty that 
the change in relaxation time is nonspecific rather than an indication of a drug-protein 
complex, and suggested some control experiments to rule out the nonspecific possibility. 
Accordingly, we studied the effect of drug-drug interactions on T  \ by using a series of 
solutions of benzylpenicillin at varying concentrations. The results of measurements of 
chemical shifts and relaxation rates are recorded in Fig.5.13 (p.239) and Table 5.11 (p.239), 
respectively.
Significant changes in occur with increase in benzyl-penicillin concentration.
T 1
Chemical shifts do not change by more than 0.1 ppm (5H). Furthermore, the changes in the 
relaxation rates are paralleled by changes in chemical shifts, i.e., protons of the phenyl group 
more affected. This is not the case upon adding increasing percentages of BSA to a fixed 
penicillin concentration, as may be seen from Table 5.12, p.241. Therefore, the assumption 
that the decrease of T \  in presence of albumin could be accounted for by interactions 
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Table 5.11: concentration effect on -— (sec  ^  values of benzylpenicillin
*  1
(M)* Me Me ArCH2 3-H 5-H 6 -H Fh(5:
0 .1 1.54 1.67 0.85 0 .2 0 0.27 0.23 023
0 .2 3.03 2.87 1.52 0.47 0.53 0.67 037
0.4 3.23 2.94 1.61 0.47 0.52 0 .6 6 C.43
1.0 4.35 4.0 2.33 0.69 0.72 0.89 C.84












Fig. 5.13 : Effect of concentration on 6 ppm values of benzylpenicillin.
A d d ition  o f  m ore p en ic illin  to  a g iv en  p en icillin -a lb u m in  so lu tion  should  increase the
relaxation  rate — (i.e.  d ecrease T  i ) ,  b ecau se more p en ic illin  increases the v isc o s ity  o f  the 
T  l
so lu tion , in creases the p o ss ib ility  o f  drug-drug interaction, and certain ly should  not decrease  
any in term olecu lar relaxation  e ffe c ts  o f  the protein on  the drug. H ow ever, Table 5 .13  (p .241)  
1
sh ow s a d ecrease in  —— w ith  in crease in p en icillin  con centration , w hich  is  exactly  op posite  
T !
to w hat on e ex p ec t i f  the d ecrease in  T  j w ere due to v isc o s ity  o f  the solution.
Jardetzky and cow ork ers188’ 189 studied other n o n sp ec if ic  alternatives w h ich  m ight 
cause broaden ing o f  peaks, su ch  as in crease in  v iscosity , e f fe c t  o f  u sing proteins other than 
album in on  relaxation  rates, e tc ., and all w ere ruled out as the cau se for broadening o f  peaks.
S in c e  the d ecrease in  T  i w as found to be d irectly  proportional to the total protein  
concentration  (at constant drug con centration ), as sh ow n  b e lo w , therefore it is  reasonable to 
attribute this d ecrease in T  j to  a sp ec ific  interaction b etw een  drug and protein.
T h e relaxation  tim es o f  a ser ie s  o f  0 .2  M  b en zy lp en ic illin  so lu tion  in  D 2 O in p resen ce o f  
the fo llo w in g  increasing  p ercen tages o f  B S A  were m easured: 0 , 1.2, 2 .5 , 3 .6 , 5 .0 , 6 .6 , 8 .0 ,
and 10 %. T h e T 1 and — dat a are g iv e n  in  Table 5 .1 4  (p .2 4 2 ). T h e ch an ges o f  the ch em ica l 
T 1
shifts w ere n eg lig ib le .
5S.2J.  Cephalosporins
In th is sec tio n , u sin g  a grou p  o f  cephalosporins w ith  vary in g  b ind ing affin ities to  serum  
album ins, the resu lting ch a n g es  in  T \  o f  the resonance sig n a ls  arising from  the various  
h yd rogen -con ta in in g  parts o f  the m o lec u le , w ere m easured.
Addition of more penicillin to a given penicillin-albumin solution should increase the
relaxation rate — (i.e. decrease T  i), because more penicillin increases the viscosity of the 
T  l
solution, increases the possibility of drug-drug interaction, and certainly should not decrease 
any intermolecular relaxation effects of the protein on the drug. However, Table 5.13 (p.241)
shows a decrease in — with increase in penicillin concentration, which is exactly opposite
T 1
to what one expect if the decrease in T \ were due to viscosity of the solution.
Jardetzky and coworkers188’189 studied other nonspecific alternatives which might 
cause broadening of peaks, such as increase in viscosity, effect of using proteins other than 
albumin on relaxation rates, etc., and all were ruled out as the cause for broadening of peaks.
Since the decrease in T  j was found to be directly proportional to the total protein 
concentration (at constant drug concentration), as shown below, therefore it is reasonable to 
attribute this decrease in T  i to a specific interaction between drug and protein.
The relaxation times of a series of 0.2 M benzylpenicillin solution in D2 O in presence of 
the following increasing percentages of BSA were measured: 0, 1.2, 2.5, 3.6, 5.0. 6 .6 , 8.0,




In this section, using a group of cephalosporins with varying binding affinities to serum 
albumins, the resulting changes in T \  of the resonance signals arising from the various 
hydrogen-containing parts of the molecule, were measured.
- 2 4 0 -
Table 5.12 : Chemical shifts (ppm) o f 0 2  M benzyl penicillin-BSA soluions
BSA % Me Me ArCH2 3-H 5-H 6-H Ph(5]
0 .0 1.48 1.56 3.64 4.22 5.40 5.49 7.33
1 .2 1.47 1.56 3.63 4.21 5.41 5.48 7.32
2.5 1.48 1.56 3.64 4.22 5.42 5.49 7.33
3.6 1.47 1.55 3.63 4.21 5.42 5.48 7.33
5.0 1.47 1.55 3.63 4.21 5.41 5.48 7.32
6 .6 1.46 1.54 3.63 4.20 5.40 5.47 7.31
8 .0 1.46 1.54 3.62 4.20 5.40 5.47 7.31
1 0 .0 1.47 1.55 3.63 4.20 5.41 5.48 7.32
Table 5.13 : T i (sec) and ——(sec ^  of benzylpenicillin signals as a function of drug
T  i
concentration at constant BSA concentration (2.5%) in D
(M)a Me Me ArCH2  3-H 5-H 6-H Ph(5H)
0.2
T i  0.33 0.35 0.70 1.19 1.37 1.23 1.50
—  3.06 2.86 1.41 ° - 8 4  °*7 3  0 8 1  0.67
T  i
0.4
T  i 0.37 0.40 0.62 L 7 7  x 9 0  l J 3  l 6l
2.67 2.51 1.62 0.56 0.53 0.58 0.62
T  i
a Molar concentration o f  benzylpenicillin
- 2 4 1 -
Table 5.14 : T \ (sec) a n d  (sec ^  of solutions o f 0.2M benzylpenicillin + BSA in D 2 O :
T 1
BSA % MeC* MejS ArCH;
T i T 1 T i
(■=?-) 
1 1




0 .0 0.33 0.35 0 .6 6
(3.03) (2 .8 6 ) (1.52)
1 .2 0.32 0.35 0.72
(3.13) (2 .8 6 ) (1.39)
2.5 0.32 0.35 0.72
(3.13) (2 .8 6 ) (1.39)
3.6 0.40 0.43 0.77
(2.50) (2.33) (1.30)
5.0 0.49 0.47 0.79
(2.04) (2.13) (1.27)
6 .6 0.43 0.47 OJA
(2.33) (2.13) (1.35)
5.0 0.42 0.46 0.75
(2.38) (2.17) (1.33)
1 0 .0 0.48 0.50 0.76
(2.08) (2 .0 0 ) (1.32)
3-H 5-H 6 -H Ph(5H
T 1 T i T i T 1
( rV ( ^ - )   ^ 1 y 1
, 1 
' T ,
2.14 1.89 0.53 1.50
(0.47) (0.53) (0.67) (0.37)
1.36 1.44 1.29 1 .6 6
(0.74) (0.69) (0.78) (0.60)
1 .1 6 1.33 1.19 1.45
(0 .S6 ) (0.75) (0.84) (0.69)
1 .1 0 1.32 1 .1 0 1.34
(0.91) (0.76) (0.91) (0.75;
1.06 1.24 1.13 1.26
(0.94) (0.81) (0 .8 8 ) (0.79)
0.79 1.04 0.96 1.07
(1.27) (0.96) (1.04) (0.93)
0.S4 1.04 0.92 1 .0 2
(1.19) (0.96) (1.09) (0.98)
0.51 1 .0 1 0.93 1 .0 0
(1.23) (0.99) (1.08) (1 .0 0 )
According to the relative extent of change in T \ , the major part of the drug molecule 
involved in binding to the serum albumin can be identified.
In this study, the cephalosporins chosen were classified according to their binding 
affinities (see results reported in section 5.5.1) into :
a) strongly binding : cephalothin, cephazolin;
b) moderate affinity : cefotaxime, cephaloridine;
c) weak affinity : cephalexin, cefadroxil.
The NMR chemical shifts and assignments of the protons of the studied cephalosporins 
were identified and discussed in chapter three.
Small changes (0.03 - 0.05 ppm) in chemical shifts of all spectra of each cephalosporin 
(0.1 M) in the presence of several concentrations of serum albumin were observed [Table 
5.15, pp.244-245]. These might result from error in referencing (HOD peak at 4.80 ppm) as 
the changes were not uniform, i.e., with increasing protein concentration the peaks 
sometimes appeared upfield and in other cases lowfield. ( Therefore, the study of drug- 
protein interactions cannot be carried out on the basis of die changes in chemical shifts).
The effects of BSA (or HSA) concentration on the relaxation rates of studied
cephalosporins are summarized in Figs. 5.14 - 5.17 (pp.246-247) as plots of — for each
T  l
T  i free
proton versus the concentration of protein. Table 5.16 (p.248) reports the —   ratios
T i bound
for each cephalosporin and for all observable protons.
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Table 5.15 : Effect of serum albumin on chemical shifts (5 ppm) of 0.1 M cephalosporins 








6 -H 7-H c h 3 PhCH2 Aromatics 
1 2
0 .0 3.34 3.61 4.71 4.87 5.08 5.64 2 .1 0 3.90 7.04 7.36
0.5 3.34 3.60 4.70 4.87 5.08 5.62 2.09 3.88 7.03 7.36
1 .0 3.34 3.61 4.70 4.87 5.08 5.62 2.09 3.88 7.03 7.36
1.5 3.35 3.61 4.71 4.88 5.09 5.64 2 .1 0 3.90 7.03 7.36
2 .0 3.35 3.62 4.71 4.88 5.10 5.64 2 .1 0 3.90 7.04 7.36
2.5 3.34 3.60 4.74 b.p. 5.10 5.64 2 .1 1 3.90 7.04 7.37
5.0 b.p. b.p. 4.75 b.p. 5.11 5.65 2 .1 2 3.91 7.05 7.37
1 0 .0 b.p. b.p. b.p. b.p. b.p. 5.68 2 .1 2 3.92 7.06 7.37
b) Cephazolin
0 .0 3.42 3.79 3.92 4.50 5.07 5.65 2.71 5.52 9.28
0.5 3.40 3.77 3.91 4.48 5.06 5.64 2.70 5.51 9.25
1 .0 3.40 3.77 3.91 4.48 5.06 5.64 2.70 5.51 9.25
1.5 3.40 3.77 3.91 4.48 5.06 5.64 2.69 5.51 9.26
2.5 3.42 3.79 3.93 4.51 5.09 5.66 2.71 5.54 9.27
5.0 b.p. b.p. b.p. b.p. 5.10 5.66 2.71 5.54 9.28
c) Cephaloridine
Cone. 1-CH2 3-CH2 6 -H 7-H PhCH2 Thi.H Pyr.H
ofS.A.% a  p a  p 1 2 1 2  3
0 .0 3.14 3.56 5.32 5.52 5.12 5.64 3.86 6.99 7 32 8.08 8.55 8.91
0.5 3.15 3.58 533 5.53 5.14 5.65 3.88 7.00 732 8.08 8.55 8.94
1 .0 3.15 3.57 5.33 5.53 5.13 5.65 3.87 6.99 733 8.07 8.56 8.93
15 3.14 3.56 5.32 5.52 5.15 5.67 3.89 7.01 7.33 8.10.8.58 8.95
2.5 3.17 3.58 5.36 5.53 5.13 5.67 3.88 7.01 7.33 8.10 8.57 8.94
5.0 3.18 3.54 5.36 5.50 5.13 5.65 3.86 6.98 7.31 8.07 8.56 8.92
Table 5.15 cont.
d) Cefadroxil
Cone. 2-CH2 3-CH2 6-H 7-H PhCH
ofS.A.% a P
0.0 3.21 3.49 2.09 ■£39 5.73 4.95 '
12 3.21 3.48 2.08 •£39 4.73 4.95
25 321 3.49 2.08 ■£39 5.73 4.95
5.0 b.p. b.p. 2.04 b.p. 5.71 b.p.
6.6 b.p. b.p. 2.02 --P- 5.70 b.p.
e) Cephalexin
0.0 3.17 3.46 2.07 5.05 5.65 524
0.5 3.17 3.46 2.07 5.05 5.65 5.24
1.0 3.15 3.46 2.05 5.04 5.65 523
13 3.14 3.43 2.04 5.02 5.62 5.22
2.0 3.11 3.45 1.97 5.03 5.65 5.23
2.5 3.15 3.48 2.03 5.C6 5.66 526








3’-CH3 NOMe 6-H 7-H Ph.H
0.0 3.39 3.67 4.70 4.S7 2.08 3.97 520 5.81 6.99
1.0 3.41 3.69 4.72 4.89 110 3.99 522 5.83 7.02
1.S 3.40 3.68 4.71 4.87 2.08 3.98 521 5.81 7.00
2.6 3.39 3.67 4.73 4.8S 2.08 3.97 5.20 5.81 6.98
3.6 3.39 3.67 b.p. b.p. 2.07 3.96 520 5.80 6.98
4.7 3.39 3.67 b.p. b.p. 2.07 3.96 5.19 5.80 6.98
5.7 339 3.67 b.p. b.p. 2.06 3.96 5.19 5.79 6.98








NOMe 6-H 7-H Ph.H
0.0 3.75 3.93 5.12 4.08 521 5.94 7.14
0.5 3.75 3.93 5.12 4.08 531 524 7.14
1.0 3.75 3.93 5.12 4.08 532 5.95 7.14
1.5 3.75 3.93 5.12 4.08 531 5.94 7.14
20 3.76 3.94 5.13 4.09 532 525 7.14
25 3.76 3.94 5.13 4.08 531 5.95 7.14
a Cone, of S.A.%=concentration of senxn aibumin in %, b.p.=broad peak, 
Hii.H=thienyI protons, Pyr.H=pyridyl praons, Ph.H=phenyl protons.
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o.s 1.5 2.0 2.5
HSA (%)HSA (%)
Fig.5.14 : Changes in of 0.1 M cephalothin protons . 1 p a i a * i rT i  Fig.5.15: Changes in —  of 0.1 M cephazolin protons
as function of HSA concentration (%) 
(N.B. Other protons show insignificant — changes).
1
as function of HSA concentration (%)
(N.B. Other protons show insignificant —7— changes).
M
Fig.5.16 : Changes in —  of 0.1 M cephaloridine protons
a s  f u n c t io n  o f  U S A  c o n c e n t r a t io n  (% )
Tlii-i li ionyl, I’ysPyriily l
(N.B. Oilier prolons show insignificanl ‘ changes).
Fig.5.17: Changes in —  of 0.1 M cefotaxime protons
T  l ’
a s  fu n c t io n  o f  I I S A  c o n c e n t r a t io n  (% )
(N.B. Oilier prolons show insignilieanl — changes).
1 1
2-CH2 3*.-ch2 6-H 7-H R r' Notes
a P a 0 1 2 3 1 2 3
Cafalexln i / ^ f 2.13 2.44 0.47 0.35 1.22 9.40 0.49 HSA
R * H
1/ Tlb 0.67 0.69 0.52 0.S5 0.64 0.55 0.57
r =
NH, ! ^lf/^lb
0.31 0.28 1.11 1.57 0.52 1.38 1.16
Cafadroxll 1 / T lf 2.56 2.70 0.45 0.67 1.52 1.19 0.69 11.05 aiT^affeeted by





















Cafotax 1 Na 




















by HOD peak at
R * M^-^^NOCH,
W Tib 0.67 0.40 0.91 1.01 1.23 0.99 0.86 2.65 BSA
Cafalorldlne l S * i r 2.70 3.57 3.33 3.d3 0.75 0.64 0.76 0.59 0.86 1.45 0.35 0.19
*■ - O ’ ^ i b 1.69 1.67 1.69 11.96 1.23 1.12 0.86 0.75 0.97 0.71 0.97 0.97 HSA
-g U ,- Tl(/rib 0.63 0.47 0.51 0.65 1.64 1.75 1.13 1.27 1.13 0.49 2.77 5.11
Caphalothln Na l/lj^ 0.32 0.26 0.27 0.20 0.20 0.24 0.17 0.23 0.17 0.15 c:not telatyped >
R s -O-CO-CHj
V * i b
due to broadness
r\ Y t <  ;
iS a ch,-
2.56 2.56 1.92 (c) 1.27 1.06 1.11 1.45 1.44 0.74 of peak.
Ti<Aib 6.0 9.85 7.11 0.35 4.45 6.53 6.30 8.47 4.93 HSA
Cefazolin Na ^ i r 0.33 0.64 0.22 0.48 0.20 0.30 0.29 0.21 0.12
R * 2.86 2.86 2.63 5.10 0.45 0.52 0.42 0.51 0.26 HSA
R’s



















R- J T ? ' jNOOnTl f/Alb 23.27 1.05 4.29 1 . 40 3.33 3.55 1 .05
Wx.5.16: Free and bound relaxation tl... ( T ^  ,nd bound r.tio. for „ ch proton





5.6.1 Discussion of fluorimetry results
F ig. 5 .7  (p .225 ) sh ow s the dram atic ch an ge in  the A N S  flu orescen ce upon ad dition  o f  
H S A . It w as reported216,217  that th e b ind in g  sp ec ie s  is  the an ion  rather than the neutral 
m o lecu le  o f  A N S . Proteins such  as serum  album in  are k n ow n  to  b ind  strongly w ith  sm a ll
918organic m o lecu les  w ith  anionic groups . T h erefore, in  ca se  o f  A N S , the acid group  m igh t  
interact w ith  p ositive ly  charged resid ues in  th e protein  to  form  co m p lex e s , w ith  the b in d in g  
reinforced b y  the hydrophobic interactions b etw een  the protein  and A N S . The m ost stron g ly  
hydrophobic sites on  the protein w ere  probably prim arily  in v o lv ed  in  the b ind in g . T h e  
fluorescen ce change o f  the probe w h en  bound to serum  album in  cou ld  b e due to ch an ge in  
the charge o f  protein m olecu les219. T h e  h ydrophobic nature o f  the b ind in g  site can  accou n t
917for m ajor part o f  the b lue shift flu orescen ce exh ib ited  b y  A N S  .
T h e enhancem ent in  fluorescence in ten sity  o f  A N S  w as approxim ately linear at h ig h  
concentration  o f  serum  albumin, 1 .0  X  10 - 5  M  (F ig .5 .1 1 , p .2 3 5 ), su ggestin g  a proportional 
increase in  the bound form o f  A N S  in  th e system . T h e curve o f  lo w  concentration o f  serum  
album in, 1.0 X  10_6  M  (Fig. 5 .9 , p .2 3 0 ) , m igh t in d icate that the A N S  w as o n ly  p artia lly  
bound (due to saturation o f  the b ind in g  s ites  o f  the protein).
F ig . 5 .9  as w e ll as Table 5 .6  (p .2 2 8 ) sh o w  the reduction  in  th e fluorescence in ten sities o f  
A N S-serum  album in com p lex  upon  addition  o f  ceph alosp orins, as in dication  o f  a reversib le  
com p etition  b etw een  A N S  and drug for  the sam e b ind in g  sites. I f  the com p etition  w as n ot  
reversib le, the affinity o f  A N S w ou ld  rem ain the sam e, but the total num ber o f  b in d in g  s ites
990w ould  h ave b een  greatly reduced . In  our ca se  the total num ber o f  b ind ing sites  rem ained  
the sam e and com petition  resulted in  a reduced affin ity o f  the A N S  for serum album in , 
indicating the reversib ility  o f  com p etition .
B ased  on  the Scatchard plots (F ig . 5 .9  and F ig . 5 .1 1 ), A N S  appeared to  have o n e  prim ary  
bind ing site  on  H S A  and 3 prim ary s ites  on  the B S A  m o lec u le  under the d escrib ed
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exp erim en ta l con d ition s. T h e intercepts o f  the Scatchard  p lo ts obtained  for  A N S  in  the 
p resen ce  o f  ceph alosp orins occu r at the sam e p oint, therefore in d icating  b ind in g  at th e sam e  
or adjacent sites.
C om parison  o f  the H S A  and B S A  fluorim etry resu lts (T ables 5 .8 , p .2 3 1 . and 5 .1 0 , 
p .2 3 6 )  sh ow ed  m inor d ifferen ces in  the binding con stan ts o f  A N S  for H S A (Ka = 3 .36  x  
lO ^ M )  and that for B S A  (Ka = 4 .5 0  x  lO ^ M ) .  A s  for  the affin ity constants o f  
cep h alosp orin s, o n ly  sm all variations occurred w ith  H S A  and B S A , but in  ea ch  ca se  a sim ilar  
va lu e  w as ob served  for the studied antibiotics, that is  a stron ger b ind in g  for ceph aloth in , and 
re la tively  w eak er b in d in gs for cep h azo lin  and ce fo ta x im e.
T h e stability  o f  a drug-protein  com p lex  is  ex p ressed  b y its b ind ing constant, w h ich  is
9 9 1
a lso  im portant for the pharm acokinetic behaviour o f  the drug . A ccord in g ly , cephaloth in , 
cefa tr iz in e and cep h azo lin  can  b e c lassified  as h ig h ly  b oun d , w ith  affin ities h igh er than4*0 X  
103 M - 1 , ce fo tax im e can  b e c la ssified  as m oderately b oun d , ce fa lex in , w ith  affin ity  b e low
2 .0  X l O 3 M - 1 , as w ea k ly  bound.
o 1
R esu lts o f  b ind ing constants o f  cefotaxim e (~  4 .0  X  1 0  M  ), d esa cety lce fo ta x im e (~
2 .0  X  1 0 3 M - 1 ) and ce fo tax im e lacton e (10  X  1 0 3 M - 1 ) in d icate that the d egree o f  b inding  
to serum  album in probably  d epends on  the overall p o larity  o f  the m o lecu le , i .e .,  the increased  
p olarity  o f  the m o lecu le  m ay  reduce the binding affinity.
5.6.2 Discussion of NMR results
T h e form ation  o f  in term olecu lar com p lexes can  b e  d etected  b y  ob serv in g  th e accom p an yin g  
ch an ges in  either the relaxation  tim e or the ch em ical sh ifts  or  both.
5.6.2.1 Benzylpenicillin
It appears, from  the b en zylp en icillin -a lbu m in  re laxation  m easu rem ent resu lts (section  
5 .5 .2 .1) there is  indeed  a sign ifican t decrease in  T i v a lu es , greater for the p h en y l and C -3
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protons, than either th e proton  on  C - 6  or C -5. T h ese  ch an ges in the relaxation  tim es o f  the 
peaks concerned reflects a restriction  in  their rotational freedom  as the m o le c u le  b inds to the
1 8 7
protein  . F ig .5 .18  (p .2 5 2 )  sh o w s that the re la tive decrease in  the relaxation  tim e o f  
b en zylp en icillin  (0 .2  M ) is  foun d  to  b e a fun ction  o f  protein concentration , a lthou gh  th is is  
n ot strictly linear. T h e ob serv ed  relaxation  rate in creases m ore from 0  to 1.2 % than from  1.2  
to 1 0  % album in con centration , e sp e c ia lly  in  ca ses  o f  arom atic proton and the proton  o f  the  
carbon 3. This latter fin d in g  m ay in d icate the d ep en dence o f  relaxation o n  th e p en ic illin  : 
album in ratio. B e lo w  1.8 x  lO ^ M  (1.2% ) B S A  concentration  the ratio is  greater than 1000 ,
i.e ., at 1.8 x  HT4  B S A  (w h ere the s lo p e  break s-dow n ), the num ber o f  p en ic illin  m o le c u le s  is  
about 1 0 0 0  tim es h igh er than that o f  album in m o lec u les , w hich  m eans that the latter sh ould  
b e saturated with p en ic illin , w ith  the con seq u en ce  that the bound ligan d  in creases rapid ly :
is  the representative relaxation  rate from  — free to — bound w ith  a lin ear e ffe c t  Ti Ti Ti
from  0  to 1.8 x H T 4 ( 0  to 1 .2  % ) B S A  concentration . In cases o f  con centration s greater than  
1 .8  x  1 0 - 4  ( > 1 .2  % ) the p en ic illin  b ind in g  to the saturated album in d ecreases in d u cin g  a fa ll  
in slop e, as show n in  F ig .5 .1 8 .
A s m entioned ab ove, the d ecrease in  T  j va lu es o f  the phenyl and C -3  protons w as  
greater than those o f  th e  other protons in  the p en ic illin  m olecu le. T h is result m igh t in d icate  
that these protons w ere in v o lv ed  in  the form ation  o f  pen icillin -protein  co m p lex , w h ile  other  
portions o f  the m o lecu le  retained freedom  o f  m otion  to  a greater extent. A s  th e p h en y l group  
is a very  hydrophobic structure, this su ggests the hydrophobic nature o f  b in d in g  o f  p en ic illin  
( v ia  arom atic protons) to  B S A . T h e broadening o f  the proton signal attached to  carbon-3 can  
be exp lain ed  as fo llo w s  : B S A  contains 16 h istid in e residues per m o le c u le 158, w h ich  are 
p o sitiv e ly  charged in  the range pH  6  - 7 222. T herefore, the p ossib ilty  e x is t  for  an io n ic  
interaction betw een  th e p o s it iv e ly  charged h istid in e and the carboxyl group  (at C -3 ) o f  the  
p en icillin , affecting the T i o f  the p  proton at C -3 . T h is  m ight be su ggested  as another site  o f  
penicillin -protein  interaction.
I0 .5 -
B SA (% )
F ig .5 .1 8  : C h a n g e s  in  r e la x a t io n  r a t e s  ( — —) o f  th e  p h e n y l p r o t o n s  a n d  t h o s e  o f
 ^ 1 1 (C. I M )
C 3 , C 5 a n d  C$ o f  b e n z y lp e n ic ill in ^ /a s  a  f u n c t io n  o f  B S A  c o n c e n t r a t io n .
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5 .6 .2 . 2  D i s c u s s i o n  o f  c e p h a l o s p o r i n s  N M R  r e s u l t s
In th e an a lysis o f  N M R  spectra o f  cep h alosp orin s in  p resen ce o f  serum  album in, the 
ch em ica l sh ifts sh ow ed  n eg lig ib le  changes [Table 5 .1 5 , p p .2 4 4 -2 4 5 ], w h ile  relaxation  tim es 
( T i )  sh o w ed  variable ch an ges depending o n  the nature o f  the p roton-con ta in in g  groups in the 
cep h alosp orin  m o lec u le  (F ig s .5 .1 4 -5 .1 7 , p p .2 4 6 -2 4 7 ). T h o se  w h ich  w ere preferentially  
stab ilised  b y  the form ation  o f  the com p lex  w ere  a ffected  to  a greater ex ten t than those o f
223 224grou p s w h o se  rotational freedom  w as n ot restricted ’ . A  corresponding d ecrease o f  the
relaxation  tim es w as ob served  [Table 5 .1 6 , p .2 4 8 ].
T h e in sign ifican t ch an ges in  the ch em ica l sh ifts  o f  th e  free and bound m o le c u le s  o f  the 
stud ied  ceph alosp orins [see  Table 5 .15] in d icate a rapid exch an ge b etw een  the tw o  states 
supported b y  the shape o f  the spectra and our fluorim etric resu lts w h ich  in d icate that the 
ceph alosp orins exch an ge rapidly w ith  at least o n e  site  o n  H S A , and three sites on  B S A .
A s sh ow n  under the d iscu ssion  o f  p en ic illin -a lb u m in  interaction, th e form ation o f  
in term olecu lar co m p lex es can  be detected b y  ob serv in g  the accom p an yin g  ch an ges in the 
relaxation  tim e. T h e an a lysis  o f  N M R  spectra h elp ed  to a ssess  w h ich  part o f  the m olecu le  
participate in  drug-protein  in teractions158,164.
T  i f ree
A s the —  ---------  ratio increases esp e c ia lly  for protons that g e t  c lo se  to the serum
T ibouna
album in as a con seq u en ce  o f  stronger in teractions, therefore, it is  lo g ic a l to  in vestigate the 
drug-binding sites as w e ll as extent o f  b ind ing b y  com p arin g  those T  i  proton ratios.
T h e results presented  in  Table 5 .16  sh o w ed  that th e relaxation  rates ( “ - )  o f  certain
p roton-contain ing groups w ere increased b y  ap proxim ately  tw o  to  ten fo ld , depending on  
strength o f  b ind ing, in  the presence o f  2 .5%  serum  album in . A ccord in g ly , the results in  
Table 5 .1 6  indicate that, cephalothin  and cep h a zo lin  w ere  stron gly  bound to  H S A  (as they  
sh ow ed  larger ch an gin g  increm ents in the relaxation  rates). B oth  drugs sh ow ed  tw o  classes
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o f  b ind in g  sites for serum album in , o n e  w ith  very  strong affin ity near 2 -C H 2  and 3 ’-C H 2 
(sh o w in g  a changing factor o f  7  to  12) and the other site  sh o w in g  a lesser b in d in g  affin ity
T i f ree
near the R 3 group (with a  :---------  ratio le s s  than 7).
T 1 bound
In ca se  o f  cephalothin, the actu al relaxation  rate m easurem ents Cm sec ~^) sh o w ed  the 
fo llo w in g  va lu es : in D  2 O a) 2 -C H 2  = 0 .3 2 ,0 .2 6 ;  b ) 3  —CH 2 = 0 .2 7 ,0 .2 0 ;  c)
R 3 group, 0 .2 3 ,0 .1 7 .0 .1 5 ;  +  H S A  a ) 2-CH2 =  2 .8 6 ,2 .5 6 ;  b) 3 ’-C7/ 2 =  1.92; c ) R 3 
=  1 .4 5 ,1 .4 4 ,0 .7 4 .
C ep hazolin  show ed th e fo llo w in g  va lu es : in  D 2 O a) 2-CH2  0 .3 3 , 0 .64; b) 
y - C H 2 0 .2 2 ,0 .4 8 ;  c)R  3 0 .2 1 , 0 . 1 2 ; +  H S A  a) 2-CH2 2 .8 6 ; b) 3 '-CH2 2 .6 3 ,5 .1 0 ;  and 
c ) R 3 0 .5 1 ,0 .2 6  sec’ 1.
W ith cephaloridine, w h ich  sh o w ed  relatively  strong b ind ing but le ss  than ceph aloth in  
and cep h azolin , it seem s that the in creased  polarity o f  the 3-substituem  ( C 5 H  5 N +) is  the  
cau se o f  the reduced b inding affin ity  o f  the m o lecu le  as a w h o le , and in particular, those o f
2 -C H 2  and 3 ’-C H 2 [see T ab le 5 .1 6 ]. T h e prim ary b ind ing site  appeared to  b e  the th e in y l 
m oeity , sh ow in g  the largest ch an g in g  factor com pared to the other parts o f  th e m o lecu le ,
supported b y  the fo llow in g  —7— m easu rem ent va lu es : in  D 2 O 0 .35 . 0 .1 9  sec~l \ + H S A
T  l
0 .9 7 ,0 .9 7  secA
C efotax im e show ed m oderate affin ity to serum  album in, w ith  the arom atic m o eity  as the  
prim ary b ind ing site, w ith  a ch an g in g  factor o f  2 .5  - 5 .1  com pared  to that o f  th e ab ove- 
m entioned  com pounds, and to  a le s se r  extent near the lactam  ring protons, w ith  a ratio o f  
1 .2 -1 .8  [see  Table 5 .16]. T h e  p resen ce  o f  the N O C H 3 group in  the 7-sub stitu en t m ight 
affected  the binding o f  the drug to album in.
O n the other hand, drugs lik e  cep h a lex in  and cefad rox il, w hich  are know n to  b ind  very  
T ifree
w eak ly , sh o w ed  l o w ----------------   ratios (< 2 .0 )  w h atever proton  is  considered. It se em s that the
T ibound
am ino substitution  m ight d ram atically  reduced  the b ind in g  o f  these com pounds to  a lbum in  as 
clearly  sh o w n  b y  the data o f  T able 5 .1 6 , p p .248 .
Furtherm ore, Figs_5.14 - 5 .1 7  (p p .2 4 6 -2 4 7 ) sh o w  that the relaxation rates o f  th e ch osen  
peaks for the particular cep h alosp orin  increased  w ith  the addition o f  serum album in. T he
exten t o f  ch an ge in  y — o f  so m e o f  th ese  peaks sh ow ed  d ep endence on  the drug : album in
ratio, m o st o f  w h ich  show ed rapid lin ear in crease in  —7— at lo w  album in con centration  to a
M
point w here the s lop e breaks-dow n to  a s lo w  increase in  —7— (see  F ig s .5 .14 - 5 .1 6 ); the latter
T 1
stage m igh t in d icate som e saturation o f  the b ind ing sites  on  album in. F ig .5 .1 5  (p .246 )
sh ow ed  another rapid increase o n  — wi t h H S A  concentration, after the saturation stage,
T l
w h ich  m ay in d icate availability o f  n ew  b in d in g  sites o f  sam e characters as the p rev iou s. T h is  
m igh t b e  exp la in ed  as that the p rotein  undergo an u nfo ld in g  p rocess in  case o f  cep h azo lin , 
su ch  that further sites b ecom e a ccessa b le  to  the drug.
In sum m ary, from  the ab o v e  d iscu ss io n  and data o f  T able 5 .16 , it seem s that the serum  
album in  b ind ing is  dependent u p on  the interaction b etw een  the 7 -acvl group and the
3-m eth y l substituent. In the group  o f  sites o f  h igh  affinity, the m eth y lth ien y l, 
m ethylth iad iazole or m ethyltetrazole n u c le i w ou ld  probably b ind  to serum  album in b y  m ean s  
o f  electrostatic forces. In the ca se  o f  ce fo ta x im e, the p resen ce o f  N O C H 3 group in  the 7 -a cy l 
substituent m ay  reduce extent o f  b ind in g. T h e p resen ce o f  an additional substituent lik e  N H 2 
in  the ce fa lex in  m olecu le is  characteristic o f  w eak  b inding.
5.6.3 Comparison of fluorimetry and NMR results
It is  w orthm en tion ing  that o n e  o f  the purposes o f  the p resen t study w as to  exam in e the 
p otentia ls o f  flu orescen ce probe and T j *H  N M R  tech n iq u es in  the area o f  cephalosporin- 
p rotein  interactions. B oth  m ethod s w ere ch o sen  because o f  th e  fo llo w in g  reasons :
1. T h eir  sen sitiv ity  to ch an ges u p on  b ind ing.
2 . O n ly  m icroquantities o f  m aterial required.
3. D irect evaluation  o f  the b ind in g  properties o f  ceph alosp orins.
4 . T h e  tw o  m ethods com p lem en t each  other.
5 . A v a ila b ility  o f  advanced  instrum entation.
T h e fluorim etry m ethod  w as used  to calcu late the b in d in g  param eters (affin ity  constant 
o f  b in d in g  and site  num ber) o f  the ch osen  ceph alosp orins to  b ov in e  and hum an serum  
album in , accord in g  to Scatchard’s m ethod . T he flu orescen ce probe (A N S ) w as em p loyed  as 
a reporter group m o lecu le  for flu orescen ce m easurem ents in  order to d etect b ind ing at the 
hydroph obic sites  o f  serum  album in. A N S  w as also u sed  fo r  the determ ination  o f  the b inding  
ability  o f  ceph alosp orins to album in.
T h e h igh -reso lu tion  *11 N M R  results provided in form ation  about the protons o f  the 
drug m o le c u le s  w h ich  w ere in v o lv ed  in  the binding to  se m m  album in, o n  the b asis o f
ch an ges o f  the lon gitud inal relaxation  tim es ( - 7—) o f  p roton ic sign als. Furtherm ore, the
M
technique sh ow ed  the ex ten t to  w h ich  various fu n ction a l groups o n  the drug m o lecu le
participate in  drug-protein  in teractions, b y  u tilizing the ex trem e sen sitiv ity  o f  —7 -  relaxation
• M
rates to  sm all variations in  the m o lecu lar environm ent o f  a proton  sp ec ie s  to  sh o w  clearly
h ow  m easu rem ent o f  th ese  param eters (T 1 and - 7—) revea ls form ation  o f  in term olecular
T  l
co m p lex es.
W h en  com paring resu lts o f  th e tw o  techn iqu es in  term s o f  affin ity o f  cephalosp orins
tow ards album in, both  sh o w ed  sam e order o f  rank; e .g . cep h a lex in  sh o w ed  very  w eak
1
b ind in g  to  album in ( K j  about 1.7 X  1 0  M  ), w h ile  th e N M R  m ethod  revealed  n o  
sign ifican t ch an ges in  th e relaxation  tim es o f  the protons o f  th e drug m o lec u le  o n  addition  o f  
album in  [Table 5 .1 6 ]. T h erefore, the tw o  techn iqu es c a n  co m p lem en t ea c h  other, and 
com b in ed  provid e va lu ab le in form ation  for e lu c id a tin g  th e  nature o f  b ind in g  o f  
ceph alosp orins and serum  album in.
In th e present study, th e m ajor d isadvantage o f  th e fluorim etric tech n iq u e is  the lengthy  
procedures n eed ed  for the quantification  o f  results; that o f  N M R  is  the tim e factor as it  
in v o lv ed  th e u se  o f  ser ies o f  a lbum in  concentrations, ea ch  n eed ed  at least s ix  hours to obtain  
the requ ired  T  \ spectrum .
5.6.4 Comparison with other methods from literature
M an y techn iqu es, other than fluorim etry and N M R , h a v e  b een  u sed  for  stud ies o f  b ind ing  
o f  cephalosp orins to  serum  album in , w h ich  h ave g en era lly  y ie ld ed  som ew h at lim ited  
in form ation  o n  the co m p lex  form ation. For instance, th e u se  o f  equ ilibrium  d ia ly sis  and 
ultrafiltration in  d eriv in g  structural in form ation  regarding th e nature o f  th e interaction  is  in  
general rather lim ited; o n ly  the approxim ate p ercentage o f  the ligan d  bound  is  obtained. 
O ther lim itations for  th e u se  o f  th ese  tw o  techn iqu es in c lu d e :
1 . b ind in g  to  the d ia ly sis  sac , w h ich  m ay  constitute a  m ajor o b sta c le  to  th e u se  o f  these  
techn iques.
2 . th e  lo n g  tim e cou rse exp erim en ts in v o lv in g  th e u se  o f  th ese  tw o  m eth od s m ay cau se  
denaturation o f  th e protein  or ch em ica l m odification  o f  th e drug.
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3. d isturbances o f  the eq u ilibrium  con d ition s b y factors such  as dilution.
4 . it  is  o ften  necessary to  correct for, or avoid  contribution  due to, D onnan e ffec ts .
O n  the other sid e, fluorim etry and N M R  proved to b e  o f  great v a lu e  in  p rotein -b in d ing  
stu d ies, particularly for in vestiga tion s o n  the nature o f  the b inding sites, as already d iscu ssed  
ab ove.
References
1. M artindale T h e Extra P harm acopoeia , tw enty-n in th  ed ition , p. 105 , T he  
P harm aceutical P ress, L on d on  (1 9 8 9 ).
2. B rotzu , G . R icerch e su  di u n  n u o v o  antibiotico. lavori d e U ’Instituto D ’lg ie n e  di 
C agliari, (1 9 4 8 ).
3. A braham , E .P ., L oder, P .B .: C ephalosporin  C. In E .H .F ly n n  (E d .), "C ephalosporins 
and P en ic illin s , C hem istry  and B io lo g y , A cad em ic P ress, N e w  York, pp. 1 -26  (1972).
4 . A braham , E .P . and N ew to n , G .G .F ., B io c h e m J . 7 9 ,3 7 7  (1 9 6 1 ).
5. H od gk in , D .C . and M o slen , E .N ., B io c h e m J . 7 9 ,3 9 3  (1 9 6 1 ).
6 . M orin , R .B ., Jackson , B .G ., F lyn n , E .H ., R oesk e, R .W ., J .A m .C h em .S oc. 84 , 3 4 0 0  
(1 9 6 2 ).
7. M orin , R .B ., Jackson , B .G ., F lyn n , E .H ., R o esk e , R .W ., A nd rew s, S .L ., 
J .A m .C h em .S oc. 9 1 ,1 3 9 6  (1 9 6 9 ).
8 . E lander, R .P ., in  "A ntibiotics con ta in in g  th e p -lactam  structure", A .L .D em ain  and 
N .S o lo m o n  (E d s.), Part 1, p .1 0 1 , Springer-V erlag, B erlin  (1 9 8 3 ).
9. S ig h , P .D ., Y ou n g , M .G ., Johnson, J .H ., C im arusti, C .M . and S yk es. R .B ., 
J.A n tib iotics 3 7 ,7 7 3  (1 9 8 4 ).
10. C hauvette, R .R ., F lyn n , E .H ., Jackson, B .G ., M orin , R .B ., and associates, 
J .A m .C h em .S oc. 8 4 ,3 4 0 1  (1 9 6 2 ).
11. C row foot, D ., B u nn , C .W ., R o g ers-lo w , B .W ., and T u m er-Jon es, A ., in  " T he  
C hem istry o f  P en icillin s" , H .T .C larke, J.R .Johnson, and R .R ob in son  (E ds.), 
P rinceton  U n iv ers ity  P ress, P rinceton , N .J ., p p .3 8 2 -4 1 4  (1 9 4 9 ).
- 2 5 9 -
12. M orin , R .B ., Jackson, B .G ., M u eller , R .A ., L avagnino, E .R ., Scan lon , W .B ., and 
A nd rew s, S .L ., J .A m .C h em .S oc. 8 5 ,1 8 9 6  (1 9 6 3 ).
13. H oover, J.R .E., and Stedm an, R .J .A ., in  " M ed icin a l C hem istry, 4th ed ., Part II ", 
Burger, A . (Ed.), p .84 (1 9 7 9 ).
14. A braham , E .P ., and N ew to n , G .G .F ., B ioch em .J . 6 2 ,6 5 8  (1 9 5 6 ).
15. A braham , E .P ., N ew ton , G .G .F . and H ale , C .W ., B ioch efn .J . 5 8 ,9 4  (1954).
16. Jeffery, J .D ’A ., Abraham , E .P ., and N ew to n , G .G .F ., B ioch em .J . 7 5 ,2 1 6  (1 9 6 0 ).
17. L on g, A .G ., and Turner, A .F ., Tetrahedron L etters 7 ,4 2 1  (1 9 6 3 ).
18. G alantay, E., Szabo, A ., and Fried , J., Tetrahedron Letters 7 ,4 1 5  (1963).
19. Galantay, E., Szabo, A ., and Fried , J., J.O rg.Chem . 2 9 ,3 5 6 0  (1964).
20. G reen, D .M ., L ong. A .G ., M ay , P .J., and Turner, A .F ., J .C h em .S oc. 766  (1 9 6 4 ).
21 . M eyers, A .I., and G reene, J .M ., J .O rg.C hem . 3 1 ,5 5 6  (1 9 6 6 ).
22 . H e y m e ’s, R ., Am iard, G ., and N o m in e , G ., C om pt. R end. 2 6 3 ,1 7 0  (1966).
23. W oodward, R .B ., H eusler, K ., G o ste li, J., N a eg e li, P ., O ppolzer, W ., R am age, R ., 
Ranganathan, S ., and V orbruggen , H ., J .A m .C h em .S oc. 8 8 , 852 (1966).
24 . Nagarajan, R., B oeck , L .D ., G orm an, M ., H am ill, R .L ., H igg in s, C .E., H oehn , M .M ., 
Starck, W .M . and W hitney, J .G ., J .A m .C h em .S oc. 9 3 ,2 3 0 8  (1971 ).
25 . S tapley, E .O ., A n tim icrob .A gen ts and Chem other. 2 ,1 2 2  (1 9 7 2 ).
26 . B ergan, T ., D rugs 34 (su p p l.2 ), 89  (1 9 8 7 ).
- 2 6 0 -
27 . Flynn,E.H ., " C ephalosporins and P en ic illin s, C hem istry  and B io logy" , p .4 7 0 , 614 , 
A ca d em ic  P ress, L on don  (1 9 7 2 ).
28 . B ad d iley , J., in  "P-Lactam  A ntib iotics" , Salton, M .R .G . and Shockm an, G .D . (E ds.), 
p .1 3 , A cad em ic Press, L on d on  (1 9 8 1 ).
29 . S trom inger, J.L. and Tipper, D .J ., A m .J.M ed. 3 9 ,7 0 8  (1 9 6 5 ).
30. L aw ren ce , P.J. and Strom inger, J.L., F ed .P roc .F ed .A m .S oc .E xp .B io l. J28, p .473  
A bstract 1207  (1969).
31. Spratt, B .G ., J. o f  G eneral M icro b io lo g y  1 2 9 ,1 2 4 7  (1 9 8 3 ).
32. T ipper, D .J ., Pharm acol.Therap. 2 7 ,1  (1985).
33. P erlm an, D ., " S tructure-A ctiv ity  R elation sh ips am on g  the S em isyn th etic  
A ntib iotics" , p. 149, A cad em ic P ress, L ondon (1 9 7 7 ).
34. V an H eynin gen , E ., and A h e m , L .K ., J.M ed.C hem . U ,  9 3 3  (1 9 6 8 ).
35. R agnar Norrby, S ., D rugs 3 4  (S u p p l.2 ), 105 (1 9 8 7 ).
36. Y am ana, T ., and T suji, A ., J .Pharm .Sci. 6 5 ,1 5 6 3  (1 9 7 6 ).
37. B lah a , J.M ., K n evel, A .M ., K essler, D .P ., M incy, J .W ., and H em , S .L ., J.Pharm .Sci. 
6 5 ,1 1 6 5  (1976).
38. A driaen s, P ., M eeschaert, B ., E yssen , H ., R o ets , E . and V anderhaeghe, H ., 
J.Chrom atogr. 1 4 4 ,9 3  (1 9 7 7 ).
39. K essler , D .P ., C ushm an, M ., G h eb re-S ellassie , I., K n ev e l, A .M ., and H em , S .L ., 
J .C h em .S oc.P erk in T ran s.n , 1 6 9 9  (1 9 8 3 ).
- 2 6 1 -
40 . D as Gupta, V., C an.J.Pharm .Sci. 1 6 ,2 4  (1 9 8 1 ).
41 . Sabath, L., Jago, M ., and A braham , E .P ., B ioch em .J . 9 6 ,7 3 9  (1965).
42 . B oyd , D .B ., in " C hem istry  and B io lo g y  o f  (3-Lactam A ntib iotics, V ol.I" , M orin , 
R .B .,an d  Gorman, M . (E d s.), 4 3 7 , A cad em ic P ress, N e w  York (19S2).
4 3 . L ee, C., Herr, E. and A nd erson , R ., C lin .M ed. 7 0 ,1 1 2 3  (1 9 6 3 ).
4 4 . (a) H am ilton-M iller, J.M ., N ew to n , G .G ., A braham , E .P ., B iochem .J. 1 1 6 , 371
(1 9 7 0 ).
(b) H am ilton-M iller, J.M ., R ichards, E ., A braham , E .P ., B iochem .J. 1 1 6 , 385
(1 9 7 0 ).
45 . M ozin go , R ., and F olk ers, K ., in  "The C hem istry o f  Penicillin", C larke, H .T ., 
Johnson, J.R., and R ob in son , R . (E ds.),C hapterX V III, p p .535 -656 , P rinceton  U n iv . 
P ress, Princeton, N .J. (1 9 4 9 ).
46 . de W eek, A .L . and Schneider, C .H ., J .A ntim icrob.C hem other. _6 , S u p p l.A , 161 
(1980 ).
47 . K oneeny, J., Felber, E ., and Gruner, J., J.A ntibiot. 2 6 ,1 3 5  (1973j.
4 8 . Schw artz, M .A . and B u ck w alter,F .H ., J .P h a im .S c i._ 5 1 ,1119 (1962).
4 9 . H ou, J.P., and P oo le , J.W ., J .Pharm .Sci. 6 0 ,5 0 3  (1 9 7 1 ).
50 . B roderson, R ., A cta  P harm acol.T oxicol._3, 345  (1 9 4 7 ).
51. H ou , J.P., and P oo le , J.W ., J .Pharm .Sci. 5 8 ,4 4 7  (1 9 6 9 ).
52. Schw artz, M .A ., J.Pharm .Sci. 5 8 , 64 3  (1 9 6 9 ).
- 2 6 2 -
5 3 . A braham , E .P ., in  " T op ics in  Pharm aceutical S c ie n c es  ", Perlm an D . (E d .), V o l 1. 
p p .1 -3 1 , W iley  In terscience, N e w  York (1 9 6 8 ).
5 4 . Johnson, J.R., W oodw ard, R .B ., and R ob in son , R ., i n " T h e C hem istry o f  P en ic illin  
C larke, H .T ., Joh nson , J.R, and R ob in son ,R ., (E d s.), p .4 4 0 , P rinceton  U n iv . Press. 
P rinceton, N .J. (1 9 4 9 ).
5 5 . S w eet, R .M ., and D ah l, L .F ., J .A m .C h em .S oc. 9 2 ,5 4 8 9  (1 9 7 0 ).
5 6 . H erm ann, R .B ., J .A ntib iot. 2 6 ,2 2 3  (1 9 7 3 ).
5 7 . B o y d , D .B ., H erm ann, R .B ., Presti, D .E ., and M arsh, M .M ., J .M ed .C hem . J^ 8 , 40S  
(1 9 7 5 ).
5 8 . P o llock , M .R ., in  "A ntim icrobial A gen ts and C hem otherapy ", S y lv ester  J.C. (Ed.;. 
p p .2 9 2 -3 0 1 , W illiam s &  W ilk in s, B altim ore, M aryland (1 9 6 5 ).
5 9 . Faraci, W .S ., and Pratt, R .F ., J .A m .C h em .S oc. 1 0 6 ,1 4 8 9  (1 9 8 4 ).
60 . P age, M .I., Proctor, P ., J .A m .C h em .S oc. 1 0 6 , 3 8 2 0  (1 9 8 4 ).
61 . C larke, H .T ., Joh nson , J.R., and R obinson , R . ( E d s .) ," T h e C hem istry o f  P e n ic il l in ". 
P rinceton  U n iv . P ress , P rinceton, N .J., (1 9 4 9 ).
62 . D eg e la en , J.P., L ou k as, S .L ., Feeney, J., R oberts, G .C ., and B u rgen , A .S .. 
J.C h em .S oc.P erkin  Trans.II, 8 6  (1979).
63 . R attie, E .S ., Z im m erm an, J.J., and R avin , L .J ., J .Pharm .Sci. J 5 8 ,1369  (1 9 7 9 ).
64. T suji, A ., Y am ana, T ., N akashim a, E ., D eg u ch i, Y ., N ish id e , K ., S h im izu , T.. 
H oriuchi, S. and Ish ik aw a, K ., JJPhaim .Sci. 7 0 ,1 1 2 0  (1 9 8 1 ).
- 2 6 3 -
65. Indelicato, J.M ., N o rv ila s , T .T ., and W heeler, W .J., J .C h em .S oc.C h em .C om m ., 1162  
(1972).
6 6 . Indelicato, J.M ., N o rv ila s , T .T ., P feiffer, R .R ., W heeler, W .J ., and W ilh am , W .L ., 
J.M ed.C hem . 1 7 ,5 2 3  (1 9 7 4 ).
67 . Dinner, A ., J .M ed .C hem . 2 0 ,9 6 3  (1 9 7 7 ).
6 8 . C oene, B ., Sch anck , A ., D erep pe, J.M ., and M eerssche, M .V ., J .M ed .C hem . 2 7 , 6 9 4
(1984).
69 . Hall, D .A ., J.Pharm .Sci. 6 2 ,9 8 1  (1 9 7 3 ).
70. N am iki, Y ., T anabe, T ., T oshim itsu , K ., Tanabe, J., O kim ura, Y ., K oda, S. and
M orim oto, Y ., J.Pharm .Sci. 7 6 ,2 0 8  (1 9 8 7 ).
71. M angia, A ., S ilin gard i, S ., B ortesi, F ., G risanti, G. and D i B itetto , M ., J.Pharm .Sci. 
6 8 ,6 5 2  (1 9 7 9 ).
72. Indelicato, J.M ., E n g e l, G .L ., and O cco lo w itz , J .L ., J.Pharm .Sci. 7 4 ,1 1 6 2  (1 9 8 5 ).
73. Bundgaard, H ., A rch .P h a rm .C h em i.S c i.E d .4 ,2 5  (1975).
74. Cohen, A .I., F un ke, P .T ., and Puar, M .S ., JJPharm.Sci. 6 2 ,1 5 5 9  (1 9 7 3 ).
75 . Fabre, H ., H u ssam -E dd in e, N ., and B erge, G „  J .Phann.Sci. 7 3 ,6 1 1  (1 9 8 4 ).
76. Fabre, H ., and B lan ch in , M .D ., A n a lyst V ol.IH , 1281 (1 9 8 6 ).
77 . Indelicato, J.M ., W ilh am , W .L ., and C erim ele, B .J., JP h arm .S ci. 6 5 ,1 1 7 5  (1 9 7 8 ).
78. Fabre, H ., and H u ssam -E dd in e, N ., J.Pharm .Phannacol. 3 4 ,4 2 5  (1 9 8 2 ).
- 2 6 4 -
79 . B o m ste in , M ., K link, P .R ., Farrell, B .T ., W in ely , C .L ., and B oylan , J.C., 
A m .J.H osp.Pharm . 3 7 ,9 8  (1 9 8 0 ).
80 . H ash im oto , N „  Tasaki, T ., and Tanaka, H ., J .P h an n .S ci. 7 3 ,3 6 9  (1984).
81. H ash im oto , N ., and Tanaka, H ., J .Pharm .Sci. 7 4 , 6 8  (1 9 8 5 ).
82. H ash im oto , N ., and Ichihashi, T ., P harm .R es._5 ,2 6 6  (1 9 8 8 ).
83. B ranch, S .K ., C asy, A .F., and O m in de, M .A ., J .P h arm .B iom ed .A nal. _ 5 .73 (1 9 8 7 ).
84. B ranch, S .K ., C asy, A .F ., L ip czy n sk i, A . and O m inde, M .A ., M agn .R es.C hem . 2 4 , 
4 6 5  (1 9 8 6 ).
85. L ip czyn sk i, A .M ., Ph.D . T h e s is  : T h e degradation  o f  b en zy lp en icillin  in  aqueous  
so lu tion , U n iversity  o f  B ath (1 9 8 8 ).
8 6 . N eid lem an , S .L ., Pan, S .C ., L ast, J .A ., and D o lfin i, J .E ., J .M ed .C hem . JL3,3 8 6  (1 9 7 0 ).
87. M obashery, S ., and Johnston, M ., J.O rg.C hem . 5 1 ,4 7 2 3  (1 9 8 6 ).
8 8 . K ukolja , S .,P fe il, J.L., D raheim , S .C ., and O tt, J.L., J .M ed .C hem . 1903 (1985).
89. Lam m ert, S .R ., E llis,. A .I., C hau vette, R .R ., and K ukolja , S ., J.O rg.Chem . 4 3 , 1243  
(1 9 7 8 ).
90 . D em arco , P .V ., and N agarajan, R ., in  E .H .F lyn n  (E d .) : " C ephalosporins and  
P en ic illin s , C hem istry and B io lo g y  ”, C hapter 8 , p .3 3 0 , A cad em ic  Press, N e w  Y ork  
(1 9 7 2 ).
91 . R o ets , E .E ., H oogerm artens, J .H ., and V anderhaeghe, H .J., J .A ssoc.O ff.A n al.C h em . 
6 4 ,1 6 6 ( 1 9 8 1 ) .
- 2 6 5 -
92 . G reen , G .F .H ., P age, J.E ., Staniforth, S .E ., C h em .C om m u n ., 5 9 7  (1 9 6 6 ).
93 . G reen , G .F .H ., P age, J.E ., and Staniforth. S .E ., J .C h em .S o c ., 1595  (1 9 6 5 ).
94 . S ch an ck , A ., C oen e, B ., V an M eerssch e, M ., and D erep p e, J .-M ., O rg.M agn.R es. _12, 
3 3 7  (1 9 7 9 ).
95 . B en n , R ., and Gunther, H ., A n g e  w. Chem  .Inst. E d .E ngl._22, 3 5 0  (1 9 8 3 ).
96 . V o id , R .L ., W augh, J .S ., K le in , M .P ., and P h elp s, D .E ., J .C hem .Phys. 4 8 , 3831
(1 9 6 8 ).
97 . M cM illa n , I., and S tood ly , R .J., Tetrahedron L ett. _1_1,1205  (1 9 6 6 ).
98 . Barrow , K .D ., and S p o tsw o o d , T .M ,, Tetrahedron L ett., 3 3 2 5  (1 9 6 5 ).
99 . A braham , R .J., and L oftu s, P ., '^ H  and 13C N M R  Spectroscopy" , p .4 6 , H eyden, 
L o n d o n  (1 9 8 1 ).
100. W illia m s, D .H ., and F lem ing,"  Spectroscop ic m eth od s in  O rganic C hem istry ", 
p p .1 0 8 ,141, and 144 , M cG raw -H ill, L ondon (1 9 8 0 ).
101. T ori, K ., N ish ik aw a , J., and T akeuche, Y ., T etrahedron L ett. 2 2 ,2 7 9 3  (1 9 8 1 ).
102. P asch a l, J.W ., and D orm an, D .E ., J.O rg.Chem . 4 3 ,2 0 1 3  (1 9 7 8 ).
103. D erep p e , J.M ., Sch anck , A ., C oen e, B „ M oreau , C ., and V an M eerssch e , M ., 
O rg.M agn .R eson ._H , 63 8  (1 9 7 8 ).
104. H an sen , P .E ., P rog .N u cl.M agn .R eson .S p ectrosc ., ed ited  b y  J .W .E m sley, J.Feeney, 
and L .H . S u tc liffe , P ergam on  P ress, Oxford, 1 4 ,1 7 5  (1 9 8 1 ).
105. N e u ss , N ., N ash , C .H ., L em k e, P .A ., and G rutzner, J .B ., J .A m .C h em .S oc. 93 , 2337
(1 9 7 1 ).
-266-
106. N eu ss , N ., P roc.R oy.Soc.S er.(L on don ) B 1 7 9 , 3 3 5  (1971 ).
107. W ehrli, F .W ., and W irthlin , T ., Interpretation o f  13C  N M R  spectra, p . 134 , H eyden , 
L on don  (1976).
108. W ehrli, F .W ., T op ics in  1 3C  N M R  S p ectroscop y , V o l.2 , p .343  (1 9 7 6 ), and references  
therein.
109. Terui, Y ., Tori, K ., M aeda, S ., S aw a, Y .K ., Tetrahedron L ea ., 2 8 5 3  (1 9 7 5 ).
110. M on d elli, R ., and Ventura, P ., J .C h em .S oc.P erk in T ransJI. N o .9 - 1 5 ,1 7 4 9  (1 9 7 7 ).
111. Stothers, J.B ., C arbon-13 N M R  S p ectroscop y , p .1 4 8 , A cad em ic P ress, N e w  York
(1 9 7 2 ).
112. (a) Cooper, P .D ., B a c ter io l.R ev ._ 2 0 ,2 8  (1 9 5 6 );
(b) C ollins, J.F., and R ich m on d , M .H ., N atu re 1 9 5 ,1 4 2  (1962);
(c) Cocker, J .D ., E ardley, S ., G regory, G .I., H all, M .E ., and L o n g , A .G ., 
J.C hem .Soc. C , 1 142  (1 9 6 6 ); and
(d) M orin, R .B ., A d van .D ru g  R es ._ 4 ,4 8  (1 9 6 7 ).
113. S tem h ell, S ., Q u art.R ev .C h em .S oc. 2 3 ,2 3 6  (1 9 6 9 ).
114. B enedicL R .G ., S ch m id t,W .H ., C o g h ill,R .D ., and 01eson ,A .P ., J .B a c t  4 9 , 85  (1 9 4 5 ).
115. R apson,H .C ., and B ird ,A .E ., J .Pharm .Pharm acol.Suppl. 1 5 .2 2 2 T  (1 9 6 3 ).
116. Peck ,R .L ., and F o lk ers,K ., in  reference 61 , C hapter V II, p p .144 -206 .
117. W oodw ard,R .B ., N eu b erger,A ., and Trenner,N .R ., in  reference 6 1 , Chapter X IV , 
p p .415-436 .
- 2 6 7 -
118 . D en n en ,D .W ., and D av is,W .W ., " A ntim icrob ia l A gen ts  and C hem otherapy ", 
A m erican  S o cie ty  for  M icrob io logy , A n n  Arbor, M ich ., p .531  (1 9 6 1 ).
119 . Y am an a ,T .,T su ji,A ., K iya.E . and M iy a m o to ,E ., J .Pharm .Sci. 6 6 , 861 (1977).
120 . Proctor,P., G ensm antel, N .P . and P age ,M .I., J .C h em .S oc.P erk in  Trans. II, 1185  
(1 9 8 2 ).
121 . G h eb re-sellassie ,I., H em ,S .L . and K n ev e l,A .M ., J .Pharm .Sci. 7 3 ,1 2 5  (19S4).
122 . R essler , C ., N ea g , P .M ., and M en d elso n , L .M ., J.Pharm .Sci. 7 4 ,4 4 8  (1985).
123. (a) D eW eck , A .L ., a n d B h em , G .,In tem a t.A rch .A llerg y  A ppl.Im m unol._27,
221 (1965 ).
(b) Schneider, C .H ., and D eW eck , A .L ., N ature 2 0 8 ,5 7  (1 9 6 5 ).
124. (a) M orris, J.M ., and Page, M .I., J .C h em .S oc.P erk in T ran s._2 ,21 (1 9 8 0 ).
(b) M orris, J.M ., and Page, M .I., J .C h em .S oc.P erk in T ran s._2 ,2 2 0  (1981).
125 . Jones, I.F ., P age, J.E., and R h od es, C .T ., J.Pharm .Pharm acol. 2 0 ,4 5  (196S).
126. W right, W .E ., F rogge, J.A ., A ntim icrob .A g.C h em oth er. H ,  9 9  (1 9 8 0 ).
127 . K ukolja, S ., J .M ed .C h em ._U , 1 067  (1 9 6 8 ).
128. B erge , S .M , H enderson. N .L ., Frank, M .J ., J .P h aim .S ci. 7 2 ,5 9  (1 9 8 3 ).
129 . G ou ld , E .S ., " M echanism  and Structure in  O rganic C hem istry ", H olt, Rinehart, and 
W inston , N e w  York, p p .31 4 -3 2 2  (1 9 5 9 ).
130. C ocker, J .D ., C ow ley , B .R ., C o x , J .S ., Eardley, S ., G regory, G .I., Lazenby, J .K ., 
L on g , A .G ., S ly , J.C. and S om erfie ld , G .A ., J .C h em .S oc., 1 959  (1 9 6 7 ).
- 2 6 8 -
131. Taylor, A .B ., J .C h em .S oc., 7 0 2 0  (1 9 6 5 ).
132. H atfield , L .D ., F isher, J .W ., D unigan , J.M ., B u rch fie ld , R .W ., G reene, J.M ., W ebber, 
J.A ., V a sile ff , R.J. and K in n ick , M .D ., P h ilos.T ran s.R oy.Soc.L ond .B  : B io l.S c i. 2 8 9 ,  
173 (1 9 8 0 ).
133. N ew to n , G .G ., A braham , E .P ., and Kuwabara, S ., A ntim icrob .A g.C h em oth er. 1 9 6 7 , 
4 4 9  (1 9 6 8 ).
134. R o ss , G .W ., and O ’C allaghan, C .H ., in  reference 149 , p p .6 9 -8 5  (1 9 7 5 ).
135. O ’C allaghan, C .H ., M orris, A ., Kirby, S .M ., and Shingler, A .H .,
A ntim icrob .A g.C h em oth er. _1,2 8 3  (1972 ).
136. E ggers, S .H ., K ane, V.V., and L o w e , G ., J .C h em .S oc., 1262  (1 9 6 5 ).
137. G orm an, M ., R yan , C .W ., in  reference 27 , p p .5 4 4 -5 6 9 .
138. S assiver, M .L ., L ew is , A ., in  reference 33. p p .87 -160 .
139. B o y d , D .B ., H erron, D .K ., Lunn, W .H ., Spitzer, W .A ., J .A m .C h em .S oc. 10 2 , 1812  
(1 9 8 0 ).
140. O ’C allghan, C .H ., K irby, S .M ., M orris, A ., W aller, R .E ., and D u n com b e, R .E ., 
J.B acterio l. H O , 9 8 8  (1 9 7 2 ).
141. W aller, R .E ., A n a lyst 9 8 ,5 3 5  (1 9 7 3 ).
142. B undgaard, H ., A rch.Pharm .C hem i., S ci.E d ._3 ,9 4  (1 9 7 5 ).
143. B o y d , D .B ., Lunn, W .H ., J M ed .C h em . 2 2 ,7 7 8  (1 9 7 9 ).
144. G rabow sk i, E .J., D o u g la s, A .W ., and Sm ith, G .B ., J .A m .C h em .S oc . 1 0 7 ,2 6 7  (1 9 8 5 ).
- 2 6 9 -
145 . Yamana, T ., T suji, A ., K anayam a, K ., and N ak an o , O ., J.Antibiot. 2 7 ,1 0 0 0  (1 9 7 4 ).
146 . Dinner, A ., In delicato , J .M ., P eters, L .R ., and W ilham , W .L ., J .M ed .C h em . 2 0 , 961  
(1977).
147 . R ichm ond, M .H ., and S y k es, R .B ., A dvan.M icrob .Physiol._9, 31 (1 9 7 3 ).
148 . Datta, N ., and R ich m on d , M .H ., B ioch em .J . 9 8 ,2 0 4  (1966).
149. R oss, G .W . and O’C allaghan, C .H ., in  " M eth od s in E n zy m o lo g y , V o l XLIII : 
A ntib iotics ", H ash, J.H. (E d .), p .6 9 , A cad em ic  Press, N ew  Y ork (1 9 7 5 ).
150 . L iven n ore,A .H ., C arpenterJ7.H ., H o lley ,R .W ., and du V in geau d .V ., J .B io l.C hem . 
1 7 5 ,7 2 1  (1 9 4 8 ).
151 . L ev in e ,B .B ., A rch .B io ch em .B io p h y s. 9 3 ,5 0  (1 9 6 1 ).
152. deK oning, J.J., K oorem an, H .J., Tan, H . and V erweij, J., J .O rg.C h em . 4 0 , 1346  
(1975).
153. Pratt, R .F., and F araci, W .S ., J .A m .C h em .S oc. 1 0 8 ,5 3 2 8  (1986 ).
154 . B oyd , D .B ., J .O rg.C hem . 5 0 , 8 8 6  (1 9 8 5 ).
155 . P age 117 in  referen ce 13
156. British P harm acopoeia , V o l.II , A 5 3  (1 9 8 0 ).
157 . G oldstein , A ., A ron ow , L ., and K alm an, S .M ., " Principles o f  D ru g A ctio n  : T he  
B asis o f  P h a r m a c o lo g y ", p p .l ,  1 4 ,1 8 ,1 5 8 ,  John W iley  and so n s, L on d on  (1 9 7 4 ).
158 . B ridges, J.W . and W ilso n , A .G .E ., in  " P rogress in  Drug M eta b o lism , V o l 1 ", 
Bridges, J.W . and C hasseau d , L . (E d s.), p p .1 9 3 -2 4 7  (1976).
- 2 7 0 -
159. B rodei, B .B ., and H ogb en , C .A .M ., J .P h arm .P h aim acol._9 ,345  (1 9 5 7 ).
160 . B ow m an , W .C ., R and, M .J., and W est G .B ., " T extb ook  o f  P harm aco logy  ", 6th ed .,
Chapters 3 9  and 4 0  (1974).
161 . G old stein , A ., Pharm acol.R ev. L  102  (1 9 4 9 ).
162. C raig, W .A . and W ellin g, P.G., Clin.Pharmacokin._2, 252 (1977).
163. G ourley, D .R ., M o d em  Trends in  P harm acol, and Ther. L 1 (1 9 6 7 ).
164 . K unin, C .M ., Clin.Pharm ac.Ther. 7 , 1 8 0  (1 9 6 6 ).
165 . B rod ie, B .B ., P roc.R .Soc.M ed . 5 8 ,9 4 6  (1 9 6 5 ).
166 . W hite, A ., Handler, P. and Sm ith, E .G . ," P rin cip les o f  B ioch em istry  ", M cG raw -H ill, 
N e w  York (1968).
167 . Jonas, A . and W eber, G ., B ioch em istry  1 0 ,1 3 3 5  (1 9 7 1 ).
168. Thorp, J.M ., in B in n s, T .B . ( E d .) ," A bsorption  and distribution o f  drugs ", pp .64-76 , 
E .S .L iv in gston e, L on d on  (1964).
169. Sud low , G ., B irkett, D .J. and W ade, D .N ., M o lec .P h a rm a co l._ n , 824  (1 9 7 5 ).
170 . K iem , E ., F eh sk e, K .J., and M uller, W .E ., W ld .R ev.N utr.D ieL  4 3 ,1 7 9  (1984).
171. K lotz , I.M ., A n n .N .Y .A c a d .S c i.2 2 6 ,18 (1 9 7 3 ).
172. N agw ekar, J.B. and K ostenbauder, H.B., J .P h aim .S ci. 5 9 ,7 5 1  (1 9 7 0 ).
173. W ise , R . and G illet, A .P ., J .In fect.D is. 1 4 2 ,7 7  (1 9 8 0 ).
174. S e lw y n , S ., T h e L ancet_l, 1104 (1 9 7 8 ).


















Briand, C ., Sarrazin ,M . and P eyrot, V., M olec.P harm acol. 2 1 ,9 2  (1 9 8 2 ).
Barza, M ., W einstein , L ., A n n .N .Y .A ca d .S c i. 2 3 5 ,6 1 3  (1 9 7 4 ).
N igh tin ga le , D ., G reene, D .S . and Q uintillian i, R „ J .P h arm acol.S ci. 6 4 ,1 8 9 9  (1 9 7 5 ).
S in gh v i, S .M ., R eald , A .F . and L e itz , M ., J.L ab.C lin .M ed. 8 9 ,4 1 4  (1 9 7 7 ).
Csiba, A ., L u d w ig , E. and M agyar, T ., G y o g y szereszet 2 9 ,2 5 1  (1 9 8 5 ).
V eronese, F .M ., B ev ilacq u a , R ., B o c cu , E . and B e n a ss i, C .A ., F arm aco-E d .S ci. 32 , 
30 3  (1 9 7 7 ).
Jun, H .W ., M ayer, R .T ., H im el, C .M . and L uzzi, L .A ., J .Pharm .Sci. 6 0 ,1 8 2  (1 9 7 1 ). 
C hignel^C -F ., M olec.P harm acol. 5>,2 4 4  (1969 ).
S ud low , G ., Birkett, D .J. and W ade, D .N ., M o lec .P h a r m a co l._ 9 ,6 4 9  (1 9 7 3 ).
M uller, W .E . and W olbert, U ., B ioch em .P h arm acol. 2 5 ,1 4 1  (1 9 7 6 ).
K im . C .K ., Y ang, J.S. and L im , Y .S ., A rch.Pharm .R es. j) , 55  (1 9 8 3 ).
K im . C .K ., Y ang, J.S. and L im , Y .S ., A rch .P haim .R es.J7 ,11  (1 9 8 4 ).
Jardetzky, O ., A d v .C h e m .P h y s /7 ,4 9 9  (1 9 6 4 ).
Jardetzky, 0 .  and W ade-Jardetzky, N .G ., M olec.Pharm ac.JU  2 1 4  (1 9 6 5 ).
F ischer, J.J. and Jardetzky, O ., J .A m er.C hem .Soc. 87 , 3 2 3 7  (1 9 6 5 ).
M eyer, M .C . and G uttm an, D .E ., J .P h a im .S ci. 57 , 895  (1 9 6 8 ).
C h ign ell, C .F ., "M ethods in  P harm acology , P h ysica l M ethod s" , V o l.2 , A pp leton -  
C entury-C roft, N e w  Y ork, pp. 1-61 (1 9 7 2 ).
- 2 7 2 -
192. G old stein , A ., Pharm acol.Rev.J^, 102  (1 9 4 9 ).
193 . K urz, H ., Trunk, H. and W eitz , B ., A rzneim itt.-F orsch . 2 7 ,1 3 7 3  (1977).
19 4 . G iacom in i, K .M ., A b an g , A . and B lasch k e, T .F ., B ri.J.C lin .Pharm acol. 14, 7 5 2
(1 9 8 2 ).
195. A braham , R.J. and L o ftu s, P ., "Proton and C arbon-13 N M R  S pectroscopy, A n
integrated approach, H e y d e n  and S on , p p .8 4 -8 6 , p p .1 2 1 -1 2 5  and 139 (1 9 8 0 ).
196. K arush, F ., J .A m er.C hem .Soc. 7 2 ,2 7 0 5  (1 9 5 0 ).
197. Scatchard, G ., A n n .N .Y .A ca d .S ci. 5 1 ,6 6 0  (1 9 4 9 ).
198. K lotz , I.M ., Walker, F .M . and P ivan , R .B ., J .A m er.C h em .S oc. 6 8 ,1 4 8 6  (1 9 4 6 ).
199. K een , P ., in  " H andbook o f  E xp erim en ta l Pharm acology. C oncepts in  B io ch em ica l  
P harm acology 28 (Part I) ", B rod ie , B .B . and G illette , J .R .(E ds.), p p .2 13 -2 3 3 , 
Springer-V erlag, N ew  Y ork, N .Y . (1 9 7 1 ).
2 0 0 . W illard, H .H ., Merritt, L .L . and D ean , J.A ., " Instrum ental M ethods o f  A n a ly s is  ", 
5th ed ., D .V an nostrad com p an y , N e w  York, 133 (1 9 7 4 ).
2 0 1 . C hignell, C .F ., M olec.P harm acol. 6 ,1  (1 9 7 0 ).
2 0 2 . Steiner, R .F ., J .B ioL C hem . 2 4 1 ,5 6 0  (1 9 6 6 ).
2 0 3 . Brand, L ., G ohlke, J.R. and R ao , S ., J .B io c h e m .j5 ,3 5 1 0  (1 9 6 7 ).
2 0 4 . M clure, W .O . and E d elm an , G .M ., B ioch em istry  5 ,1 9 0 8  (1 9 6 6 ).
2 0 5 . Stryer, L ., J .M ol.B iol. 13,4 8 2  (1 9 6 5 ).
- 2 7 3 -
2 0 6 . G eisow , M J . and B eaven , G .H ., B iochem .J. 1 6 3 ,4 7 7  (1 9 7 7 ).
2 0 7 . Freem an, R ., H ill, H .D .W ., J.C hem .Phys. 5 1 ,3 1 4 0  (1 9 6 9 ).
2 0 8 . H su , P .L ., M a, J.K. and Jun, H .W ., J .Pharm acol.Sci. 6 3 ,2 7  (1 9 7 4 ).
2 0 9 . Perrin, D .D . and D em p sey , B „  "Buffers for  p H  and M etal Ion  Control", p .77 , 
C hapm an and H all, L on don  (1 9 7 4 ).
2 1 0 . R osen bu rg , R .M . and K lo tz , I.M ., in A lexander, P. and B lock , R .J. (E d s.), " A  
laboratory m anual o f  analytical m ethods o f  p rotein  chem istry, V o l.2 , p p .1 3 1 -1 6 8  
(1 9 6 0 ).
2 1 1 . B ennett, J.V. and Kirby, W .M .M ., J .L ab.C lin .M ed. 6 6 ,7 2 1  (1 9 6 5 ).
2 1 2 . S teinberg, I.Z. and Schachm an, H .K ., B iochem istry_5, 3 7 2 8  (1 9 6 6 ).
2 1 3 . W ood , G .C . and Cooper, P .F ., C hrom atog.R ev. _12, 88  (1 9 7 0 ).
2 1 4 . O ’R eilly , R .A . and K ow itz , P .E ., J .C lin.Invest. 4 6 , 8 2 9  (1 9 6 7 ).
2 1 5 . C h ign ell, C .F., in  reference 191, pp .33-61 .
2 1 6 . E delm an, G .M . and M cC lure, W .O ., A c c .C h e m .R e s .6 5  (1 9 6 8 ).
2 1 7 . C hen, R .F ., J .B iol.C hem . 2 4 2 ,5 8 1 3  (1967).
2 1 8 . K lotz , I.M ., Triwush, H. and Walker, F .M ., J .A m .C h em .S oc. 7 0 ,2 9 3 5  (1 9 4 8 ).
2 1 9 . Brand, 1. and G ohlke, J.R ., A n n .R ev .B ioch em . 4 1 , 8 4 3  (1 9 7 2 ).
2 2 0 . Javidon, S. and M rtek, R .G ., J.Pharm .Sci. 6 2 ,4 2 0  (1 9 7 3 ).
2 2 1 . S h a ip les , D ., J .Phaim .Phaim ac. 2 8 ,1 0 0  (1 9 7 6 ).
- 2 7 4 -
2 2 2 . E d sall, J.T. and W ym an, " B io p h y sica l C hem istry ", A cad em ic P ress In c., N e w  York, 
N .Y ., p .534  (1 9 5 8 ).
2 2 3 . Jardetzky, 0 .  and Jardetzky, C .D ., in  " M eth od s o f  B ioch em ica l A n a ly s is  ", G lick , D . 
(E d .), IX , d .2 3 5 , In terscien ce P ub l., N e w  Y ork (1 9 6 2 ).
2 2 4 . C ohen, M . and H u gh es, T .R ., Jr., J .B io l.C h em . 2 3 7 ,1 7 6  (1962).
- 2 7 5 -
